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This	 project	 aimed	 to	 provide	 a	 greater	 understanding	 of	 limb	 development	
through	the	characterisation	of	Mendelian	disorders.	The	more	specific	aim	was	
to	 identify	 the	 developmental	 basis	 of	 the	 Post	 Axial	 Longitudinal	 Limb	
Reduction	 Deformity	 (PALLRD)	 seen	 in	 the	 autosomal	 recessive	 Miller	
syndrome	caused	by	mutations	in	Dihydroorotate	Dehydrogenase	(DHODH)[1].		
	
In	 addition	 whole	 exome	 sequence	 analysis	 was	 used	 to	 identify	 further	
causative	variants	in	a	group	of	individuals	with	Non	Classical	Miller	syndrome.	
These	 individuals	were	negative	 for	mutations	 in	DHODH	 although	 they	had	a	
clinically	 overlapping	 PALLRD.	 A	 single	 novel	 variant	 was	 discovered	 in	
Fibroblast	Growth	Factor	Receptor	1	gene	(FGF1)	in	one	individual	in	this	cohort.	






Serial	 Analysis	 of	 Gene	 Expression	 (DGE-SAGE)	 produced	 gene-expression	
profiles	of	the	forelimbs	and	hind	limbs	from	14.5	days	post	conception	(d.p.c)	
murine	 embryos.	 This	 data	 included	 known	 differentially	 expressed	 genes	 as	
well	 as	 novel	 candidate	 genes	 that	 are	 putative	 regulators	 of	 limb	 growth.	
Whole	 mount	 In	 Situ	 Hybrisation	 (WISH)	 and	 Quantitative	 Real	 Time	
Polymerase	Chain	Reaction	(qRTPCR)	provided	corroborating	evidence	for	the	
differential	 expression	 of	 a	 subset	 of	 these	 genes	 between	 the	 forelimbs	 and	
hind	limbs.		
	
This	 project	 suggests	 a	 role	 for	DHODH	 in	 limb	 bud	 cell	 proliferation.	 It	 also	
demonstrates	a	novel	potentially	dominant	negative	mutation	within	FGFR1	in	
an	 individual	 with	 a	 limb	 deformity.	 Finally	 a	 subset	 of	 genes	 involved	 in	
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difficulties	 with	 daily	 activities.	 Current	 treatments	 are	 limited.	 This	 project	
focused	 on	 a	 specific	 type	 of	 limb	 malformation	 in	 which	 individuals	 fail	 to	
develop	 the	 correct	numbers	of	 fingers	and	 toes.	Abnormal	 genes	 cause	 these	
conditions.	Miller	syndrome	is	an	example	of	such	a	condition.	Miller	syndrome	
causes	 an	 abnormal	 facial	 structure	 and	 loss	 of	 the	 5th	 fingers	 and	 toes.	 The	
gene,	 which	 causes	 Miller	 syndrome,	 has	 already	 been	 found.	 The	 gene	








to	be	produced	 in	 the	 cells	by	 adding	other	 factors	known	 to	be	 important	 in	
growing	arms	and	legs	but	we	could	not	find	any	relationship	between	them.	
Advances	in	sequencing	technology	know	as	Next	Generation	Sequencing	(NGS)	
allows	all	 of	 your	genes	 to	be	 rapidly	 sequenced	 to	 allow	diagnosis	of	 genetic	








Finally	we	 looked	 at	 genes	 that	 are	 involved	 in	 the	 differential	 growth	 of	 the	




































































































































































































Chapter 1  
Introduction  
 
Developmental genetic analysis of Post-Axial Longitudinal 
Limb Reduction Defect (PALLRD) in Miller Syndrome and 
Non Classical Miller Syndrome 
	
The	 broad	 objectives	 of	 this	 project	were	 to	 identify	 novel	 disease	 associated	
genes	and	through	the	study	of	them	further	understand	limb	development.	The	
more	 specific	 aim	 was	 to	 identify	 the	 developmental	 basis	 of	 the	 Post	 Axial	
Longitudinal	 Limb	 Reduction	 Deformity	 (PALLRD)	 seen	 in	 the	 autosomal	
recessive	 Miller	 syndrome	 caused	 by	 mutations	 in	 Dihydroorotate	
Dehydrogenase	 (DHODH)[1].	 In	 addition	 this	 work	 aimed	 to	 identify	 further	
causative	variants	in	a	group	of	individuals	with	atypical	Miller	syndrome,	using	
whole	 exome	 sequence	 analysis.	 These	 individuals	 had	 clinically	 overlapping	








or	 without	 ulnar	 and	 fibular	 hypoplasia	 [3].	 Normal	 intelligence	 is	 typical	 in	
Miller	 syndrome	and	 internal	malformations	are	 rare[3].	DHODH	was	 the	 first	
Mendelian	 disease	 gene	 identified	 on	 whole	 exome	 sequencing[1].	 All	 of	 the	
pathogenic	 variants	 discovered	 in	 DHODH	 were	 compound	 heterozygous	
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mutations[1].	 Functional	 investigation	 of	 mutations	 in	 DHODH	 in	
complementation	assays	in	yeast	demonstrates	loss	of	protein	function[3].	
	
Chapter	 2	 investigated	 the	 role	 of	 DHODH	 during	 limb	 development.	 This	




expression	 in	 murine	 embryonic	 development;	 no	 previous	 study	 has	
investigated	 the	 localization	 of	 DHODH	 during	 development.	 Initially	 I	
investigated	 the	 expression	 pattern	 of	 DHODH	 during	 development.	 The	
hypothesis	was	 that	DHODH	 would	 be	 localized	 to	 the	 regions	 of	 the	 embryo	
affected	in	individuals	with	Miller	Syndrome,	namely	craniofacial	structures	and	
limbs.	The	method	 that	 I	 chose	was	Whole	Mount	In	Situ	Hybridisation	(WISH)	
and	 Colorimetric	 and	 Fluorescent	 Immunohistochemistry	 in	 wild	 type	 (WT)	
murine	 embryos	 10.5	 days	 post	 conception	 (d.p.c).	 This	 work	 demonstrated	
Dhodh	 is	 expressed	 predominantly	 in	 the	 distal	 limb	 bud	 mesenchyme	
underlying	the	Apical	Ectodermal	Ridge	(AER).	 In	addition	it	was	expressed	in	
the	 pharyngeal	 arches	 at	 9.5	 to	 11.5	 days	 post	 conception	 (d.p.c),	 consistent	
with	 the	 human	 disorder.	 Therefore	 the	 work	 demonstrated	 a	 specific	
expression	 pattern	 consistent	 with	 regions	 affected	 in	 the	 individuals	 with	
Miller	syndrome.		
	
I	 hypothesized	 that	 cells	 undergoing	 high	 proliferation	 rates	 require	 de	 novo	
pyrimidine	biosynthesis.	The	hypothesis	 for	 this	work	was	 that	partial	 loss	of	




of	 Carbamoyl-Phosphate	 Synthetase	 2	 Aspartate	 Transcarbamylase	 And	




phenotype.	 Published	 studies	 of	 the	 treatment	 of	 murine	 dams	 with	
Leflunomide,	 a	 chemical	 inhibitor	 of	 DHODH	 also	 results	 in	 an	 analogous	
phenotype[6].	 Many	 studies	 have	 suggested	 an	 association	 between	
proliferative	expansion	of	the	hand	plate	and	correct	digit	patterning[7].		
	
To	determine	whether	DHODH	was	distributed	 in	 areas	of	 cell	 proliferation,	 I	
undertook	 comparative	 localization	 of	 Dhodh	 expression	 and	 expression	 of	
established	 proliferative	 markers,	 Nmyc	 proto-oncogene	 (Nmyc)	 and	
Proliferating	 Cell	 Nuclear	 Antigen	 (Pcna)[8,	 9].	 Triplicate	 biological	 and	
technical	 replicates	 were	 carried	 out	 to	 confirm	 the	 expression.	 Optical	
projection	 tomography	 (OPT),	 which	 allows	 3D	 image	 capture,	 was	 used	 to	
image	each	embryo.	The	expression	pattern	was	very	similar	and	appeared	 to	
co-localise.	 I	 went	 onto	 confirm	 this	 on	 three-dimensional	 computational	
mapping	of	the	gene	expression	patterns	within	the	limb	bud.	This	allowed	the	
expression	 of	 Dhodh,	 Nmyc	 and	 Pcna	 to	 be	 compared	 on	 a	 reference	 model,	
demonstrating	 their	 co-expression.	 Therefore	Dhodh	 is	 expressed	 in	 areas	 of	
cell	proliferation	within	the	limb	bud.	This	is	consistent	with	both	the	reported	




I	 generated	 and	 validated	 an	 immortomouse	 limb	 bud	 cell	 line	 from	 10.5dpc	









Therefore	 this	 limb	cell	 line	showed	decreased	cell	proliferation	when	 treated	
with	Leflunomide,	a	DHODH	antagonist.		
	
To	 investigate	 the	 regulators	 of	 Dhodh	 expression	 in	 the	 distal	 limb	 bud,	 I	
decided	to	examine	putative	regulation	of	Dhodh	by	limb	morphogens,	including	
Bmp,	Fgf	 or	Shh.	 The	 limb	bud	 cell	 line	was	 stimulated	with	 each	morphogen	
and	 assayed	 at	 different	 time	 points	 to	 assess	 immediate	 early	 response,	
delayed	 response	 and	 indirect	 transcriptional	 effects,	 but	 no	 statistically	
significant	alteration	in	Dhodh	expression	was	observed.	
	
Following	 on	 Chapter	 3	 utilized	 next	 generation	 sequencing	 to	 analyse	 the	
cohort	 of	 four	 unrelated	 individual	 with	 atypical	 Miller	 syndrome;	 these	




phenotype	 (loss	 of	 the	 5th	 ray)	 and	 normal	 upper	 limbs.	 PALLRD	 is	 an	
uncommon	 diagnosis	 –	 the	 rarity	 and	 phenotype	 heterogeneity	 of	 the	
individuals	made	genotyping	more	challenging.	Parental	DNA	was	not	available	
for	 all	 patents	 at	 the	 time.	 However	 at	 the	 time	 of	 this	 research	 there	 were	
papers	 being	 published	 on	 whole	 exome	 sequencing	 of	 small	 cohorts	 of	
unrelated	individuals[10].	Therefore	a	whole	exome	approach	was	chosen	for	is	






in	 collaboration	 with	 the	 IGMM	 Bioinformatics	 service.	 Approximately	 15000	




by	 filtering	 out	 non-pathogenic	 Single	Nucleotide	 Polymorphisms	 (SNPs).	 The	
filtering	 strategy	 that	 I	 used	 was	 based	 on	 the	 genome	 analysis	 tool	 kit	 best	
practice[11].		I	used	two	analytical	models	based	on	the	mode	of	inheritance	of	
causative	 variants.	 The	 data	 was	 annotated	 against	 public	 databases	 and	 I	
applied	 quality	 scores,	 computational	 conservation	 and	 damaging	 prediction	
tools	 to	 further	 curate	 the	 data.	 The	 dominant	 model	 analysis	 identified	 a	
number	of	 candidate	variants.	 I	 also	studied	 the	data	using	a	 recessive	model.	
However	the	recessive	model	did	not	generate	any	candidate	variants.		
	
One	of	 the	 four	 cases	was	 found	 to	 carry	a	de	novo	mutation	 in	 the	Fibroblast	
Growth	 Factor	 Receptor	 1	 gene	 (FGFR1)	 on	 dominant	 model	 analysis	 of	 the	
exome	sequencing	data.	This	was	a	novel	phenotypic	association	in	humans	but	
is	 consistent	 with	 the	 conditional	 knockout	 of	 Fgfr1	 in	 the	 limb	 bud	 of	
embryonic	 mice[2].	 	 Validation	 of	 this	 mutation	 demonstrates	 that	 the	
application	of	whole	 exome	 sequencing	 and	 filtering	protocols	 can	be	used	 to	
determine	causal	variants	 in	a	patient	with	a	 rare	monogenic	disease.	 	Due	 to	




genes	 for	 targeted	 Sanger	 sequencing	 in	 the	 other	 individuals,	which	 are	 also	
presented	in	chapter	3.		
	
The	 work	 in	 chapter	 4	 aimed	 to	 investigate	 if	 this	 novel	 FGFR1	 variant	 was	
pathogenic.	 The	 FGFR1	 mutation	 in	 individual	 R24H4	 is	 a	 missense	 single	









Individual	R24H4	presented	with	PALLRD	 isolated	 to	 the	 lower	 limbs.	 Sanger	
sequencing	confirmed	a	mutated	base	in	FGFR1	in	this	individual	–the	mutation	
was	 not	 present	 in	 either	 phenotypically	 normal	 parent	 and	 is	 therefore	 de	
novo.		
	
To	 investigate	 the	 functional	 significance	 of	 the	 novel	 variant	 in	 FGFR1	 I	
generated	 two	 HEK293	 cell	 lines,	 which	 expressed	 GFP	 tagged	 wild	 type	 or	
mutant	FGFR1	protein	under	tetracycline	induction.	The	FlpIn	Trex	system	from	
Invitrogen	 was	 used	 for	 this	 work.	 The	 GFP	 tagged	 protein	 allowed	 direct	
visualisation	of	the	localisation	of	the	mutant	and	wild	type	FGFR1	proteins.	The	
HEK	 293	 cells	 were	 counterstained	 with	 DAPI	 and	 Phallloidin.	 This	
demonstrated	 that	both	proteins	 localize	 in	 a	 similar	manner	 through	out	 the	





its	 capacity	 to	 activate	 the	 MAPK/ERK	 (mitogen-activated	 protein	
kinases/extracellular	 signal-regulated	 kinases)	 signalling	 pathway.	 The	
importance	of	this	pathway	in	limb	development	has	been	established[13].		The	
HEK	 293	 cells	 containing	 either	 the	 FGFR1	 wild	 type	 protein	 or	 the	 FGFR1	
mutant	protein	were	cultured	with	or	without	tetracycline	 for	24	hours.	 	Cells	
were	then	cultured	in	the	presence	or	absence	of	the	Fibroblast	Growth	Factor	2	




detection	 of	 phosphorylated	 ERK	 in	 the	 absence	 of	 expression	 of	 the	mutant	




Finally	 in	 chapter	 5,	 I	 compared	 the	 differential	 gene	 expression	 profile	 of	
embryonic	 mouse	 forelimb	 and	 hindlimb	 at	 a	 later	 stage	 of	 development,	
embryonic	day(E)	14.5.	The	murine	limb	initiates	at	E9.5	from	the	lateral	plate	






the	 differential	 patterning	 (fingers	 versus	 toes)	 and	 growth	 between	 the	





stage	 of	 development	 and	 to	 determine	 if	 pathways	 involved	 in	 growth	 are	
distinct	 between	 the	 forelimb	 and	 hind	 limb.	 In	 addition	 we	 examined	 the	
expression	of	genes	known	 to	be	 involved	 in	 fore	and	hind	 limb	patterning	at	
earlier	 stages	 of	 development	 to	 see	 if	 they	 remain	 up	 regulated	 after	
specification	is	complete.	
	
Digital	 Gene	 Expression	 Serial	 Analysis	 of	 Gene	 Expression	 (DGE-SAGE)	
produced	 gene-expression	 profiles	 of	 the	 forelimbs	 and	 hind	 limbs	 from	
14.5dpc	 murine	 embryos.	 This	 data	 included	 known	 differentially	 expressed	
genes	 as	 well	 as	 novel	 candidate	 genes	 that	 are	 putative	 regulators	 of	 limb	
growth.	My	 contribution	was	 to	 validate	 the	 genes	 expressed	 differentially	 in	
the	murine	forelimb	and	hindlimb	found	on	DGE	SAGE	with	Whole	mount	In	Situ	
Hybrisation	 (WISH)	 and	 Quantitative	 Real	 Time	 Polymerase	 Chain	 Reaction	
(qRTPCR).	 qRTPCR	 and	 WISH	 provided	 corroborating	 evidence	 for	 the	
differential	 expression	 of	 a	 subset	 of	 these	 genes	 between	 the	 forelimbs	 and	
hindlimbs.	The	novel	candidate	genes	 included	genes	known	to	be	 involved	 in	
growth	 and	 in	 metabolic	 pathways,	 such	 as	 purine	 biosynthesis.	 The	 library	
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also	 demonstrates	 a	 novel	 potentially	 dominant	 negative	 mutation	 within	
FGFR1;	 this	 is	 the	 first	 study	 to	 functionally	 characterize	 a	 FGFR1	 mutation	




The Role Of DHODH In Limb Bud Development 
	
2.1 Introduction 
The	 research	 question	 for	 this	 chapter	 was	 does	 DHODH	 expression	 overlap	
with	regions	of	proliferation	during	development	and	does	inhibition	of	DHODH	
impair	 proliferation?	 The	 hypothesis	 was	 that	 cells	 undergoing	 high	
proliferation	 rates	 require	 de	 novo	 pyrimidine	 biosynthesis.	 Therefore	




provides	 insight	 into	 growth,	 patterning,	 embryogenesis	 and	 evolution[18].	
During	 limb	 development,	 a	 homogeneous	 mass	 of	 undifferentiated	
mesenchymal	 cells	 transitions	 to	 a	 complex	 collection	 of	 organised	 tissues	 to	
form	the	functional	 limb.	 	Numerous	signalling	pathways	play	 integral	roles	 in	
limb	development	and	their	precise	spatio-temporal	regulation	is	crucial	to	the	
accurate	formation	of	the	limb.	This	regulation	and	the	integration	of	signalling	
pathways	 remains	 an	 important	 area	 of	 study.	 The	 developing	 limb,	 as	 an	
appendage,	 is	 particularly	 susceptible	 to	 experimental	 interrogation	 and	
manipulation	in	chick	and	murine	models.	
	
Congenital	 limb	 defects	 are	 one	 of	 the	 most	 common	 birth	 defects[19].	 The	
aetiological	 characterisation	 of	 these	 limb	 defects	 provides	 insight	 into	 limb	
development	 pathways.	 Next	 generation	 sequencing	 has	 enabled	 the	 genetic	
aetiology	 of	 previously	 uncharacterised	 limb	 defects	 to	 be	 identified.	 This	
provides	insight	into	novel	regulators	of	limb	development	pathways		
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2.1.2 Overview of Limb Bud Development 
The	 limb	 buds	 initiate	 at	 specific	 locations	 within	 the	 lateral	 plate	
mesoderm[20].	Proliferation	of	 the	mesoderm	at	 these	sites	causes	outgrowth	
from	 the	 embryonic	 somites,	 with	 the	 mesoderm	 enveloped	 in	 a	 layer	 of	
ectoderm[18].	 As	 the	 limb	 bud	 elongates,	 the	 distal	 end	 expands	 to	 form	 the	
hand/foot	 plate,	 which	 will	 subsequently	 generate	 digits[21].	 The	 proximal	
mesenchyme	 is	 first	 to	differentiate	 as	 it	 undergoes	 condensation	 to	 form	 the	
proximal	 skeleton.	 The	 more	 distal	 mesenchyme	 progenitors	 remain	
undifferentiated	 and	 continue	 to	 proliferate;	 at	 later	 time-points	 they	 also	
undergo	 chondrogenesis	 to	 form	 the	 more	 distal	 skeletal	 elements[22].	
Subsequently,	apoptosis	of	the	inter-digital	mesenchyme	occurs	to	form	distinct	
digits[23].	 The	 limb	 bud	 initiates	 at	 9.5	 days	 post	 coitum	 (dpc)	 in	 murine	
models,	with	 the	majority	 of	mouse	 limb	bud	 specification	occurring	between	
9.5dpc	 and	 12.5dpc.	 After	 12.5dpc	 the	 patterned	 skeletal	 structures	 continue	
their	growth	until	birth.		
2.1.2.1 Limb Bud Axes 
The	 developing	 limb	 has	 three	 major	 axes:	 the	 proximo-distal	 (PD)	 axis,	 the	
antero-posterior	 (AP)	 axis	 and	 the	 dorso-ventral	 (DV)	 axis[24].	 The	 PD	 axis	
extends	from	the	shoulder	to	the	digits,	the	AP	axis	extends	from	the	first	to	fifth	
digit	 and	 the	 DV	 axis	 from	 the	 dorsal	 to	 the	 palmar	 surface[24].	 Distinct	




2.1.2.2 Determinants of Growth and Patterning 
The	proliferative	expansion	(growth)	and	specification	(patterning)	of	the	limb	
bud	is	predominantly	controlled	by	the	integration	of	morphogen	signalling	and	




gradient	with	cell	responding	differently	 to	distinct	 levels	of	 the	molecule[25].	
Major	morphogen	 classes	 that	 act	 in	 limb	development	 include	 the	Fibroblast	
Growth	Factor	 (FGF)	 family	of	proteins,	 the	Bone	Morphogenic	Protein	 (BMP)	
family	 of	 proteins,	 Sonic	 Hedgehog	 and	 WNT[26-29].	 Major	 transcription	
regulators	 include	 the	HOX	 family	 and	 the	T-box	 (Tbx)	 family	of	 transcription	
factors[20,	30].	The	HOX	 family	 are	 characterised	by	 the	presence	of	 the	DNA	
binding	homeobox	domain;	the	39	human	HOX	genes	exist	in	four	chromosomal	
clusters	and	constitute	master	regulators	of	embryonic	morphogenesis[31].			
2.1.3 Limb Bud Initiation 	
The	limb-forming	potential	of	cells	within	the	lateral	plate	mesenchyme	(LPM)	
is	 both	 autonomous	 and	 specified	 prior	 to	 limb	 bud	 formation[14].	 This	 was	
demonstrated	by	transplantation	of	cells	 from	wing-forming	areas	of	the	chick	
embryo,	which	led	to	the	formation	of	ectopic	wings	at	the	site	of	grafting[32].	
However,	 the	precise	 regulatory	networks	 that	 control	 limb	bud	 initiation	are	
yet	to	be	fully	characterised.		
	
The	 location	 of	 limb	 bud	 initiation	within	 the	 LPM	 appears	 to	 be	 directed	 by	
expression	 of	 Hox	 gene	 family	 members10365960.	 Hoxc4	 and	 Hoxc5	 are	
expressed	 predominantly	 within	 the	 area	 of	 the	 mesenchyme	 at	 which	 the	
forelimb	initiates[14].	Hoxc9,	Hoxc10	and	Hoxc11	are	restricted	to	the	hindlimb	





of	 exogenous	 FGF	 to	 the	 interlimb	 LPM	 driving	 ectopic	 limb	 formation.	
Subsequent	 work	 has	 demonstrated	 that	 it	 is	 Fgf10	 that	 is	 critical	 to	 limb	
initiation;	Fgf10	 knockout	mice	 fail	 to	 form	 forelimbs	 or	 hindlimbs[34].	Fgf10	
expressed	by	 the	 limb	mesenchyme	 induces	and	maintains	FGF8	 release	 from	
the	 overlying	 ectoderm[34].	 Reciprocally,	 FGF8	 release	 positively	 regulates	
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the	 forelimb,	 while	 Tbx4	 in	 combination	 with	 transcription	 factor	 paired-like	
homeodomain	1	(Pitx1)	is	expressed	only	in	the	hindlimb[16].	These	factors	are	
reported	to	play	critical	roles	in	limb	bud	initiation[16].	Loss	of	Tbx5	results	in	
the	 complete	absence	of	 the	 forelimb;	 in	 contrast	 the	hindlimb	bud	 forms	but	
does	not	progress	 in	Tbx4	null	mice[20].	 	Both	Tbx5	 and	Tbx4	 are	essential	 in	
regulating	 Fgf10	 expression	 by	 the	 LPM	 and	 the	 establishment	 of	 the	 FGF	




contribute	 to	 limb	 bud	 initiation,	 with	 exogenous	WNT	 also	 found	 to	 induce	
ectopic	 limb	 formation[35-37].	 In	addition,	 recent	work	has	demonstrated	 the	
role	 of	 epithelial	 to	 mesenchymal	 transition	 (EMT)	 during	 limb	 bud	
initiation[38].	 This	 is	 driven	 in	 part	 by	 Fgf10	 and	 Tbx5	 expression[38].	 This	
indicates	 that	 not	 only	 proliferation	 but	 also	 EMT	 augments	 mesenchyme	
expansion	during	initiation[38].		
2.1.4 Proximo-Distal Axis   
Outgrowth	 in	 the	 proximo-distal	 axis	 is	 mediated	 by	 the	 Apical	 Ectodermal	
Ridge	(AER)[22]. The	AER	 is	an	area	of	specialised	epithelium	that	runs	along	
the	distal	 limb	bud	 tip;	 it	 is	visible	 from	10dpc	 in	 the	developing	murine	 limb	
bud[22].	 AER	 formation	 is	 driven	 by	 expression	 of	 FGF10	 and	 BMP4	 within	
early	 limb	mesenchyme[34,	39,	40].	 	 In	turn,	the	AER	expresses	FGF,	BMP	and	




The	AER	 is	critical	 to	 limb	development	and	experimental	removal	of	 the	AER	
leads	 to	 truncation	 of	 the	 limb	 with	 loss	 of	 distal	 elements.	 However,	 this	
phenotype	 can	 be	 rescued	 by	 addition	 of	 exogenous	 FGFs[21],[41].	 The	 AER	
expresses	Fgf8	from	the	time	of	its	formation,	with	the	subsequent	expression	of	
three	other	FGF	ligand	genes	(Fgf4,	Fgf9	and	Fgf17).	The	AER-FGFs	are	reported	
to	 maintain	 the	 undifferentiated	 state	 of	 mesenchymal	 cells	 and	 drive	
proliferation[42].	Fgf8	 expression	 is	 also	 important	 in	 the	maintenance	 of	 the	
ectodermal-mesenchymal	FGF	 signalling	 loop	described	above.	 Loss	of	Fgf8	 in	
animal	models	results	in	smaller	limbs	and	delayed	Shh	expression	causing	loss	





expression	 in	early	 limb	bud	development	 is	sufficient	 to	specify	the	proximo-
distal	 axis	 but	 the	 proliferative	 expansion	 of	 the	 limb	 bud	 is	 affected[7].	 This	
indicates	early	specification	of	limb	elements[7].		
2.1.4.2 Modelling PD Axis in Limb Development 
Different	models	have	been	proposed	to	explain	PD	outgrowth	and	patterning;	
these	 include	 the	 progress-zone	 model,	 the	 early-specification/expansion	
model,	 the	 two-signal	 model	 and	 the	 differentiation	 model[46-48].	 The	
apparent	 early	PD	patterning	 in	 the	work	described	above,	 in	 addition	 to	 fate	
mapping	 experiments	 in	 chick,	 suggest	 that	 mesenchyme	 in	 the	 PD	 axis	 is	
specified	early	and	the	specified	progenitors	continue	to	proliferate.	This	led	to	
the	 early	 specification/expansion	model.	However,	 there	 are	 no	 characterised	
markers	of	progenitor	specification	to	test	this	hypothesis[49].	
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2.1.4.2.1 Progress-zone Model 
In	 contrast,	 the	 classic	 progress-zone	model	 proposes	 a	 progress-zone	within	
the	 mesenchyme	 beneath	 the	 AER	 containing	 unspecified	 progenitor	 cells	
undergoing	 rapid	 proliferation[50].	 The	 proliferation	 drives	 outgrowth	 of	 the	
limb	bud,	which	moves	the	AER	further	from	the	proximal	limb	mesenchyme[7].	
These	 proximal	 cells	 therefore	 lose	 morphogen	 signals	 from	 the	 AER	 and	
subsequently	 differentiate[7].	 It	 is	 postulated	 that	 the	 time	 of	 exit	 from	 the	
progress	 zone	 determines	 proximo-distal	 identity[7].	 Although	 this	 does	 not	
clearly	explain	 the	possible	early	specification	within	 the	PD	axis,	 it	correlates	
with	the	area	of	proliferation	observed	in	limb	proliferation	assay[18].	
2.1.4.2.2 Two-signal Model 
The	 more	 recent	 two-signal	 model	 proposes	 that	 mutually	 antagonistic	
morphogens	released	from	the	flank	mesenchyme	and	from	the	AER	determine	
the	 PD	 patterning.	 Retinoic	 acid	 (RA)	 is	 secreted	 from	 the	 flank	mesenchyme	
and	FGF	from	the	AER	to	establish	two	gradients[47].	RA	is	reported	to	induce	
Meis1	 and	Meis2	 expression	 and	 thereby	 confer	 proximal	 identity;	 in	 contrast	
AER-FGFs	 induce	 Hoxa11	 and	 Hoxa13	 expression	 and	 establish	 distal	
identity[47].	However,	some	reports	indicate	that	the	expression	of	these	genes	
does	not	overlap	precisely	with	presumptive	PD	skeletal	elements[45].	The	two-
signal	 model	 is	 more	 complex	 than	 the	 progress-zone	 model,	 as	 the	 type	 of	
morphogen	signal,	 in	addition	to,	 its	concentration	and	the	length	of	exposure,	
determines	identity[18].	




AER-FGF	 signalling	 is	 proposed	 to	 modify	 this	 state,	 ensuring	 that	 the	 distal	
limb	 mesenchyme	 remains	 in	 an	 undifferentiated	 proliferative	 state[48].	 The	
differentiating	 front	 is	 the	 region	 seperating	 the	 differentiating	 proximal	 cells	
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and	 the	 dividing	 distal	 cells[48].	 Again	 increasing	 distance	 from	 the	 AER	 and	
thereby	loss	of	AER-FGF	signalling	determines	when	cells	stop	proliferating	and	




2.1.5 Antero-Posterior Axis 
The	 growth	 and	 patterning	 of	 the	 antero-posterior	 axis	 is	 controlled	 by	 Shh;	
SHH	 is	 secreted	 from	 a	 specialised	 signalling	 centre	 in	 the	 posterior	
mesenchyme	known	as	the	Zone	of	Polarising	Activity	(ZPA)[28].	Wolpert	first	
proposed	the	French-flag	model	of	AP	development	prior	to	the	identification	of	
Shh[51-53].	 This	model	 hypothesised	 that	morphogen	 diffusion	 across	 the	 AP	
axis	 would	 specify	 digits,	 with	 distinct	 ranges	 of	 morphogen	 concentration	
determining	digit	 identity.	Since	the	discovery	of	SHH,	 it	has	become	apparent	
that	SHH	has	a	crucial	role	in	the	development	of	the	digits[54,	55].		
2.1.5.1 ZPA and AP Patterning 
The	ZPA	was	identified	by	classical	limb	bud	graft	experiments;	small	regions	of	
ectopic	mesenchyme	were	transplanted	in	the	chick	limb	bud.		Grafting	the	ZPA	
to	 the	 anterior	 limb	 bud	 results	 in	 a	mirror	 image	 polydactyly[56].	 The	 same	
mirror	 image	 duplication	 phenotype	 occurred	 on	 transplantation	 of	 SHH	
producing	cells	too	the	anterior	mesenchyme[57].		
	
AP	 axis	 morphogenesis	 and	 the	 ZPA	 are	 established	 by	 the	 reciprocal	










and	 the	 inhibitory	 receptor	Patched	1	 (PTCH1)[18].	 In	 addition	 increased	Shh	
expression	 inhibits	 the	 conversion	 of	 GLI3	 to	 its	 repressor	 form,	 GLI3R,	
resulting	 in	 an	 accumulation	 of	 the	 GLI3	 activator	 (GLI3A),	 a	 positive	
transcriptional	 regulator	 in	 the	 posterior	 mesenchyme[18,	 62].	 This	 causes	
restriction	 of	 GLI3R	 and	 GLI3A	 to	 the	 anterior	 and	 posterior	 mesenchyme	
respectively[18].	 Genetic	 inactivation	 of	 GLI3	 in	 both	 mouse	 and	 humans	
commonly	results	in	polydactyly,	with	extra	digits	anteriorly	due	to	loss	of	GLI3	
repression.	 	 Futhermore	 SHH	 promotes	 continued	 expression	 of	 5’Hoxd	 and	
Hoxa13	 genes,	which	 are	 involved	 in	 distal	 pattering,	 regulating	 digit	 identity	
and	number[63].	




part	 of	 digit	 3[57].	 Digit	 1	 develops	 independently	 of	 SHH	 signalling;	 this	 is	
regulated	 by	 SALL4,	 TBX5	 and	 HOX	 transcription	 factors.	 Long	 range	 SHH	
signalling	 determines	 digit	 2	 specification	 in	 animal	 models,	 although	 the	
mechanism	 of	 long	 range	 SHH	 signalling	 is	 debated[64].	 It	 has	 recently	 been	
reported	 that	 SHH	 accumulates	 in	 protruding	 actin	 filopodia,	 which	 extend	





digit	2,	5	and	3[7].	However,	 there	 is	discrepancy	 in	animal	models	and	other	
studies	 report	 that	 digit	 5	 is	 formed	 last,	 requiring	 the	 longest	 exposure	 to	
SHH[7].	This	discrepancy	between	models	may	be	due	to	the	different	number	
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of	 digits	 between	 species[7].	 In	 the	 chick	 model,	 inhibition	 of	 SHH	 with	
cyclopamine	 (SHH	 antagonist)	 disrupts	 the	 cell	 cycle	 and	 impairs	 the	
proliferative	expansion	of	the	hand	plate,	with	loss	of	the	posterior	digits[66].	In	
contrast,	 this	 study	 found	 that	 inhibition	of	proliferation	directly	 resulted	 in	a	
transient	 inhibition	 of	 SHH	 and	 loss	 of	 anterior	 digit	 patterning.	 This	 was	
considered	to	be	due	to	exposure	of	the	anterior	hand	plate	to	higher	levels	of	
SHH	as	a	result	of	its	reduced	size;	this	resulted	in	loss	of	SHH	independent	digit	
specification.	 Corroborating	 fate	 mapping	 experiments	 have	 shown	 that	 cells	
that	express	SHH	for	longer	form	more	posterior	digits.	It	 is	hypothesised	that	
other	 factors	 will	 also	 contribute	 to	 digit	 identity	 in	 co-ordination	 with	 SHH	
signalling	but	these	require	further	characterisation[2].	
2.1.6 Whole Limb Bud Morphogen Networks  
Although	the	growth	and	patterning	of	the	PD	axis	and	the	AP	axis	are	discussed	
separately,	 these	 processes	 occur	 concurrently	 and	 there	 is	 considerable	
interaction	between	the	signalling	pathways	involved[18,	66].	The	AER	and	ZPA	




2.1.6.1 SHH-GREM1-FGF Network 
This	 led	 to	 the	 identification	 of	 the	 SHH-GREM1-FGF	 signalling	 network[67].	
SHH	 activates	 GREM1,	 which	 antagonises	 BMP	 signalling;	 this	 results	 in	
upregulation	 of	 AER-FGFs[67].	 The	 feedback	 loop	 is	 completed	 by	 the	
maintenance	of	SHH	expression	by	AER-FGFs[67].	As	the	limb	bud	expands,	SHH	
and	GREM1	expression	domains	grow	apart,	terminating	the	feedback	loop[68].	
Termination	 is	 reinforced	 by	 the	 AER-FGF	 and	 GLI3R	 mediated	 inhibition	 of	




Upregulation	 of	 the	 Cyp26b1	 gene	 by	 SHH	 further	 integrates	 AP	 and	 PD	







These	 interactions	highlight	 the	 importance	of	 considering	 the	AP,	PD	and	DV	
axis	 together	 rather	 than	 as	 distinct	 entities	 (Figure	 2.1)[7].	 Mathematical	






Figure 2.1 An overview of limb bud development[7]. At the initiation of limb bud 
development two areas of signalling are established; the Apical Ectodermal Ridge 
(AER) located in the tip of the ectoderm expressing genes encoding Fibroblast 
Growth Factor (FGFs) and the Zone of Polarising Activity located in the posterior 
mesenchyme producing sonic hedgehog (SHH)[24].  It is postulated that Retinoic 
Acid (RA) confers proximal identity and AER-FGFs, which antagonise RA, induce 
distal cell identity[7].  BMP concentration is initially high in the developing limb and is 
required for AER formation[7]. 1b) Ectodermal WNT (e-WNT) activates FGFs. GLI-3 
restriction of Hand-2 and 5’Hoxd gene expression establishes posterior identity[7]. 
2a) It is been postulated that activation of AER-FGF signalling and ZPA-SHH 
signalling induce PD and AP patterning respectively by creating morphogen 
gradients[7, 24]. Studies indicate that low-level BMP regulates AER length[7]. 2b) 
Digit 1 (thumb) and the radius form in the anterior SHH-independent area. Digit 2 
and part of digit 3 are activated by long range signalling of SHH. The remainder of 
digit 3, digit 4, digit 5 and ulna are formed from the descendants of SHH producing 
cells[7]. BMP concentration is high again and involved in digit identity[7]. 3.  A 
differentiation front has been described which is the boundary between proximal 
cells which are no longer under influence of AER-FGF and WNT signalling and 
differentiate into cartilage (Sox9 expression) and distal cells which remain 
undifferentiated with undetermined AP/PD identity[24].  This is self-regulated by 
AER-FGF, ZPA-SHH and WNT signalling[7].  
 
2.1.7 The Spatiotemporal Expression of Limb Bud Morphogens 
Experiments	 inactivating	 limb	 bud	 genes	 at	 different	 time	 points	 in	 animal	
models	have	highlighted	the	temporal	component	of	limb	bud	development[64].		
SHH	is	initially	required	for	establishing	the	AP	axis,	however	later	it	has	a	role	
in	 the	 proliferation	 of	 specified	 mesenchyme	 progenitors[66].	 BMP4	
(mesenchymal)	and	BMPR1	(ectodermal)	are	 required	 for	development	of	 the	
AER;	inactivation	of	Bmp4/Bmpr1	disrupts	formation	of	the	AER	and	results	in	
truncation	 of	 the	 limb[67].	 In	 contrast,	 conditional	 inactivation	 of	Bmp4	 after	
establishment	 of	 the	 AER	 results	 in	 a	 lengthening	 of	 the	 AER	 and	
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polydactyly[67].	 This	 highlights	 the	 differential	 temporal	 effect	 of	morphogen	
signalling	during	limb	development.		
	
The	precise	 spatio-temporal	 regulation	of	gene	expression	 is	 therefore	 critical	
to	accurate	limb	formation.	Cis-regulatory	modules	(CRM)	play	a	critical	role	in	
governing	gene	expression	in	the	limb	bud[72].	These	CRM,	within	segments	of	
non-coding	 sequence,	 can	 lie	 distant	 to	 the	 gene	 promoter,	 up	 or	
downstream[18].	 Recent	 studies	 have	 shown	 that	 CRMs	 interact	 with	 the	
promoter	through	chromatin	looping[18].	The	CRM	regulating	Shh	in	the	limb	is	
one	of	 the	better-characterised	 enhancers;	 it	 is	 termed	 the	 zone	of	 regulatory	
sequence	 (ZRS)[72].	 Disruption	 of	 the	 ZRS	 can	 lead	 to	 loss	 of	 Shh	 expression,	
such	 as	 in	 the	 ZRS	 mutant	 mouse,	 or	 ectopic	 Shh	 expression,	 such	 as	 in	 the	
Sasquatch	 mouse[72].	 The	 expression	 of	 the	 Hox	 genes	 and	 Fgf8	 are	 also	
regulated	 by	 enhancers,	 which	 act	 via	 chromatin	 loops	 within	 the	 recently	
discovered	topological	chromatin	domain[73].	Further	research	into	these	three	
dimensional	 chromatin	 structures	 and	 their	 regulation	 of	 the	 5’Hox	 genes	 is	
being	undertaken[74].		
2.1.8 DHODH and Limb Development 
Compound	 heterozygous	 mutations	 in	 DHODH	 have	 been	 identified	 in	





of	 43kDA	 and	 is	 395	 amino	 acids	 in	 length[75].	 It	 is	 located	 on	 the	 inner	
mitochondrial	 membrane.	 CAD	 (carbamoyl-phosphate	 synthetase	 2,	 aspartate	
transcarbamylase	 and	 dihydroorotase),	 DHODH	 and	 UMPS	 (uridine	
monophosphate	 synthase)	 catalyse	 the	 six	 enzymatic	 steps	 of	 the	 de	 novo	
pyrimidine	 biosynthesis	 pathway[3].	 	 DHODH	 catalyses	 the	 fourth	 enzymatic	
reaction	 the	 conversion	 of	 dihydroorotate	 to	 orotate[3].	 CAD	 encodes	 a	
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trifunctional	 protein	 that	 catalyses	 the	 first	 three	 enzymatic	 steps	 of	 the	
pyrimidine	biosynthesis	pathway;	UMPs	catalyses	the	final	two	steps[3]	(Figure	
2.2).		
Pyrimidines	 participate	 in	 diverse	 cellular	 processes	 fundamental	 to	 cell	
survival;	 they	 are	 required	 for	 nucleic	 acid	 synthesis,	 uridine	 diphosphate	
(UDP)	sugar	glycosylation	and	formation	of	cytosine	diphosphate	precursors	of	
membrane	 phospholipids.	 Pyrimidine	 may	 be	 derived	 from	 pyrimidine	
scavenging	 or	 de	 novo	 synthesis,	 with	 the	 requirement	 for	 de	 novo	 synthesis	
greater	in	high	pyrimidine	usage	states,	such	as	rapid	proliferation.	
	
DHODH	 was	 the	 first	 Mendelian	 disease	 gene	 identified	 on	 Whole	 Exome	
Sequencing	(WES),	highlighting	the	role	of	Next	Generation	Sequencing	(NGS)	in	
rare	Mendelian	disease	aetiology[1].	Congenital	defects	 in	metabolic	pathways	




Figure 2.2 The de novo pyrimidine biosynthesis pathway. CAD (carbamoyl-
phosphate synthetase 2, aspartate transcarbamylase and dihydroorotase), DHODH 
(dihydro orotate dehydrogenase) and UMPS (uridine monophosphate synthase) 
catalyse the six enzymatic steps of the de novo pyrimidine biosynthesis pathway in 
vertebrates[3].  CAD catalyses the first three reactions resulting in the conversion of 
glutamine to dihydroorotate (DHO)[3].  DHODH is located in the inner mitochondrial 
membrane and catalyses the quinone mediated oxidation of DHO to orotate (orotic 
acid OA). Finally UMP synthase coverts OA to uridine monophosphate (UMP)[3].  
	 36	
2.2 Methods 
2.2.1 Whole mount and tissue in situ hybridization  
2.2.1.1 Primers and DNA Template 
The	 genomic	 sequences,	 of	murine	 genes	 of	 interest,	were	 obtained	using	 the	




forward	 primer	 with	 a	 T7	 RNA	 polymerase	 site	 (TAATACGACTCACTATAGG)	
added	to	the	5’	end	of	the	reverse	primer.	PCR	of	mouse	genomic	DNA	(outbred	
albino	 mouse	 strain	 CD-1)	 was	 performed	 to	 generate	 a	 riboprobe	 DNA	













IGMM)	were	digested	using	Not1,	HindIII	 and	BamH1	respectively	 in	order	 to	





2.2.1.3 Synthesis of DIG-labelled Riboprobe 
Digoxigenin	(DIG)	 labelled	(Roche)	antisense	riboprobes	were	generated	by	 in	
vitro	 transcription	 of	 purified	 riboprobe	 DNA	 template	 using	 T7	 RNA	
polymerase.	Digoxigenin	 (DIG)	 labelled	 (Roche)	Gli1,	Shh,	 and	Ptch1	antisense	
riboprobes	were	generated	by	in	vitro	transcription	of	purified	riboprobe	DNA	
template	using	T3	RNA	polymerase.		
2.2.1.4 Whole mount in situ hybridization  
Mouse	embryos	at	10.5	days	post	stage-coitum	(dpc)	were	dissected	and	fixed	
overnight	 in	 4%	 paraformaldehyde	 at	 4°C.	 Embryos	 were	 then	 dehydrated	
through	a	methanol	series	before	storing	in	100%	methanol	at	-20°C.	Embryos	
to	 be	 used	 for	 in	 situ	 hybridisation	were	 removed	 from	 storage	 at	 -20°C	 and	
brought	 to	 room	 temperature	 through	 the	 addition	 of	 fresh	 100%	methanol.	
Embryos	 were	 then	 subjected	 to	 a	 series	 of	 graded	 methanol	 washes	 until	
rehydrated	in	PBST	(PBS	+	0.1%	Tween	20).		
	
Proteinase	 K	 (10μg/ml)	 (Roche)	 was	 used	 to	 permeabilise	 the	 tissue	 by	
digesting	embryos	for	20	minutes	(optimized	for	developmental	stage	and	batch	
of	proteinase	K).	In	an	effort	to	reduce	non-specific	binding,	embryos	were	then	




Once	 embryos	 were	 washed	 extensively	 in	 PBST	 to	 remove	 any	 traces	 of	
fixative,	 they	 were	 placed	 in	 2ml	 tubes	 with	 a	 little	 PBT	 and	 250μl	 of	 pre-
hybridisation	buffer	warmed	to	60°C,	waiting	until	 the	embryos	had	settled	to	
the	bottom	of	the	tubes.	Fresh	hybridisation	buffer	was	then	added	and	samples	
were	 incubated	 in	 a	 60°C	 water	 bath	 for	 2	 hours	 (with	 regular	 agitation).	












this	 solution	 was	 replaced	 with	 a	 MAB	 +	 2%	 BMB	 +	 20%	 heat	 treated	 lamb	
serum	 solution	 containing	 a	 1/2000	 dilution	 of	 anti-DIG	 antibody	 coupled	 to	
alkaline	 phosphatase	 (Roche)	 and	 left	 overnight	 at	 4°C	 on	 a	 roller.	 Embryos	







macroscope	 and	 then	mounted	 and	 scanned	 using	 a	 Bioptonics	 OPT	 Scanner	
3001	 (Bioptonics,	 UK).	 The	 OPT	 scans	 were	 reconstructed	 using	 Bioptonics	
proprietary	 software	 (Bioptonics,	 MRC	 Technology,	 Edinburgh,	 UK)[76].	 The	
images	were	 thresholded	 and	merged	 to	 a	 3D	 image	 output	 using	 Bioptonics	
Viewer	software.		
2.2.2 Immunohistochemistry  
Slides	with	 20µM	 transverse	 sections	 of	 10.5	 dpc	 CD1	 albino	mouse	 embryos	
were	prepared	as	below	 in	 the	 section	on	 tissue	preparation	 for	 tissue	 in	 situ	
hybridisation.	The	parameter	of	 the	slides	was	drawn	around	with	a	PAP-pen.	
Slides	were	placed	in	a	Coplin	jar	and	washed	three	times	with	PBG	solution	pH	
7.4	 (gelatine,	 glycerol,	 BSA).	 The	 slides	 were	 preincubated	 with	 PBG	 for	 20	




pH	7.4.	 The	 slides	which	 had	 been	 incubated	with	 a	mouse	 primary	 antibody	
were	incubated	with	anti-mouse	secondary	antibody	conjugated	with	Alexa	594	
for	 60	minuutes.	 The	 slides	which	 had	 been	 incubated	with	 a	 rabbit	 primary	





times	 in	 dH20.	 Slides	 were	 mounted	 with	 20	 µl	 of	 Vectashield®	 containing	
4,6'diamidino-2-phenylindole	 (DAPI,	 blue)	 and	 coverslips.	 Slides	were	 imaged	
at	5x	and	10x	magnification	using	 the	Discovery	microscope	with	appropriate	
filters;	 488,	 594	 and	 461	 for	 FITC,	 Texas	 red	 and	DAPI	 blue	 respectively.	 For	
colorimetric	 immunohistochemistry	 the	 same	 protocol	 was	 followed	 up	 the	
blocking	 step	at	which	point	 the	Vectastain	ABC	protocol	was	 followed	as	per	
the	 manufacturer’s	 instructions.	 The	 substrate	 used	 was	 DAB	 (Vector	
Laboratories)	and	slides	were	mounted	in	Vectashield	(Vector	Laboratories).	
2.2.3 Three Dimensional Computational Mapping 
2.2.3.1 Creating Reference Data 
OPT	derived	3D	reference	data	were	imported	into	Amira	(FEI,	Oregon,	USA)	for	
processing.	 Amira	 was	 used	 to	 visualise,	 crop	 and	 clean	 data	 to	 the	 relevant	




(Bill	Hill,	 IGMM,	 Edinburgh)	was	 firstly	 used	 to	 convert	 .am	 files	 to	NIFTI	 file	
format	 (.nii),	 and	 these	 data	 were	 then	 read	 into	 ITK-Snap	 (University	 of	
Pennsylvania,	USA).	 This	 free	 software	was	used	 to	 create	 a	 smoothed	binary	
contour	object	based	on	the	grey-level	object	which	were	then	saved	as	binary	
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.nii	 files.	 The	 free	 software	 Netgen	 (Joachim	 Schöberl,	 Vienna	 University	 of	
Technology,	Austria),	was	then	used	to	generate	the	tetrahedral	mesh	based	on	




within	 the	 IGMM	 and	 available	 from	 https://github.com/ma-tech.	 All	 steps	 in	
generating	these	objects	were	done	on	workstations	running	Linux	(SuSE).	
2.2.3.2 Warping Multiple Experimental Data Onto Reference Objects 
Whole	mouse	embryo	RNA	in	situ	hybridisation	data	scanned	by	OPT	and	saved	
in	 Woolz	 file	 format	 were	 read	 into	 WlzWarp	 (Bill	 Hill	 &	 Zsolt	 Husz,	 IGMM,	
Edinburgh),	 a	 graphical	 user	 interface	 that	 allows	 interactive	warping	 (elastic	
deformation)	 of	 source	 (experimental)	 data	 onto	 a	 target	 (reference)	 object	
using	 the	constrained	distance	 transform[77].	This	 is	accomplished	by	placing	
pair-wise	points	of	equivalence	between	source	and	target	while	WlzWarp	uses	
the	target	mesh	created	earlier	to	warp	the	grey-level	object.	OPT	scans	of,	for	
example,	 NBT/BCIP	 stained	 WISH	 data	 are	 scanned	 twice,	 once	 to	 capture	
anatomy	 from	 autofluorescence	 and	 once	 to	 capture	 the	 gene	 expression	
staining.	 The	 former	 is	 used	 to	 place	 points	 of	 equivalence	 while	 the	 same	
points	 can	 then	 be	 used	 to	 create	 the	warp	 of	 the	 gene	 expression	 data.	 Any	






2.2.4 Whole Mount Immunohistochemistry  




dehydrated	 on	 ice	 through	 a	methanol	 series,	 15	minutes	 for	 each	 step;	 25%	
methanol/PBS,	 50%	 methanol/PBS,	 75%	 methanol/PBS,	 100%	 methanol.	
Embryos	were	then	bleached	and	blocked	in	methanol:30%	hydrogen	peroxide	
(5:1)	 for	 90	 minutes	 at	 4oC	 with	 agitation.	 Embryos	 were	 washed	 in	 100%	
Methanol	 for	10	minutes	at	4oC.	The	embryos	were	rehydrated	on	 ice	through	
75%	 methanol/25%	 PBS,	 50%	 methanol/PBS,	 25%	 methanol/75%	 PBS,	
0/1%Triton	 X-100/PBS	 for	 15	 minutes	 for	 each	 step.	 The	 embryos	 were	
washed	 twice	 in	PBSST	 (5%	 sera,	 0.1%	Triton	 in	PBS)	 for	 1	 hour	 at	 4oC	with	
agitation.	Primary	antibodies	were	diluted	in	in	PBST	and	incubated	O/N	at	4oC	
with	 agitation	 for	2	nights.	 	A	negative	 control	with	no	primary	antibody	was	
included.	The	antibodies	were	washed	out	with	PBSST,	two	15minute	washes	at	
room	 temperature	 (RT)	 followed	 by	 five	 1hour	washes	 at	 4oC	with	 agitation.	
The	 secondary	biotin	antibodies	were	diluted	 in	 in	PBSST	and	 incubated	with	
the	embryos	O/N	at	4oC	with	agitation.	The	antibodies	were	washed	out	with	
two	 15minute	washes	 at	 RT,	 followed	 by	 5	 times	 1	 hour	washed	 at	 4oC	with	





were	 then	 washed	 in	 PBT	 (0.2%	 BSA,	 0.1%	 Tween-20	 in	 PBS).	 For	 HRP	
detection	 embryos	 were	 incubated	 in	 0.3mg/ml	 DAB	 in	 PBT	 for	 20	 minutes.	
Hydrogen	peroxide	0.03%	was	added	and	embryos	were	incubated	for	a	further	
10	minutes.	The	embryos	were	 rinsed	4	 times	with	PBS	and	post	 fixed	 in	4%	
PFA	for	1	hour	at	RT.	Embryos	were	then	cleared	as	above	a	final	time.		
2.2.5 Tissue in situ hybridisation 
2.2.5.1 Tissue section in situ pre-hybridisation and hybridisation solutions  
10.5	dpc	albino	CD-1	mice	embryos	were	dissected	from	the	uterus	and	rinsed	
in	 PBS.	 They	were	 fixed	 in	 4%	 paraformaldehyde	 for	 one	 hour.	 The	 embryos	
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were	then	cryoprotected	by	being	incubated	overnight	(O/N)	in	5%	sucrose	at	
4oC.	 The	 following	 day	 they	were	 incubated	 in	 20%	 sucrose	 at	 RT	 until	 they	
sank	 (2-3	 hours).	 The	 embryos	 were	 placed	 in	 optimal	 cutting	 temperature	
compound	(OCT)	at	room	temperature	to	remove	excess	sucrose	(20	mins)	and	
then	 embedded	 in	OCT	 in	plastic	moulds	 on	dry	 ice	 (30	minutes).	 The	plastic	
moulds	 containing	 the	 OCT	 block	 embedded	 with	 the	 embryo	 were	 then	
wrapped	in	aluminium	foils	and	placed	in	a	sealed	box	and	stored	at	-80oC.		
	
All	 equipment	was	 cleaned	using	ETOH.	The	embryos	embedded	 in	OCT	were	





(RNAse	 free	 –	baked	 for	4	hours).	 	All	 solutions	were	made	using	0.1%	DEPC	
sterile	water/Ultrapure	RNAse/DNAse	free	water	or	0.1%	DEPC	PBS.	Solutions	
were	made	up	in	numbered	50	ml		Falcon	tubes.	Washes	and	incubations	were	
carried	 out	 at	 RT,	 unless	 otherwise	 stated.	 6.7	 ml	 of	 98%	 Triethanolamine	





Heparin	 (20	mg/ml);	 and	 10	ml	 ultrapure	H2O.	 A	 sealed	 plastic	 hybridisation	
chamber	was	designed	to	fit	the	hybridisation	oven	and	constructed	by	the	MRC	




**Hybridisation	 Solution:	 Aliquots	 of	 hybridization	 buffer	 were	 preheated	 to	
85oC	 for	 15	 min	 on	 the	 hot	 block.	 	 	 The	 riboprobe	 was	 added	 to	 the	















1	 PBS	 RT	 5	min	
2	 PBS	 RT	 5	min	
3	 0.2	M	HCl	 RT	 10	min	
4	 PBS	 RT	 5	min	
5	 PBS	 RT	 5	min	
6	 0.1	M	TEA	 RT	 1	min*	
7	




0.1	 M	 TEA	 +	 acetic	
anhydride	
RT	 10	min*	








11	 30%	EtOH	 RT	 2	min	
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12	 50%	EtOH	 RT	 2	min	
13	 70%	EtOH	 RT	 2	min	
14	 90%	EtOH	 RT	 2	min	
15	 100%	EtOH	 RT	 2	min	
16	 100%	EtOH	 RT	 2	min	


















and	 stored	 in	 aliquots	 at	 –20oC	 and	 working	 solutions	 (1x)	 were	 made	 by	




Levamisole	 (800µl	 of	 125	 mM)	 was	 added	 to	 50	 ml	 TBST	 to	 a	 final	
concentration	of	2mM.		








1	 5x	SSC	(remove	parafilm)	 60oC	 5	min	
2	 2x	SSC/50%	formamide	 60oC	 20	min	
3	 TNE	 RT	 10	min	
4	 TNE	 37oC	 10	min	
5	 TNE	+	RNase	A	 37oC	 35	min	
6	 TNE	 RT	 10	min	
7	 TNE	 RT	 10	min	
8	 2x	SSC	 60oC	 15	min	
9	 2x	SSC	 60oC	 15	min	
10	 0.2x	SSC	 60oC	 15	min	
11	 0.2x	SSC	 60oC	 15	min	
12	 1x	TBST	 RT	 15	min	
13	 Dry	slides	 -	 -	
14	 1x	Blocking	Reagent	 RT	 1	h	
15	 Anti-DIG-AP	(1:2000)	 RT	 1	h	
16	 1x	TBST	+	Levamisole	 RT	 15	min	
agitation	
17	 1x	TBST	+	Levamisole	 RT	 15	min	
agitation	
18	 APB	Buffer	 RT	 15	min	
agitation	





20	 Ultrapure	H20	 RT	 5	mins	








2.2.6 Western blotting 
SDS	 PAGE	 protein	 separation	 was	 used	 to	 analyse	 protein	 expression	 and	
quantification.	 Cells	 were	 lysed	with	 radioimmuno-precipitation	 assay	 (RIPA)	
buffer.	 Micro	 Bicinchoninic	 Acid	 (BCA)	 protein	 assay	 kit	 was	 used	 as	 per	
manufacturers	 instructions	 for	 protein	 quantification	 with	 absorbance	
measured	at	562nm	on	a	BP800	spectrophotometer.	20μg	of	protein	from	each	
sample	was	made	up	to	equal	volume	with	RIPA	buffer	prior	to	addition	of	6X	









Membranes	 were	 blocked	 with	 5%	 milk/TBST	 for	 60	 minutes	 with	 gentle	
agitation.	Membranes	were	 then	washed	three	 times	 in	TBST	(10	minutes	per	
wash).	Membranes	were	probed	with	a	primary	antibody	 in	2%	BSA/TBST	at	
appropriate	 concentrations	 (see	 table)	 at	 4°C	 overnight,	with	 gentle	 agitation.	
The	antibody	was	removed	and	the	membranes	washed	again	three	times	with	
TBST	 (5	 minutes	 per	 wash).	 Mouse	 or	 rabbit	 HRP-conjugated	 secondary	
antibody	 (1:5000)	 in	 2%	 BSA/TBST	 was	 used	 for	 detection.	 Enhanced	
chemiluminescence	(ECL	protocol)	as	per	manufacturers	instructions	was	used	
for	visualisation.	1ml	of	ECL	solution	 (1:1	mixture	solution	A:	 solution	B)	was	
pipetted	 on	 to	 the	 protein	 side	 of	 the	 membrane	 and	 incubated	 at	 room	
temperature	 for	 1	minute.	 The	membrane	was	 blotted	 to	 remove	 excess	 ECL	
solution	and	wrapped	in	saran	film	and	transferred	to	the	radiograph	box.	The	




washing	 membranes	 were	 reprobed	 with	 a	 second	 primary	 antibody,	 alpha-
tubulin	control	(1/25000)	in	2%	BSA	TBST	as	described	above.	
2.2.7 Quantitative Real Time PCR method (qRT-PCR) 
The	RNA	was	extracted	using	an	RNeasy	Plus	kit	as	per	manufacturers	protocol	
(Qiagen).	1μg	of	each	 individual	RNA	was	reversed	 transcribed	 to	cDNA	using	
random	 primers	 p(dN)6	 and	 AMV	 Reverse	 Transcriptase	 from	 a	 First	 strand	
cDNA	 synthesis	 kit	 according	 to	manufacturers	 instructions	 (Roche).	 A	 1/100	
dilution	of	completed	cDNA	reaction	was	used	as	a	template	for	qRT	PCR	using	
mouse	Actb	and	Gapdh	as	control	housekeeping	genes.	Intron-spanning	primers	
were	designed	using	 the	Primer	3	 software	 (http://frodo.wi.mit.edu).	None	of	
the	 primers	 amplified	 a	 product	 with	 a	 genomic	 DNA	 template.	 Real-time,	
quantitative	 fluorescent	PCR	was	performed	 in	 triplicate	using	the	LightCycler	




for	 10	 seconds,	 60°C	 for	 20	 seconds	 	 and	 72°C	 for	 10	 seconds.	 Quantification	
was	performed	in	triplicate	on	the	individual	cDNA	samples	and	normalized	to	
Actb	 RNA	 measurements	 using	 Ct	 values	 exported	 from	 the	 real-time	 PCR	
instrument.	
2.2.8 Fluorescence activated flow cytometry (FAC) 












15	 minutes	 at	 room	 temperature.	 10	 mls	 of	 PBS-EDTA	 (final	 concentration	
1mM)	 was	 added	 to	 the	 cells.	 The	 cells	 were	 then	 pelleted	 and	 supernatant	
discarded.	PBS-EDTA	wash	was	repeated	a	further	time.	The	cells	were	blocked	
with	 1ml	Antibody	Buffer	 (49.5ml	 PBS,	 1g	BSA	+	 500μl	 10%	Triton	 X)	 added	
dropwise	 on	 the	 vortex	 and	 incubated	 for	 30	 minutes	 at	 room	 temperature.	
Cells	were	pelleted	and	supernatant	carefully	discarded	by	pouring.	The	pellet	
was	resuspended	in	100	μl	anti-BrdU	(1:75	with	antibody	buffer)	and	incubated	
for	 30	minutes	 at	 room	 temperature.	 The	 cells	 were	 washed	with	 PBS-EDTA	
(1mM)	as	above.	The	pellet	was	resuspended	in	100	μl	anti-rat	Alexa	488	(1:200	
with	antibody	buffer)	and	incubated	for	30	minutes	at	room	temperature.	The	
cells	were	washed	 in	PBS-EDTA	(1mM).	The	cells	were	 finally	 resuspended	 in	
PBS-EDTA	containing	0.1mg/ml	RNAse	A	and	50	µg/ml	propidium	iodide	for	60	
min,	 at	 4oC	 in	 the	 dark.	 Cell	 sorting	 was	 performed	 on	 a	 FACScalibur	 (BD	
Biosciences)	by	Elizabeth	Freyer,	MRC	HGU.	
2.2.9 Generating Limb Bud Cell Line	
Immortomuse	embryos	were	harvested	and	the	tails	tips	taken	for	genotyping.	
The	 tails	 tips	 were	 incubated	 in	 50ul	 of	 NaOH	 at	 850C	 for	 95	 minute.	 The	
eppendorfs	containing	the	tail	tips	and	the	NaOH	were	centrifugedand	placed	on	
ice.	50ul	of	trizma	was	added	and	stored	at	-200C	until	ready	for	genotying	PCR.	
The	 embryos	 were	 secured	 on	 an	 agarose	 plate	 using	 a	 fine	 tungsten	 wire.	
Catarct	scissors	were	used	to	remove	the	limb	bud	tip.	The	tissue	was	placed	in	
a	96	well	plate	and	gently	dispesed	with	a	pastette.	Cell	were	cultured	in	DMEM	
(10%	 FCS,	 1%	 penstrep)	 with	 the	 addition	 of	 IFNϒ	 (Interferom	 gamma	






2.2.10 Whole Mount Immunohistochemistry 
Pregnant	 CD1	 mice	 were	 injected	 with	 100mg/kg	 of	 EdU.	 Embryos	 were	
harvested	2	hours	post	injection	and	EdU	was	visualised	using	the	Click-iT	Alexa	




Triton	 X-100/PBS	 for	 20	 minutes	 at	 RT.	 The	 embryos	 were	 washed	 in	 3%	
BSA/PBS	twice	for	3	minutes	at	RT.	The	Click-iT	reaction	cocktail	was	prepared	
as	 per	 the	 manufacturer’s	 protocol	 (C10339,	 Thermoscientific)	 The	 reaction	
contains	1xClick-iT	EdU	reaction	buffer,	CuS04,	alexa	fluor	594	azide,	1xClick-iT	
EdU	 buffer	 additive.	 The	 embryos	 were	 incubated	 in	 the	 dark	 at	 RT	 for	 30	
minutes	 in	 this	 reaction	 cocktail.	 The	 reaction	 cocktail	 was	 removed	 and	 the	
embryos	were	washed	well	 in	3%	BSA/PBS.	They	were	then	washed	a	 further	
time	 in	 1xPBS.	 Embryos	 were	 incubated	 in	 Hoeschst	 33342	 solution	 for	 30	
minutes	 at	 RT	 in	 the	 dark.	 Embryos	 were	 washed	 well	 twice	 in	 1ml	 of	 PBS.	









Mutations	 within	DHODH	 have	 recently	 been	 identified	 in	 the	 developmental	
disorder	Miller	syndrome[1].	This	syndrome,	also	termed	Post-axial	Acrofacial	
Dysostosis	(POADS),	is	characterized	by	craniofacial	and	limb	anomalies[3].	The	
limb	 defects	 primarily	 comprise	 post-axial	 longitudinal	 limb	 reduction	
deformities	 (PALLRD),	with	 loss	of	 the	 fifth	 ray	 in	all	 four	 limbs.	This	 chapter	
describes	 work	 that	 aimed	 to	 investigate	 the	 role	 DHODH	 plays	 in	 limb	 bud	
development	 and	 in	 doing	 so	 identify	 the	 mechanisms	 underlying	 the	 limb	
reduction	deformity	observed	in	individuals	with	Miller	Syndrome.	
2.3.1 DHODH expression pattern in the developing limb  
Numerous	 pathways	 are	 engaged	 in	 limb	 development	 and	 these	 require	
precise	 temporal	 and	 spatial	 regulation[7].	 These	 pathways	 control	 the	 two	





during	 embryonic	 development	 and	 particularly	 within	 the	 limb	 bud.	 Work	
within	the	FitzPatrick	group	demonstrates	that	the	mutations	in	DHODH	found	
in	Miller	 syndrome	 impair	 function	of	 the	enzyme;	 this	was	undertaken	using	
yeast	complementation	assays[3].However,	this	impairment	in	DHODH	function	
does	not	lead	to	widespread	anomalies	and	defects	are	primarily	localized	to	the	
limb	 and	 craniofacial	 structures.	 Given	 the	 universal	 requirement	 for	
pyrimidine,	 this	 requires	 interrogation.	No	previous	 studies	 have	 investigated	
the	 localization	 of	 DHODH	 during	 development.	 I	 therefore	 aimed	 to	 assess	
whether	DHODH	expression	was	localized	to	similar	regions	in	the	embryo.	
	
To	 undertake	 this	 work,	 I	 used	 two	 distinct	 methods	 to	 confirm	 DHODH	
localization:	 in	 situ	 hybridization	 and	 immunohistochemistry.	 Both	 methods	
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were	performed	in	murine	embryos	collected	at	day	9.5	to	day	11.5	post	coitum	
(E9.5	 to	 E11.5).	 This	 is	 the	 period	 that	 encapsulates	 limb	 outgrowth,	 from	
primitive	limb	bud	to	early	specification.		In	situ	hybridization	was	used	in	both	
whole	 embryos	 and	 tissue	 sections.	 The	 whole	 embryo	 in	 situ	 hybridization	
(WISH)	provided	better	 signal	 than	 the	 tissue	section;	 the	 reason	 for	 this	was	
unclear	but	may	have	occurred	due	the	additional	preparation	required	or	the	
different	 hybridization	 protocols	 used	 in	 each	 technique.	 This	 demonstrates	
expression	of	Dhodh	in	the	distal	limb	bud	mesenchyme,	with	localization	in	the	
mesenchyme	underlying	the	AER.	Figures	show	embryos	at	E10.5	but	WISH	was	
also	 undertaken	 at	 E9.5	 and	 E11.5	 (Figure	 1.3).	 These	 demonstrate	 a	 similar	
expression	pattern.		
	
Immunohistochemistry,	 using	 both	 colorimetric	 and	 fluorescence	 detection,	
was	 also	 undertaken.	 For	 this	 two	 DHODH	 antibodies	 were	 obtained	 and	
staining	protocols	performed	on	tissue	sections.	Both	antibodies	were	reported	
to	 work	 on	 tissue	 sections,	 although	 only	 one	 had	 been	 used	 in	 published	
work[78].	 The	 antibodies	 were	 generated	 using	 human	 DHODH	 but	 the	
antigenic	 sequence	 used	with	 the	 Sigma	 antibody	 showed	100%	homology	 to	
murine	DHODH	on	NCBI	Protein	BLAST.	The	localization	of	DHODH	was	similar	
with	both	antibodies,	 in	both	 immunohistochemistry	 techniques,	and	matched	
that	observed	on	WISH	(Figure	2.3).	Therefore	 localization	of	DHODH	appears	
consistent	 using	 both	 in	 situ	 hybridization	 and	 immunohistochemistry,	
corroborating	 this	 finding.	 Negative	 controls	 in	 both	 methods	 did	 not	
demonstrate	 specific	 secondary	 staining.	 Furthermore,	 WISH	 showed	
expression	of	Dhodh	 in	 the	pharyngeal	arches,	consistent	with	 the	craniofacial	











Figure 2.3 Expression of Dhodh and DHODH in the developing mouse forelimb 
bud at 10.5 dpc.  A. Whole mount in situ hybridisation to Dhodh using antisense 
3’UTR riboprobe to Dhodh. The macroscopic image of the developing mouse 
forelimb (Theiler stage TS17, 10.5 d.p.c.)  shows Dhodh expression in the 
mesenchyme proliferating progress zone beneath the Apical Ectodermal Ridge 
(AER). The chromogenic substrate BM purple was used to stain Dhodh expression 
purple. B. Coronal digital section of an Optical Projection Tomography (OPT) image 
of Dhodh expression detected by WISH on mouse forelimb TS17, 10.5 d.p.c. Dhodh 
expression is indicated in purple in the mesenchyme immediately proximal to the 
AER. The OPT images are automatically thresholded and merged to a 3D image 
output using Bioptonics Viewer software. Images were then sectioned using Image J 
software and expression demonstrated in purple.  DHODH immunofluorescence  
(C) and immunohistochemistry (D), in the developing mouse forelimb TS17, 10.5 
d.p.c. illustrated DHODH expression in mesenchyme proximal to AER. Scale bar 
200µm. 
	
2.3.2 DHODH and proliferation 
In	 resting	 cells,	 pyrimidine	 requirements	may	 be	met	with	 use	 of	 pyrimidine	




and	 patterning	 are	 closely	 associated	 in	 limb	 bud	 development,	 with	 models	
proposing	 limb	patterning	 is	dependent	on	adequate	proliferation	 [7,	24].	The	
localization	of	DHODH	in	the	mesenchyme	beneath	the	AER	indicates	that	 it	 is	
expressed	 within	 the	 progress	 zone	 in	 proliferating	 cells.	 This	 would	 be	
consistent	 with	 the	 requirement	 for	 de	 novo	 pyrimidine	 synthesis	 in	
proliferating	 cells.	 Our	 laboratory	 hypothesized	 that	 DHODH	may	 affect	 limb	
development	and	patterning	primarily	through	defects	 in	proliferation.	To	test	
this	 hypothesis,	 it	 was	 first	 important	 to	 confirm	 the	 expression	 of	Dhodh	 in	
proliferating	cells.	
	
To	determine	proliferating	 cells,	 I	 chose	 three	distinct	markers;	 all	 have	been	
used	 in	 published	 studies	 and	 are	 validated	 to	 discern	 proliferating	 cells.	
Proliferating	Cell	Nuclear	Antigen	(PCNA)	is	a	36kD	polypeptide	associated	with	
cell	 proliferation;	 it	 correlates	 closely	 with	 BrdU	 staining[8].	 N-Myc	 is	 a	
transcription	factor	that	drives	proliferation[9].	Phosphorylation	of	histone	H3	
at	 serine	 10	 occurs	 during	 mitosis	 and	 is	 recognized	 to	 discriminate	
proliferating	cells.	WISH	was	undertaken	for	Dhodh,	Pcna	and	Nmyc	using	E10.5	
murine	 embryos;	 the	 experiment	 was	 repeated	 in	 triplicate	 to	 confirm	
expression	 patterns	 (Figure	 2.4).	 Optical	 projection	 tomography	 (OPT)	 was	
used	 to	 image	 each	 embryo.	 OPT	 is	 a	 technique	 developed	within	 the	 unit	 to	
allow	 the	 three-dimensional	 capture	 of	 image	 data[80].	 This	 enables	 the	
accurate	localization	of	gene	expression	within	the	whole	embryo.	OPT	images	
demonstrated	 similar	 expression	 patterns	 for	 each	 of	 the	 three	 genes,	 with	
expression	 in	the	pharyngeal	arches,	 forelimb	and	hindlimb	(Figure	2.4).	 	This	
appears	 to	 confirm	 the	 co-localisation	 of	Dhodh	 and	 proliferating	 cells.	 Again,	






Figure 2.4 Expression of Dhodh and proliferation markers Nmyc and Pcna in 
the developing mouse embryo at Theiller stage 17, 10.5 dpc. Optical Projection 
Tomography (OPT) images of whole mount in situ hybridization showing Dhodh, 
Nmyc, and Pcna expression (blue) in mouse embryo Theiller Stage 17, 10.5 dpc. 
The OPT images are automatically thresholded and merged to a 3D image output 
using Bioptonics Viewer software. Images were then viewed and sectioned using 
AMIRA software and expression demonstrated in blue. The top panel shows lateral 
3D OPT, with digital transverse and coronal sections demonstrating Dhodh 
expression in the eye, fronto-nasal process, somites, pharyngeal arches, forelimbs 
and hindlimbs. The middle panel shows lateral 3D OPT, with digital transverse and 
coronal sections demonstrating Nmyc expression in the pharyngeal arches, 
forelimbs and hindlimbs. The bottom panel shows lateral 3D OPT, with digital 
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transverse and coronal sections demonstrating Pcna expression in the eye, somites, 
pharyngeal arches, forelimbs and hindlimbs. 
	
	
To	 confirm	 these	 findings,	 immunohistochemistry	 of	 tissue	 sections	 was	
performed	 using	 phospho-histone	 H3	 antibody.	 Despite	 manipulating	
experimental	 conditions,	 immunohistochemistry	 failed	 to	 give	 satisfactory	




multiple	 riboprobes;	 this	 enabled	 the	 expression	 of	 several	 mRNAs	 to	 be	
analysed	within	 the	 single	 embryo[80].	 I	 envisaged	 that	 this	 technique	might	
allow	 confirmation	 of	 the	 co-expression	 of	 Dhodh	 and	 proliferative	 genes.	
Reagents	 were	 obtained	 from	 the	 authors	 and	 the	 protocol	 attempted.	
Unfortunately,	 I	was	unable	 to	 replicate	 the	 success	of	 the	paper	and	was	not	
able	to	verify	co-localisation.		
2.3.2.1 Mapping of the Expression 
To	determine	more	precisely	the	comparative	 localization	of	Dhodh,	Nmyc	and	




The	 three	 dimensional	 images	 of	 gene	 expression	 were	 mapped	 on	 to	 the	
reference	 limb	 using	 AMIRA	 software	 and	 in	 house	 Wlz	 Warp	 software	 (Bill	
Hill);	 this	 technique	 has	 been	 used	 previously	 to	 study	 embryonic	 gene	
expression[81].	The	ability	 to	collate	 the	genes	expression	pattern	 from	WISH	











Figure 2.5 Comparison of expression patterns of Dhodh and Proliferation 
Marker Nmyc in Mouse Limb Bud Theiller Stage 17, 10.5 dpc. Mapped gene 
expression onto reference mouse fore and hind limb buds, Theiller stage 17, 10.5 
dpc. All gene expression data is derived from 3D OPT images of whole mount in situ 
hybridization (BM purple). The top panel demonstrated digital sagittal sections of the 
reference mouse forelimbs and the bottom panel shows digital sagittal sections of 
the reference mouse hind limbs; Dhodh expression is shown in blue, Nmyc 




Figure 2.6 Comparison of expression patterns of Dhodh and Proliferation 
Marker Pcna in Mouse Limb Bud Theiller Stage 17, 10.5 dpc. Mapped gene 
expression onto reference mouse fore and hind limb buds, Theiller stage 17, 10.5 
dpc. All gene expression data is derived from 3D OPT images of whole mount in situ 
hybridization (BM purple). The top panel demonstrates digital sagittal sections of the 
reference mouse forelimbs and the bottom panel shows digital sagittal sections of 
the reference mouse hind limbs Dhodh expression is shown in blue, Pcna 
expression is shown in red and the overlap is purple/magenta. Scale bar 300µm. 
	
	
2.3.2.2 Proliferation Assays in Developing Mouse Limb 
The	 incorporation	 of	 BrdU	 into	 the	 DNA	 of	 proliferating	 cells	 constitutes	 the	
gold	standard	in	assays	of	proliferation.	Unlike	the	static	proliferative	markers	
described	 above	 that	 provide	 an	 indirect	 gauge	 of	 proliferation,	 BrdU	
incorporates	 into	 proliferating	 cells	 in	 vivo[82].	 However,	 there	 are	
disadvantages	 to	 the	 use	 of	 BrdU	 in	 whole	 embryos.	 The	 detection	 of	 BrdU	
incorporation	 necessitates	 denaturation	 of	 DNA	 and	 subsequent	 labelling	 by	
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antibody[82].	 The	 denaturation	 process	 destroys	 many	 cellular	 epitopes	 and	
achieving	antibody	penetration	can	be	difficult	due	to	its	size[82].		
	
EdU	 acts	 in	 a	 similar	 manner	 to	 BrdU,	 incorporating	 into	 the	 DNA	 of	
proliferating	 cells;	 both	 represent	 synthetic	 nucleoside	 analogs	 of	 thymidine.	
However,	the	EdU	Click-iT	TM	system	(Invitrogen)	allows	detection	of	EdU	with	
a	copper	catalyzed	cycloaddition	reaction	between	the	terminal	alkyne	group	of	
EdU	 and	 a	 fluorescently	 labeled	 azide.	 This	 requires	 neither	 denaturation	nor	
antibody	 detection,	 with	 their	 inherent	 disadvantages.	 EdU	 has	 been	 used	 to	
assay	 proliferating	 cells	 in	 the	 chick	 embryo	 but	 had	 never	 been	 used	 in	 the	
mouse	embryo[83].	I	collated	methods	of	both	EdU	use	in	the	chick	embryo	and	
previous	BrdU	labeling	of	the	murine	embryo	to	develop	a	protocol	for	EdU	use	
in	 murine	 embryos[83],[84].	 This	 involved	 intraperitoneal	 administration	 of	
EdU	to	the	mother	and	subsequent	collection	of	embryos	at	four	hours;	similar	
and	 shorter	 time	 courses	 have	 been	 reported	 using	 BrdU	 in	 the	 murine	
embryo[84],[85].	The	EdU	Click-iT	TM	system	was	used	to	label	whole	embryos.	
This	 does	 demonstrate	 incorporation	 of	 EdU	 into	 cells	 within	 the	 developing	
limb	but	the	signal	is	substantially	weaker	than	in	internal	viscera	(Figure	2.7).	





is	 likely	 to	 be	 due	 to	 problems	 with	 consistent	 EdU	 penetration[86].	
Intraperitoneal	 injection	 of	 EdU	 relies	 on	 haematogenous	 spread	 into	 the	
developing	embryo;	the	vascular	structure	at	E10.5	are	rudimental	and	do	not	
extend	 into	 the	distal	 limb	bud[87].	 Further	 optimization	of	 the	protocol	may	
enable	 more	 reliable	 labeling	 of	 the	 limb	 bud,	 although	 the	 quantity	 of	 EdU	
required	for	injection	makes	this	costly.	
	
In	 summary,	 this	 work	 provides	 evidence	 that	 Dhodh	 is	 expressed	








Figure 2.7 Expression of Dhodh and proliferation marker EdU in the 
developing mouse embryo at Theiller stage 17, 10.5 dpc. Top panel shows OPT 
images of whole mount in situ hybridization demonstrating Dhodh expression in 
blue. The OPT images are automatically thresholded and merged to a 3D image 
output using Bioptonics Viewer software. Images were then viewed and sectioned 
using AMIRA software and expression demonstrated in blue. Lateral 3D OPT, digital 
transverse and coronal sections demonstrate Dhodh expression in the eye, fronto-
nasal process, somites, pharyngeal arches, forelimbs and hindlimbs. The bottom 
panel shows whole mount labelling of mouse embryo Theiller Stage 17, 10.5 dpc 
with EdU, blue represents EdU positive cells. EdU is positive in the developing 
internal organs including heart and intestine as well as weak signal in the somites, 




Figure 2.8 Comparison of expression patterns of Dhodh and Proliferation 
Marker EdU in Mouse Limb Bud Theiller Stage 17, 10.5 dpc. Mapped gene 
expression onto reference mouse fore and hind limb buds, Theiller stage 17, 10.5 
dpc. The top panel demonstrated digital sagittal sections of the reference mouse 
forelimbs and the bottom panel represents digital sagittal sections of the reference 
mouse hind limbs Dhodh expression is shown in blue, EdU positive tissue is shown 
in red and the overlap is purple/magenta. Scale bar 300µm. 
 
Figure 2.9 RT-PCR to detect the expression of mesenchymal (Etv4, Etv5 and 




Figure 2.10 Western Blot demonstrating downstream signalling in 
immortomouse limb bud cell line on stimulation with BMP2 or basic FGF.  The 
top Western Blot demonstrates DHODH, 51kDa, is present in HEK293, 3T3 and 
Immortomouse limb bud cell lines. The immortomuse limb bud cell lines were 
incubated with growth factors (in serum free media) for 30 minutes prior to protein 
extraction and western blot analysis with antibodies against pSMAD and pERK, 
downsteam markers of BMP and FGF signalling pathways. This demonstrated that 
the limb bud cell line was responsive to these morphogens.  
	
	
2.3.3 Generating a Limb bud cell line 
In	 order	 to	 investigate	 the	 requirement	 of	 DHODH	 in	 proliferating	 cells,	 I	
decided	to	study	the	effects	of	Dhodh	inhibition	in	vitro.	To	do	this,	I	required	an	
appropriate	cell	 line.	There	are	no	commonly	available	cell	 lines	derived	 from	
murine	limb	bud[88].	Those	that	have	been	derived	are	not	well	characterized	
and	no	cell	 lines	had	been	derived	 from	the	period	of	early	 limb	development	




The	 Immortomouse	 carries	 the	 simian	 virus	 40	 (SV40)	 large	 tumour	 antigen	
(TAg)	 gene;	 this	 TAg	 is	 thermolabile	 (from	 SV40	 strain	 tsA58)	 to	 impair	 its	
function	 in	 vivo[89].	 The	 gene	 is	 under	 control	 of	 the	 mouse	 major	
histocompatibility	 complex	 promoter	 H-2Kb	 to	 allow	 broad	 expression.	When	
cells	are	grown	at	permissive	 temperature	 (33oC),	expression	of	 this	gene	has	
been	used	to	generate	many	conditional	immortalised	cell	lines[89],[90].		
	
The	 distal	 limb	 bud	was	 obtained	 and	 disaggregation	 of	 the	 cells	 undertaken.	
Following	 disaggregation,	 cells	 were	 cultured	 at	 33oC	 in	 the	 presence	 of	
Interferon	 Gamma	 (IFNγ);	 this	 stimulates	 TAg	 expression	 via	 H-2Kb.	 The	 cell	
line	was	grown	for	several	passages	prior	to	its	characterization.	Another	group	




mesoderm	 in	 which	 Dhodh	 is	 expressed.	 Prior	 to	 using	 this	 cell	 line,	 it	 was	
important	to	confirm	that	this	was	the	case.	Significantly,	the	cell	line	remained	
mesenchymal	 in	morphology	 through	 the	 culture	 period,	 although	 did	 have	 a	
tendency	to	aggregate	in	culture.	PCR	was	performed	to	confirm	that	these	cells	
retained	 the	expression	of	genes	 that	characterize	 limb	development[90];	PCR	
demonstrated	 expression	 of	 several	 of	 these	 genes	 (Figure	 2.9).	 Finally	 I	








2.3.4 DHODH Inhibition and Cell Proliferation In Vitro 
Cell	proliferation	plays	a	crucial	role	in	expansion	of	the	hand	plate.	Numerous	
papers	suggest	that	it	is	this	proliferation	that	enables	accurate	digit	patterning	
[20537528].	It	 is	reported	that,	 in	animal	models,	 limb	defects	associated	with	
digital	 loss	 are	 correlated	 with	 a	 limb	 bud	 of	 reduced	 dimensions[91].	 In	
addition,	 local	 treatment	 of	 the	 amphibian	 limb	 bud	 with	 mitotic	 inhibitor	
colchicine	 resulted	 in	 a	 smaller	 limb	 with	 loss	 of	 digits[91].	 Therefore,	
dysfunction	 of	 DHODH	 may	 impair	 cell	 proliferation	 and	 cause	 the	 limb	
abnormalities	observed.	
	
I	 performed	 proliferation	 assays	 in	 my	 murine	 limb	 bud	 cell	 line	 using	 A77	
1726,	 an	 active	metabolite	 of	 DHODH	 inhibitor	 leflunomide.	 Leflunomide	 and	
A77	1726	 inhibit	DHODH	by	binding	 to	prevent	 access	 to	 the	active	 site.	This	
demonstrated	that	treatment	with	A77	1726	led	to	a	reduction	in	cell	count	in	a	




assays	 with	 BrdU	 demonstrated	 that	 there	 were	 significantly	 less	 cells	
proliferating	 (incorporating	 BrdU)	 over	 the	 assay	 period	 (Figure	 2.11).	 This	
therefore	confirms	that	DHODH	inhibition	does	impair	cell	proliferation	in	this	
mesenchymal	 limb	 cell	 line.	 I	 decided	 to	 use	 chemical	 inhibition	 of	 DHODH	
rather	 than	genetic	 inhibition	with	siRNA	due	to	 its	ease	of	use.	 In	addition,	 it	
may	 replicate	 the	 situation	 in	 Miller	 syndrome	 where	 the	 mutant	 DHODH	 is	
expressed	 but	 lacks	 normal	 DHODH	 function.	 Obviously	 with	 any	 chemical	
inhibition	there	is	the	risk	of	off-target	effects.	Leflunomide	is	reported	to	also	






Figure 2.11 The effect of A771726 (DHODH antagonist) on Proliferation of 
Immortomouse Limb Bud Cells.   
The Immortomouse Limb Bud Cell Line was incubated with increasing 
concentrations of A771726 an active metabolite of Leflunomide (DHODH 
antagonist) for 72 hours at 37oC.  
A. Cells were counted using a haemocytometer and demonstrated a decrease in 
cell number with increasing concentration of A771726.  
B. Cell cycle analysis of the effect of A771726 (DHODH antagonist) on the 
incorporation of BrdU in the immortomouse limb bud cell line. The mouse limb bud 
cells were incubated with increasing concentrations of A771726 an active metabolite 
of Leflunomide. Cells were treated with Propidium Iodide (PI) and BrdU; DNA 
content was assessed by fluorescent activated cell sorting (FACS).  The graph 
shows the percentage of cells incorporating BrdU (P2) decreased with increasing 
dose of A771726  
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2.3.5 Regulators of DHODH expression 
This	work	has	demonstrated	that	Dhodh	 is	expressed	 in	 the	distal	 limb	bud	at	






phenotype	 observed	 in	 Miller	 syndrome.	 However,	 the	 mechanisms	 that	
regulate	 this	DHODH	 expression	 remain	 uncertain.	 Therefore,	 the	 next	 aim	 of	
this	 project	 was	 to	 investigate	 the	 pathways	 that	 may	 regulate	 DHODH	
expression.	 The	 distribution	 of	 DHODH	 expression	 within	 the	 mesoderm	
underlying	 the	 AER	 overlaps	 with	 the	 site	 of	 action	 of	 major	 limb	 bud	
morphogens.		
2.3.5.1 Sonic Hedgehog 
SHH	 is	 the	 major	 determinant	 of	 antero-posterior	 patterning	 and	 digit	
specification	in	the	limb	bud.	Disruption	of	SHH	pathways	results	in	limb	defects	
with	 gain	 or	 loss	 of	 digits	 in	 both	 humans	 and	 animal	 models.	 WISH	
demonstrates	restriction	of	Shh	expression	to	the	ZPA	(Figure	2.12).	In	contrast,	
Gli3	was	expressed	across	the	distal	limb	bud;	GLI3	is	processed	in	the	anterior	
limb	 bud	 to	 generate	 the	 shortened	 repressor	 form	 whereas	 posteriorly	 the	






Figure 2.12 Whole mount in situ hybridization showing Gli3 (B) and Shh (C) 
expression in wild type mouse embryo TS 17/10.5dpc and Ptch1 (A) at 
TS19/11.5dpc. This demonstrates expression of the Shh pathway genes. Shh is 
restricted to the posterior Zone of Polarising Activity (ZPA). Gli3 encodes a 
transcription factor that in its full length form, GLI3A, is an activator of the Shh 
pathway and is restricted to the posterior limb bud. The C-terminally truncated form, 
GLI3R acts as a repressor and is expressed in the anterior limb bud. Ptch1 encodes 
a receptor for the hedgehog family and transduces hedgehog signalling by 
associating with smoothened protein (SMO). These Shh pathway genes are 








the	 ZRS	 mouse,	 or	 alternately,	 aberrant	 anterior	 Shh	 expression	 in	 the	







Figure 2.13 Wholemount in situ hybridisation showing expression of Dhodh in 
the Zone of Regulatory Sequence (ZRS) mutant and control. The Zone of 
Regulatory Sequence (ZRS) is a long range cis-regulator that controls 
spatiotemporal expression of Shh in the limb bud. A. Diagram showing the cassette 
inserted within the ZRS, which disrupts its function and leads to loss of Shh 
expression. B. WISH showing lack of Shh expression in mutant limb bud embryo 
(TS17, 10.5dpc). C. WISH showing Dhodh expression in wild type limb bud mouse 
embryo (TS17, 10.5dpc). D. 3D OPT thresholded, coronal section demonstrating 
Dhodh expression in the wild type mouse embryo (TS17, 10.5dpc.) E. WISH 
showing Dhodh expression in the ZRS mutant embryo TS17, 10.5dpc. F. 3D OPT 
thresholded, coronal section demonstrating Dhodh expression in the ZRS mutant 
mouse embryo (TS17, 10.5dpc). 
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2.3.5.2 FGF and BMP Signalling 
FGF	 family	 proteins	 are	 critical	 to	 normal	 limb	 development.	 Paracrine	
secretion	of	FGFs	engage	cell	survival,	cell	proliferation	and	cell	motility	within	
the	 developing	 limb.	 FGFs	 play	 a	 crucial	 role	 in	 both	 growth	 and	 patterning.	
FGF4	 and	 FGF8,	 secreted	 from	 the	AER,	mediate	 proliferation	 in	 the	 progress	
zone	to	enable	outgrowth	of	the	limb	bud	and	expansion	of	the	hand	plate.	FGF4	
and	FGF8	signal	through	FGFRs	in	the	mesenchyme	underlying	the	AER.	Distinct	
FGFRs	 are	 expressed	 in	 this	 region	 including	 FGFR1.	 A	major	 effector	 of	 FGF	
signaling	is	the	MAPK	pathway;	phosphorylation	of	ERK	is	a	marker	of	pathway	
activation.	Whole	mount	immunohistochemistry	was	undertaken	to	investigate	
localization	 of	 phospho-ERK	 in	 the	 limb	 bud.	 Although	 ERK	 activation	 also	
occurs	via	other	pathways,	FGF	signaling	is	the	predominant	activator	of	ERK	in	
the	developing	 limb.	This	demonstrated	 staining	 for	phospho-ERK	 in	 the	 limb	
bud,	 with	 signal	 concentrated	 peripherally,	 similar	 to	 DHODH	 distribution	
(Figure	 2.14).	 The	 specificity	 of	 this	 staining	 is	 uncertain	 as	 background	was	




perform	multiple	 roles	 in	 limb	development	 including	 regulating	 the	AER	and	
digit	patterning.	Phosphorylation	of	SMAD	constitutes	an	important	mediator	of	
BMP	 signaling.	BMP4	 is	 expressed	 in	 the	mesoderm	 beneath	 the	 AER	 (Figure	
2.16)	and	regulates	digit	number	and	identity.	Loss	of	BMP4	 in	murine	models	
leads	 to	 digit	 defects,	 including	 preaxial	 polydactyly	 [94].	 Whole	 mount	
immunohistochemistry	for	phospho-SMAD	again	demonstrated	peripheral	limb	
bud	 staining	 (Figure	 2.14).	 Therefore,	 this	 work	 indicates	 that	 FGF	 and	 BMP	
signaling	 pathways	 are	 activated	 in	 the	 regions	 of	 Dhodh	 expression.	 This	







Figure 2.14 Whole mount immunohistochemistry pERK (A), pSMAD (B) and 
control(C). Embryos ts 17, 10.5 dpc were fixed and stained for phosphorylated ERK 
(pERK) and phosphorylated SMAD (pSMAD) as markers of downstream FGF and 
BMP signalling respectively. The staining of pERK and pSMAD can be visualised in 
the limb bud in A and B respectively in contrast to the control C. These 
phosphorylated proteins are concentrated in the peripheral mesenchyme beneath 
the AER.  
	
	
2.3.5.3 Cell models  
To	investigate	putative	regulation	of	Dhodh	expression	by	BMP	or	FGF	signaling,	
I	 undertook	 further	 work	 in	 vitro	 using	 my	 validated	 limb	 bud	 cell	 line.	 I	
stimulated	 the	 cell	 line	 with	 FGF	 Basic,	 BMP	 and	 Purphorphamine,	 a	 SHH	
pathway	 agonist.	 Initial	work	 assessed	 alteration	 in	Dhodh	 expression	 at	 1,	 4	
and	 24	 hours;	 no	 statistically	 significant	 difference	 in	Dhodh	 expression	 was	
observed	at	any	time-point	with	any	of	the	morphogens.	These	time	points	were	
examined	to	assess	for	an	 immediate	early	transcriptional	response,	a	delayed	





Dhodh	 expression	 at	 earlier	 time	 points	 to	 confirm	 that	 upregulation	was	 not	




Due	 to	 concerns	 that	 Interferon	 Gamma	 stimulation	 may	 impact	 on	
transcription,	 I	 recapitulated	 the	 experiment	 using	 another	mouse	 embryonic	
cell	line,	Swiss	3T3	cells.	This	fibroblast	cell	line	is	derived	from	mesenchyme	of	
the	 whole	 E17.5	 murine	 embryo.	 These	 cells	 have	 been	 used	 previously	 to	






cohesion	 genes	 which	 are	 responsible	 for	 a	 similar	 but	 distinct	 limb	 defect.	
Further	 work	 would	 include	 3D	 computational	 mapping	 of	 these	 expression	





 Incubation 3T3 cell line SHH, FGF or BMP for 5, 30 or 60 minutes 
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Figure 2.15 Expression profiling of Dhodh in Immortomouse limb bud cell line 
and 3T3 mouse embryonic fibroblast cell line incubated with SHH agonist 
(Purphorphamine), FGF or BMP for different time periods. 
Expression profiling of Dhodh in Immortomouse limb bud cell line and 3T3 mouse 
embryonic fibroblast cell line incubated with SHH agonist (Purphorphamine), FGF or 
BMP for different time periods. Expression was determined using quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR). Values were 
normalized to housekeeping gene Actb. Data shown is the mean of 3 biological 
independent experiments. Each experiment contained triplicate qPCR wells as 
technical repeats for each condition. 
A. Incubation of Immortomouse limb bud cell line with SHH agonist, FGF or BMP for 
1, 4 or 24 hours. There was no significant difference between Dhodh expression in 
control conditions versus incubation with the growth factors for 1, 4 or 24 hours.  
B. The experiment was repeated at earlier time points. There was no significant 
difference between the expression of Dhodh in the Immortomouse cell line 
incubated with growth factors for 5, 30 or 60 minutes.  
C. The experiment was repeated at the early time points in 3T3 cell line and no 
significant difference in Dhodh expression between the control condition and 


















Figure 2.16 Whole Mount in situ Hybridisation of other genes involved 
in limb development/limb defects. WISH demonstrating the expression 
patterns of other genes involved in limb development including cohesion 






The	 work	 in	 this	 chapter	 investigated	 the	 Post	 Axial	 Longitudinal	 Limb	
Reduction	Defect	 (PALLRD)	observed	 in	Miller	 syndrome.	Although	mutations	
within	 DHODH	 cause	 this	 phenotype,	 the	 mechanism	 by	 which	 DHODH	
dysfunction	results	in	the	limb	deformity	was	uncertain.	My	work	demonstrates	
that	 DHODH	 is	 expressed	 at	 the	 periphery	 of	 the	 developing	 limb,	within	 the	
mesenchyme	 underlying	 the	 AER.	 It	 also	 indicates	 that	 DHODH	 expression	
occurs	 in	 areas	 of	 cell	 proliferation.	 Finally,	 chemical	 inhibition	 of	 DHODH	
inhibits	proliferation	of	 a	 validated	 limb	bud	 cell	 line.	This	work	 is	 consistent	
with	 the	 hypothesis	 that	 impaired	 proliferative	 expansion	 causes	 the	 limb	
phenotype.	However	further	work	is	required	to	confirm	these	findings.	
2.4.1 De novo Pyrimidine Biosynthesis Pathway 
DHODH	 catalyzes	 the	 fourth	 step	 in	 the	 de	 novo	 pyrimidine	 biosynthesis	





2.4.1.1 Human Orotic Aciduria 
Human	mutations	 in	UMPS	 are	 recognized	 to	 cause	orotic	 aciduria[97].	Orotic	
aciduria	is	an	autosomal	recessive	disorder	caused	by	compound	heterozygous	
mutations	 within	 UMPS;	 these	 are	 reported	 to	 cause	 loss	 of	 protein	
function[98].	 It	 is	 characterized	 by	 megaloblastic	 anaemia	 and	 orotic	 acid	
crystalluria.	 There	 is	 often	 an	 associated	 intellectual	 disability	 and	
immunodeficiencies	are	reported	 in	a	minority	of	cases[99].	There	 is	however	




2.4.1.2 Pyrimidine Dose Effect  
Therefore,	 despite	 disruption	 of	 de	 novo	 pyrimidine	 biosynthesis	 in	 orotic	
aciduria,	 no	 limb	 phenotype	 results.	 The	 reason	 for	 this	 is	 uncertain.	 It	 may	
occur	because	the	pathogenic	mutations	in	UMPS	are	less	disruptive	to	de	novo	
pyrimidine	 biosynthesis	 than	 those	 observed	 in	 DHODH	 in	 Miller	 syndrome.	
There	is	no	comparative	experimental	data	to	support	or	refute	this.	However,	
there	 is	 certainly	 accumulation	 of	 substrates	 in	 orotic	 aciduria	 to	 indicate	
downstream	inhibition	of	the	pathway[99].	The	phenotype	caused	by	disruption	
of	 pyrimidine	 biosynthesis	 does	 appear	 to	 be	 dose	 sensitive;	 no	 homozygous	
mutations	causing	complete	DHODH	loss	of	function	are	found	in	humans.	This	
is	 presumably	 due	 to	 its	 early	 lethality.	 In	 contrast,	 heterozygotes	 with	 one	
pathogenic	 DHODH	 allele	 and	 one	 wild	 type	 allele	 show	 no	 developmental	
phenotype.	 Although	 UMPS	 mutations	 in	 orotic	 aciduria	 cause	 no	 limb	
deformity,	 alternate	 variants	 within	 the	 drosophila	 homologue	 of	 UMPS	
(rudimentary-like)	cause	anomalous	wing	development[100].	
2.4.1.3 DHODH and the Respiratory Chain 
Alternately,	 the	paradox	 in	 limb	phenotype	between	orotic	aciduria	and	Miller	
syndrome	may	have	other	explanations.	DHODH	is	located	within	mitochondria;	
unlike	 other	 members	 of	 the	 de	 novo	 pyrimidine	 biosynthesis	 pathway	 it	
appears	 immobile	 on	 the	 inner	 mitochondrial	 membrane[101].	 DHODH	 is	
functionally	linked	to	the	respiratory	chain	and	oxidative	phosphorylation[102].	
DHODH	catalyses	oxidation	of	dihydro-oratate	 into	orotic	 acid	by	 transferring	
electrons	to	 the	respiratory	molecule	ubiquinone	via	 the	enzyme	bound	redox	
co-factor	 FMN[102].	 DHODH	 activity	 requires	 active	 complex	 III	 of	 the	
respiratory	chain,	with	inhibition	of	complex	III	impairing	DHODH	activity	and	
pyrimidine	production[103].	A	recent	study	reported	that	depletion	of	DHODH	
partially	 inhibited	 respiratory	 chain	 complex	 III,	 with	 associated	 reduction	 in	
the	 mitochondrial	 membrane	 potential	 and	 increased	 reactive	 oxygen	
species[101].	 Consistent	 with	 this	 the	 authors	 observed	 that	 DHODH	
knockdown	 induced	 growth	 retardation	 due	 to	 cell	 cycle	 arrest	 in	 G2/M;	
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pyrimidine	deficiency	typically	causes	G1/S	arrest[101].	This	is	in	contrast	with	
my	 work,	 in	 which	 inhibition	 with	 A77	 1726	 did	 not	 cause	 significant	
accumulation	within	G2/M	on	propidium	iodide	staining.	
2.4.1.4 Zebrafish perplexed and Drosophila Rudimentary 
Altered	respiratory	chain	function	may	therefore	explain	some	of	characteristics	
of	 Miller	 syndrome.	 However,	 although	 no	 mutations	 in	 CAD	 have	 been	
identified	in	humans,	the	zebrafish	perplexed	phenotype	is	caused	by	mutations	
in	CAD[4].	CAD	catalyses	the	first	three	steps	in	de	novo	pyrimidine	biosynthesis	
but	has	no	 reported	 involvement	 in	 the	 respiratory	 chain.	Perplexed	 zebrafish	
show	anomalies	of	structures	homologous	to	those	affected	in	Miller	syndrome;	
there	 is	 both	 jaw	 and	 fin	 anomalies[4].	 This	 is	 also	 consistent	 with	 the	
mutations	 in	 the	 drosophila	 homologue	 of	 CAD,	 rudimentary[5].	 The	
rudimentary	 phenotype,	 named	 on	 account	 of	 the	 malformed	 and	 reduced	
wings,	 was	 first	 identified	 over	 century	 ago[4].	 This	 demonstrates	 that	
mutations	 in	 other	members	 of	 the	de	novo	 pyrimidine	 biosynthesis	 pathway	
cause	 similar	 phenotypes,	 indicating	disrupted	pyrimidine	 synthesis	 plays	 the	
predominant	role	in	the	disorder.	
2.4.1.5 Murine Model of Leflunomide Treatment 
Treatment	 of	 pregnant	mice	with	DHODH	 inhibitor	 leflunomide	 replicates	 the	
phenotype	observed	in	both	humans	and	the	animal	models	described	above[6].	
The	 offspring	 show	 limb	 reduction	 deformities	 and	 craniofacial	 anomalies.	
Importantly,	 this	 phenotype	 was	 substantially	 reversed	 with	 concurrent	
administration	of	uridine	to	the	mother,	indicating	that	pyrimidine	deficiency	is	
critical	 to	 the	 observed	 phenotype[6].	 	 Interestingly,	 although	 major	 limb	
reduction	defects	were	reversed	by	administration	of	uridine,	there	remained	a	





2.4.1.6 Characterising Zebrafish perplexed Phenotype 
Investigation	 of	 the	 perplexed	 phenotype	 in	 zebrafish	 revealed	 that	 cad	
expression	 localizes	 in	 a	 similar	 pattern	 to	 murine	 Dhodh	 expression	 at	
equivalent	developmental	stages,	with	expression	in	the	distal	fin	and	branchial	
arches[4].	 This	 was	 also	 reported	 to	 correspond	 with	 cells	 undergoing	 rapid	
proliferation.	 Partial	 rescue	 of	 the	 jaw	 and	 fin	 defects	 was	 observed	 with	
injection	 of	 orotic	 acid	 or	 uridine	 into	 the	 embryos	 at	 24	 hours	 post	
fertilization[4].	Subsequent	work	in	this	study	addressed	whether	disruption	of	
nucleotide	 synthesis	 or	UDP	glycosylation	was	 responsible	 for	 the	phenotype.	
Nucleotide	 synthesis	 was	 inhibited	 by	 knockdown	 of	 ribonucleotide	 reductase	
R2,	 which	 catalyses	 production	 of	 all	 deoxyribonucleotides	 essential	 for	 DNA	
synthesis,	 or	 thymidylate	 synthase,	 which	 catalyses	 de	 novo	 synthesis	 of	
thymidine,	 also	 essential	 for	 DNA	 synthesis.	 	 Knockdown	 of	 ribonucleotide	
reductase	R2	caused	 severe	 defects	 and	 early	 lethality	 therefore	 could	 not	 be	
analysed	 further[4].	 In	 contrast,	 knockdown	 of	 thymidylate	 synthase	 did	 not	
replicate	the	anomalies	of	jaw	or	fin	development	observed	with	the	perplexed	
phenotype.	Mutation	of	 the	UDP-glucoronic	acid	decarboxylase	gene,	 important	
for	 UDP-glycosylation,	 demonstrated	 disrupted	 jaw	 morphogenesis	 in	 the	
zebrafish	 but	 no	 fin	 anomalies[4].	 These	 findings	 led	 the	 authors	 to	 suggest	
effects	 on	 both	 nucleotide	 synthesis	 and	 glycosylation	 contributed	 to	 the	
perplexed	phenotype.			
	
The	 common	 anomalous	 findings	 caused	 by	 mutation	 of	 different	 enzymes	
within	the	de	novo	pyrimidine	biosynthesis	pathway	indicate	the	importance	of	
pyrimidine	 synthesis	 in	 the	 disorders.	 However,	 the	 absence	 of	 structural	
anomalies	in	orotic	aciduria	had	led	some	to	suggest	a	reduction	in	orotic	acid,	
rather	 than	 pyrimidine,	 was	 responsible	 for	 the	 phenotype[97].	 The	 reason	
being	that	there	is	a	putative	reduction	in	orotic	acid	with	both	CAD	and	DHODH	
mutations	but	not	UMPS	mutations.	It	was	proposed	orotic	acid	may	play	a	role	
in	 development,	 potentially	 through	 transcriptional	 regulation.	 Although	
reduction	 in	 orotic	 acid	 may	 also	 play	 a	 role,	 the	 rudimentary-like	 (UMPS	
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2.4.2. Acrofacial Requirement for DHODH 
My	 work	 demonstrates	 that	 Dhodh	 expression	 localizes	 to	 the	 limb	 and	
craniofacial	structures	at	E9.5	to	E11.5	in	murine	embryonic	development.	This	








more	 rapidly	 than	 elsewhere	 within	 the	 embryo	 and	 are	 therefore	 more	








therefore	no	 evidence	 that	 limb	 cells	 are	proliferating	more	 rapidly	 than	 cells	
within	other	structures	at	different	stages	of	development.	
	
To	understand	 the	expression	pattern	of	Dhodh,	 it	 is	 important	 to	understand	
the	 mechanisms	 that	 regulate	 it.	 I	 aimed	 to	 determine	 in	 this	 work	 whether	
Dhodh	 was	 specifically	 up-regulated	 in	 the	 limb	 bud	 due	 to	 morphogen	
signaling.	 In	 both	 limb	 bud	 cells	 and	 3T3	 cells,	 there	 was	 no	 evidence	 of	
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significant	upregulation	of	Dhodh	expression	following	morphogen	stimulation.	
Therefore,	 although	 pyrimidine	 pool	 depletion	 due	 to	 rapid	 proliferation	may	
cause	upregulation	of	Dhodh	 in	 the	 limb	bud,	 I	did	not	 find	evidence	of	direct	
regulation	by	limb	bud	pathways.	Obviously	further	work	is	required	to	exclude	
other	 limb	 specific	 pathways	 that	may	 directly	 regulate	 the	 pattern	 of	Dhodh	
expression.		
	
There	 is	 no	 evidence	 to	 suggest	 that	 limb	 cells	 are	 constitutively	 more	
dependent	on	de	novo	pyrimidine	biosynthesis.	However,	both	the	limb	bud	and	
branchial	 arches	 have	 limited	 vasculature	 at	 E9.5	 to	 E10.5[105].	 This	 feature,	
combined	with	their	relative	peripheral	location	within	the	embryo,	may	make	









A	recent	study	 in	zebrafish	 found	 that	 treatment	of	zebrafish	with	 lefunomide	
led	 to	 almost	 complete	 abrogation	 of	 neural	 crest	 development[106].	 Neural	
crest	 cells	 contribute	 substantially	 to	 craniofacial	 structures	 and	 this	 may	
therefore	explain	the	facial	anomalies	in	Miller	syndrome.	However,	there	is	no	
recently	reported	association	between	neural	crest	lineages	and	development	of	
the	 limb	 skeleton.	An	early	 study	disrupting	 caudal	neural	 crest	with	 ablation	
led	 to	 ipsilateral	 limb	 reduction	 in	 a	 proportion	 of	 chicks	 [107];	 however	 the	
crude	 diathermy	 ablation	may	 have	 injured	 other	 structures	 and	 the	 findings	




The	morphology	of	 zebrafish	 following	 treatment	with	 leflunomide	was	noted	
to	be	similar	to	the	phenotype	of	spt5/spt6	mutants	[106];	both	these	proteins	
engage	 in	 transcriptional	 elongation.	 Subsequently,	 inhibition	 of	 DHODH	was	
found	 to	 cause	 inhibition	 of	 transcriptional	 elongation.	 This	 restricted	
transcription	of	genes	required	for	neural	crest	development.	The	mechanism	of	
inhibition	of	 transcriptional	elongation	was	not	explored	but	a	previous	study	
had	 implicated	 a	 reduction	 in	 nucleotide	 pools	 in	 defective	 elongation[108].	
This	study	indicates	DHODH	may	also	regulate	transcription	through	control	of	
the	pyrimidine	pool.	
2.4.3 Proliferative effect  
The	 hypothesis	 of	 this	 work	 was	 that	 pyrimidine	 depletion,	 due	 to	 reduced	
DHODH	activity,	 inhibits	 limb	bud	proliferation;	 this	 impairs	 expansion	of	 the	
hand	 plate	 and	 causes	 the	 limb	 reduction	 deformity	 observed.	 Certainly,	
inhibition	of	DHODH	 in	vitro	does	 impair	cell	proliferation	in	my	limb	bud	cell	
line.	 This	 is	 likely	 secondary	 to	 pyrimidine	 depletion,	 although	 I	 did	 not	
undertake	uridine	rescue.	Others	have	demonstrated	rescue	of	cell	proliferation	
with	 uridine	 supplementation	 in	 vitro	 [109],	 although	 cells	 were	 not	 derived	
from	murine	embryonic	limb	buds.	Further	work	is	required	to	confirm	rescue	
of	 proliferation	with	 uridine	 in	my	 cell	 line.	However,	whether	 due	 to	 lack	 of	
pyrimidine	or	other	mechanisms,	proliferation	is	retarded	by	leflunomide.		
	
Numerous	 studies	 indicate	 an	 association	 between	 proliferative	 expansion	 of	





repositioning	 of	 posterior	 digits.	 Models	 examining	 SHH	 digit	 patterning	
indicate	 that	 loss	 of	 SHH	 impairs	 cell	 proliferation	 and	 results	 in	 loss	 of	
posterior	 digits[66].	 In	 contrast,	 inhibition	 of	 proliferation	 alone	 has	 been	
shown	to	cause	loss	of	anterior	digits	due	to	enhanced	exposure	of	the	anterior	
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hand	 plate	 to	 SHH[66].	 However,	 other	 models	 of	 mitotic	 inhibition	 have	




growth	 demonstrated	 that	 SHH	 acts	 in	 two	 phases	 during	 limb	
development[110].	The	first	is	an	early	transient	patterning	phase	vital	for	digit	
identity.	 The	 second	 is	 an	 extended	 growth-promoting	 phase,	 which	 allows	
expansion	of	the	mesenchyme	sufficient	to	accommodate	the	full	complement	of	
digits.	 Their	 data	 did	 not	 support	 the	 classical	 antero-posterior	 formation	 of	
digits	 proposed	 by	 previous	models.	 Zhu	 et	al	 (2008)	 undertook	 experiments	
involving	the	progressively	earlier	removal	of	SHH	in	the	developing	limb	bud.	
This	 resulted	 in	 the	progressive	 loss	of	digits	 three,	 five,	 two	and	 four	 in	both	
the	 fore	 and	 hind	 limbs.	 Normal	 digit	 condensations	 were	 visualised	 in	 the	
developing	wild-type	mouse	limb	bud,	using	condensation	markers	Noggin	Lac	
Z	and	Sox9;	 this	 indicated	 that	digits	develop	 in	 the	 reverse	order	 to	 the	digit	
loss	following	SHH	removal.	Digit	four	is	formed	first	followed	by	digit	two,	five	
and	finally	digit	three.	These	experiments	support	the	hypothesis	that	SHH	loss,	
except	 at	 the	 earliest	 stage,	 results	 in	 decreased	 cell	 number	 due	 to	 both	
impaired	cell	survival	and	proliferation,	resulting	in	insufficient	mesenchyme	to	




digit	 patterning	by	 conditional	 inactivation	of	Fgfr1	 in	murine	models[2].	One	
model	 using	 the	 T(brachycury)-cre	 line	 resulted	 in	 Fgfr1	 inactivation	
throughout	the	limb	bud	mesenchyme	and	demonstrated	that	FGFR1	is	initially	
required	 for	 outgrowth	 in	 the	 proximo-distal	 axis.	 Later,	 FGFR1	 is	 vital	 for	
continued	 cell	 survival	 and	 expansion	 of	 skeletal	 precursor	 cells.	 The	 second	
mouse	model,	carrying	a	sonic	hedgehog-cre	allele	(Shhcre)	allowed	inactivation	
of	Fgfr1	 in	 the	posterior	 limb	bud	mesenchyme.	This	experiment	 showed	 that	
FGFR1	 regulates	Shh	 in	 a	 cell	 autonomous	manner	 and	 therefore	directs	 digit	
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that	 are	 lost.	 Certainly,	 on	 further	 inspection	 of	 clinical	 images	 of	 the	 feet	 of	
proband	R24H4,	with	a	mutation	in	FGFR1	(chapter	3	and	4),	it	is	possible	that	
digit	 three	 is	 missing.	 Further	 review	 of	 radiographs	 by	 experts	 would	 help	
resolve	this	uncertainty.		
	
Furthermore,	 it	would	be	 interesting	 to	dissect	 further	in	vitro	 the	role	of	FGF	
signalling	in	the	regulation	of	DHODH.	If	time	had	allowed,	the	plan	was	to	use	
classical	AER	removal	 in	 chick	wing	embryos	 to	examine	directly	 the	affect	of	
FGF	inactivation	on	cell	survival	and	DHODH	expression.	Beads	soaked	in	FGFs	
can	 be	 used	 to	 replace	 the	 AER[41];	 DHODH	 expression	 in	 underlying	
mesenchyme	could	be	examined.		
	
Individuals	 with	 primordial	 dwarfism	 demonstrate	 normal	 patterning	 of	 the	
hand	despite	a	vast	overall	reduction	in	size[111].	Primordial	dwarfism	results	
from	mutations	in	diverse	genes,	the	majority	of	which	are	involved	in	the	cell	
cycle.	 The	 precise	 mechanisms	 by	 which	 these	 mutations	 cause	 primordial	
dwarfism	 continue	 to	 be	 studied.	 However,	 it	 is	 considered	 that	 these	






in	 morphogens	 secreted	 and	 the	 resultant	 morphogen	 gradient.	 Therefore	
patterning	may	 be	maintained,	 while	 growth	 is	 reduced.	 In	 contrast,	 DHODH	
inhibition	 only	 affects	 the	 most	 rapidly	 proliferating	 cells,	 particularly	 as	
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pyrimidine-scavenging	 pathways	 remain	 intact	 and	 there	 remains	 some	
residual	DHODH	function.	Therefore,	decreased	proliferation	in	this	setting	may	
well	 cause	 digit	 loss,	 although	 further	 work	 is	 required	 to	 examine	 how	
expression	of	morphogens	and	their	targets	are	affected	by	DHODH	inhibition.			
2.5 Conclusion 
The	work	 in	 this	 chapter	 investigates	 the	 expression	 pattern	 of	Dhodh	 in	 the	
developing	 murine	 embryo.	 It	 demonstrates	 expression	 of	 Dhodh	 in	 the	
branchial	arches	and	distal	 limb	buds;	this	is	a	novel	finding	that	has	not	been	
previously	 described.	 This	 expression	 is	 consistent	 with	 the	Miller	 syndrome	
phenotype.	The	expression	of	Dhodh	was	similar	 to	 that	of	proliferative	genes	
Pcna	 and	Nmyc,	 indicating	expression	of	Dhodh	 in	 areas	of	 cell	proliferation.	 I	
derived	 and	 validated	 a	 distal	 limb	 bud	 cell	 line	 that	 subsequently	 I	 used	 to	
show	 impaired	 proliferation	 following	 DHODH	 inhibition.	 I	 was	 unable	 to	
identify	 direct	 regulation	 of	 Dhodh	 expression	 by	 common	 limb	 bud	
morphogens.			
	
Further	work	is	required	both	 in	vivo	and	 in	vitro	 to	expand	on	the	findings	 in	
this	 chapter.	 Characterisation	 of	 the	 effects	 of	 DHODH	 inhibition	 on	 limb	
development	 pathways	 is	 important,	 particularly	 in	 view	 of	 its	 potential	
modulation	of	transcriptional	elongation.	This	could	be	undertaken	both	in	vitro	
initially,	 but	 subsequently	 in	 vivo	 if	 possible.	 Optimisation	 of	 the	 EdU	
proliferation	assays	in	vivo	may	enable	direct	study	of	the	proliferative	effects	of	
DHODH	 inhibition.	 This	 would	 allow	 the	 interrogation	 of	 the	 association	
between	growth/proliferation	and	patterning.	
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Chapter 3  
The use of Whole Exome Sequencing to investigate 




The	 research	 question	 for	 this	 chapter	 was;	 what	 is	 the	 genetic	 aetiology	 of	
PALLRD	 in	 atypical	 Miller	 syndrome?	 The	 hypothesis	 was	 that	 whole	 exome	
sequencing	 of	 4	 unrelated	 individuals	 with	 atypical	 Miller	 syndrome	 can	 be	
used	to	generate	a	concise	list	of	candidate	pathogenic	variants.		
	
This	 chapter	 describes	 the	 application	 of	 whole	 exome	 sequencing	 (WES)	 to	
identify	putative	causal	genetic	variants	in	a	cohort	of	patients	diagnosed	with	
Postaxial	Acrofacial	Dysostosis	 (POADS),	 also	 termed	Miller	Syndrome.	 	These	
cases	 shared	 similar	 Post	 Axial	 Longitudinal	 Limb	 Reduction	 Deformities	
(PALLRD).		
3.1.1 Congenital Limb Defects 
In	 the	 developing	 embryonic	 limb,	 structures	 are	 organised	 along	 its	
longitudinal	 axis	 into	 proximal	 (e.g.	 arm/stylopod),	 mesial	 (e.g.	
forearm/zeugopod)	and	distal	(e.g.	hand/autopod)	segments	(Figure	3.1).	These	
structures	 are	 further	 characterised	 in	 the	 transverse	 axis	 into	 pre-axial	
(radius/tibia)	and	post-axial	(ulna/fibula)[112].	This	nomenclature	is	the	basis	
of	classification	systems	adopted	to	describe	congenital	limb	deformities,	which	
indicate	 both	 the	 axis	 involved	 and	 the	 elements	 affected[113].	 These	
classifications	assist	in	the	accurate	recording	and	diagnosis	of	limb	defects.	Our	




























Figure 3.1 The skeletal elements of the limb. The limb is organised into a 
proximal stylopod region, mesial zeugopod element and distal autopod segment.  
	
Congenital	 limb	deformities	 are	one	of	 the	most	 common	birth	defects	with	 a	
current	 reported	 prevalence	 of	 37	 per	 10,000	 live	 births	 in	 European	
populations[19].	 These	 limb	 defects	 may	 cause	 profound	 disability	 due	 to	
functional	 loss	 and	 in	 addition	 will	 often	 have	 a	 significant	 psychological	
impact[114].	Surgical	options	are	limited	and	may	involve	multiple	procedures,	
bulky	 external-fixators,	 orthotics	 or	 amputation.	 Limb	 reduction	 deformities	
comprise	 over	 10%	 of	 congenital	 limb	 defects,	 with	 a	 prevalence	 of	 5.4	 per	
10,000	live	births[19].	In	contrast,	PALLRD	are	less	common	with	a	prevalence	
of	only	0.3	per	10000	live	births[115].	The	majority	of	these,	two-thirds	in	one	





both	 clinically	and	 scientifically.	 It	 enables	 clinicians	 to	provide	a	 firm	genetic	
diagnosis,	 which	may	 be	 of	 value	 to	 both	 the	 individual	 and	 their	 parents.	 It	
facilitates	 appropriate	 counselling	 to	 discuss	 the	mode	 of	 inheritance	 and	 the	
potential	 impact	 on	 future	 pregnancies.	 Where	 applicable	 unaffected	 family	
members	 can	 be	 screened	 for	 recessive	 causal	 variants.	 In	 certain	 disorders,	
diagnosis	 allows	 therapeutic	 intervention,	 such	 as	 hormone	 therapy,	 to	 be	
initiated.	 In	 addition,	 study	 of	 causal	 genes	 provides	 insight	 into	 the	 limb	
development	 pathways,	which	 are	 not	 only	 relevant	 to	 congenital	 defects	 but	
also	 to	 late	 onset	 disease.	 Many	 developmental	 effectors	 also	 function	 in	 the	
growth	plate,	during	fracture	union	and	in	carcinogenesis[116-118].	The	study	
of	limb	development	also	informs	tissue-engineering	methodologies	that	may	in	
the	 future	 allow	 the	 treatment	 of	 children	 with	 specific	 development	
disorders[119].		
3.1.2 Post Axial Longitudinal Limb Reduction Deformities (PALLRD) 
This	 project	 focuses	 on	 the	 genetic	 analysis	 of	 postaxial	 longitudinal	 limb	
reduction	 deformities	 (PALLRD).	 Numerous	 genes	 are	 involved	 in	 limb	 bud	
development	 but	 relatively	 few	 genes	 are	 known	 to	 cause	 PALLRD.	 PALLRD	
may	 occur	 in	 isolation	 or	 in	 association	with	 a	 developmental	 syndrome;	 the	
latter	 is	 more	 common	 in	 cases	 of	 bilateral/multiple	 limb	 involvement.	
Examples	 of	 such	 syndromes	 include	 Ophthalmo-acromelic	 Syndrome	 (OAS),	
also	 termed	 Waardenburg	 Anophthalmia	 Syndrome,	 and	 Miller	 Syndrome[3,	
120].		
	
OAS	 is	 characterized	 by	 severe	 bilateral	 eye	 malformations	 and	 absence,	 or	
hypoplasia,	of	the	5th	ray	in	both	upper	and	lower limbs.	Homozygous	loss-of-
function	 mutations	 in	 SMOC1	 have	 been	 identified	 as	 the	 cause	 of	 OAS[120,	
121].	 The	 mouse	 ortholog	 of	 this	 gene,	 Smoc1,	 shows	 dynamic	 and	 tissue-
specific	 expression	 during	 embryonic	 development	 and	 is	 an	 early	marker	 of	




The	 features	 of	Miller	 syndrome	 include	 severe	micrognathia,	 cleft	 lip	 and/or	
palate	and	coloboma	of	 the	eyelids,	 in	addition	 to	hypoplasia	or	aplasia	of	 the	
posterior	 elements	 of	 the	 limbs[3].	Mutations	within	 the	 gene	DHODH,	 which	
encodes	 the	 DHODH	 enzyme	 critical	 for	 de	 novo	 pyrimidine	 synthesis,	 have	
recently	been	identified	as	causal	 in	Miller	syndrome[1]. The	FitzPatrick	group	




SMOC1	and	DHODH	share	no	obvious	 functional	 link	but	give	rise	 to	a	similar	
and	 specific	 PALLRD	 phenotype	 (Figure	 3.2).	 In	 addition,	 although	 most	
commonly	associated	with	polydactyly,	a	similar	phenotype	has	been	observed	





Figure 3.2. The feet of three unrelated infants demonstrating the PALLRD 
phenotype produced by three different genes. The OAS phenotype caused by 
mutations in the SMOC1 gene, Miller syndrome phenotype caused by mutations in 
the DHODH gene and Pallister Hall phenotype caused by mutations in the GLI3 
gene.  Clinical Images, Professor D.R. FitzPatrick.  
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3.1.3 Non-classical Miller Syndrome 
The	diagnosis	of	POADS	/	Miller	syndrome	in	our	cohort	was	based	on	common	
associated	clinical	features.	However,	although	all	four	individuals	demonstrate	
a	 degree	 of	 commonality	 with	Miller	 syndrome,	 there	 are	 significant	 atypical	
characteristics.	PALLRD	in	association	with	cleft	palate	in	three	individuals	and	
the	 absence	 of	 significant	 visceral	 anomalies	 is	 consistent	 with	 the	 POADS	
phenotype.	 However,	 in	 contrast	 to	 classical	 Miller	 syndrome,	 all	 individuals	
demonstrate	 a	 bilateral	 but	 isolated	 upper	 or	 lower	 limb	 phenotype;	 all	 four	
limbs	are	typically	affected	in	classical	Miller	syndrome[3].	In	addition,	none	of	
our	 cohort	 demonstrate	micrognathia	 or	 coloboma.	 The	 cohort	was	 therefore	
described	to	have	non-classical	Miller	syndrome.	
	
Consistent	 with	 the	 atypical	 phenotype,	 all	 individuals	 were	 negative	 for	
mutations	in	DHODH.	No	mutations	in	other	components	of	de	novo	pyrimidine	
biosynthesis	 were	 identified	 either;	 all	 were	 negative	 for	 mutations	 in	 CAD	
(carbamoyl-phosphate	 synthetase	 2,	 aspartate	 transcarbamylase	 and	
dihydroorotase)	and	UMPS	(Uridine	monophosphate	synthase).	The	craniofacial	
and	limb	phenotype	demonstrated	in	this	cohort	may	therefore	represent	novel	
syndromes.	 This	 project	 used	 Next	 Generation	 Sequencing	 (NGS)	 to	 further	
interrogate	this	cohort.		
3.1.4 Next Generation Sequencing	
The	 completion	 of	 the	 Human	 Genome	 Project,	 undertaken	 using	 traditional	
Sanger	 sequencing,	 provided	 a	 reference	 human	 genome	 sequence.	 This	
reference	genome,	in	combination	with	the	development	of	NGS,	has	enabled	a	
huge	 surge	 in	 Mendelian	 disease	 gene	 discovery[124].	 Next	 generation	
sequencing,	or	massively	parallel	sequencing,	allows	multiple	strands	of	DNA	to	
be	 sequenced	 simultaneously	 and	 can	 be	 used	 to	 study	 the	whole	 genome	 at	
base	 pair	 resolution	 in	 one	 experiment.	 There	 are	 two	 genome	 wide	
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approaches,	Whole	 Genome	 Sequencing	 (WGS)	 and	Whole	 Exome	 Sequencing	
(WES).	WGS	involves	sequencing	the	complete	genome	in	contrast	to	WES	that	
sequences	only	the	coding	regions,	approximately	1%	of	the	genome[124].	WES	
has	 been	 extended	 to	 include	 splice	 acceptor	 and	 donor	 sites,	 untranslated	
regions	and	certain	microRNA	encoding	genes[125].	WES	provides	a	more	cost	
effective	 and	 expedient	 strategy	 and	 has	 therefore	 become	 the	 predominant	
methodology	in	the	recent	study	of	the	genetic	aetiology	of	Mendelian	disorders.	
There	 are	 multiple	 different	 NGS	 sequencing	 platforms	 available,	 utilising	
different	technologies,	and	the	field	continues	to	advance	rapidly.	Despite	this,	
there	 are	 similarities	 between	many	 of	 the	 NGS	 systems.	 The	majority	 of	 the	
NGS	systems	require	library	preparation.		For	WES,	solution	based	exon	capture	
is	 most	 commonly	 used,	 with	 commercial	 kits	 available	 from	 Nimblegen,	
Illumina	and	Agilent[126].	Despite	 technical	differences,	 these	systems	appear	
comparable	 and	 are	 estimated	 to	 cover	 95%	 of	 the	 exome[124].	 Library	
preparation	 involves	 random	 fragmentation	 of	 sample	 DNA	 to	 generate	
sequences	 of	 the	 appropriate	 length	 for	 the	 platform	 (Figure	 3.3).	 These	
sequences	 are	 then	 end	 repaired	 and	 short	 sequences,	 termed	 adaptor	
sequences,	 ligated	 to	 the	 ends	 of	 the	 strands.	 The	 aqueous	 capture	 involves	
hybridisation	with	biotinylated	DNA	or	RNA	baits;	 the	Agilent	kit	used	for	this	
project	 includes	 RNA	 baits.	 The	 hybridised	 fragments	 are	 pulled	 down	 with	
magnetic	 streptavidin	 beads,	 which	 target	 the	 biotinylated	 baits.	 The	 short	
sequence	 fragments	 are	 amplified	 by	 PCR	 and	 undergo	 massively	 parallel	
sequencing.	 In	 addition,	multiplexing	 allows	 a	 number	 of	 DNA	 libraries	 to	 be	
sequenced	simultaneously	through	addition	of	a	distinct	 ‘barcode’	sequence	to	




recorded	 each	 time	 a	 nucleotide	 is	 incorporated	 into	 the	 newly	 synthesised	
chain.	 This	 is	 more	 efficient	 than	 traditional	 techniques,	 which	 separate	 the	
synthesis	 reaction	and	 the	sequence	determination.	 Individual	nucleotides	are	
sequentially	applied	to	the	platform	and,	where	incorporated	into	an	elongating	
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polymer,	 this	 is	 detected	 and	 recorded	 at	 each	 discrete	 locus.	 This	 produces	
reads	 (strings	 of	 bases)	 that	 can	 be	 reassembled	 on	 a	 reference	 sequence	 to	
determine	origin.	Examples	of	sequencing	by	synthesis	include	pyrosequencing,	
ion	 semi-conductor	 sequencing	 and	 single	 molecule	 real	 time	 sequencing	
(SMRT).	The	Illumina	HiSeq	used	in	this	project	works	by	using	sequencing	by	
synthesis	 through	 reversible	 terminator	 technology[127].	 The	 speed	 and	
efficiency	 of	 the	 Illumina	 HiSeq	 makes	 it	 one	 of	 the	 most	 commonly	 used	
platforms.	 The	 reversible	 terminator	 chemistry	 on	 the	 Illumina	 platform	
operates	 by	 the	 addition	 of	 all	 four	 nucleotides	 simultaneously;	 each	 has	 a	
different	 fluorophore	 attached	 to	 the	 external	 phosphate	 group.	 The	
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Figure 3.3, Library Preparation  for Whole Exome Sequencing 
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The	 majority	 of	 published	 studies	 have	 therefore	 used	WES	 in	 preference	 to	
WGS	 as	 the	 lower	 cost	 enables	 a	 greater	 number	 of	 samples	 to	 be	 sequenced	
and	 so	 increase	 the	 power	 of	 the	 study[128].	 	 The	 huge	 quantity	 of	 data	
generated	by	WGS	also	requires	greater	infrastructure	to	store	and	process	the	




WES	 has	 led	 to	 the	 published	 discovery	 of	 over	 180	 novel	 disease	 associated	
genes	 in	 rare	 monogenic	 disorders[130].	 A	 pubmed	 search	 of	 ‘whole	 exome	
sequencing’	in	the	title/abstact	of	papers	returned	in	excess	of	2000	published	
research	 articles.	 Despite	 the	 undoubted	 success	 of	 WES	 in	 disease	 gene	
discovery,	there	remain	challenges	and	limitations	to	the	technique.	Successful	
application	 of	 WES	 relies	 on	 satisfactory	 cohort	 selection,	 adequate	 exome	
capture	 and	 appropriate	 data	 analysis.	 Regions	 of	 the	 exome	 with	 high	 GC	
content	 remain	 challenging	 to	 sequence	and	 repetitive	 sequences	or	duplicate	
regions	 are	 often	 difficult	 to	 align[126].	 	 Uneven	 exon	 capture	 is	 also	
problematic	and	can	introduce	bias[126].	Other	limitations	include	areas	where	
knowledge	 of	 the	 precise	 protein	 coding	 sequence	 or	 alternate	 exons	 is	
inadequate	and	loss	of	sequence	that	cannot	be	aligned	to	the	reference	genome	
at	 the	 base	 calling	 stage[125].	 There	 is	 also	 discussion	 regarding	 additional	
regions	 of	 the	 genome	 that	 may	 be	 included	 in	 exome	 capture	 to	 optimise	
variant	 discovery,	 with	 proposals	 that	 other	 miRNAs,	 promoters	 and	 ultra-
conserved	 elements	 should	 be	 included[125].	 Awareness	 of	 these	 limitations	
should	guide	experimental	design.	
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3.1.6 WES Data Analysis - Filtering Strategies 
A	Single	Nucleotide	Polymorphism	(SNP)	is	defined	as	a	nucleotide	substitution	
that	 occurs	 with	 a	 frequency	 of	 greater	 than	 1%	 in	 the	 general	 ‘control’	
population[131].	The	term	Single	Nucleotide	Variant	(SNV)	 is	more	commonly	
applied	to	a	rarer	population	of	variants	with	a	mean	allele	frequency	of	<1%.	
The	 principal	 challenge	 in	 WES/WGS	 is	 determining	 the	 significance	 of	







Three	major	 groups	 of	 filter	 exist	 to	 curate	 variants	 following	 pre-processing	
and	 read	 alignment;	 these	 are	 quality	 filters,	 variant	 filters	 and	 knowledge	





SNVs,	 although	 sequencing	 introduced	 variants	 will	 also	 be	 removed.	 These	
filters	 include	 genotype	 assessment	 to	 confirm	 that	 a	 putative	 causal	 variant	
adopts	 the	 expected	 inheritance	 pattern[133].	 Variants	 are	 compared	 with	
datasets	 of	 non-pathogenic	 polymorphisms	 and	 population	 variants	 such	 as	
dbSNP	and	the	1000	genome	project[134,	135].	This	is	an	effective	filter	as	over	
95%	of	the	variants	found	on	WES	have	been	previously	reported	in	the	general	
population[125].	 Although	 this	 approach	 is	 useful	 when	 investigating	 rare	
Mendelian	 disease,	 dbSNP	 is	 now	 reported	 to	 contain	 some	 rare	 pathogenic	
alleles[125].	 Minor	 allele	 frequency	 (MAF),	 the	 frequency	 at	 which	 the	 allele	
occurs	 in	 the	population,	 should	be	 taken	 into	 consideration	 to	 avoid	 filtering	
out	 potentially	 recessive	 causal	 variants[125].	 Carriers	 of	 these	 variants	 are	
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often	phenotypically	indistinguishable	from	the	general	population	and	will	be	
included	 in	 these	 databases.	 Variants	 that	 do	 not	 alter	 protein	 amino	 acid	
sequence	 are	 typically	 excluded.	 Computational	 prediction	 tools	 can	 also	 be	
used	to	predict	the	consequence	of	candidate	variants.	These	tools	are	based	on	
evolutionary	conservation	and	many	predict	the	functional	affect	of	amino	acid	
substituition	 on	 protein	 structure	 and	 function.	 Only	 those	 variants	 predicted	
damaging	or	pathogenic	are	included.	
	
The	 knowledge	 filter	 is	 designed	 to	 prioritise	 variants	 most	 likely	 to	 be	
causative.	 It	 entails	 selecting	 variants	 that	 occur	 in	 genes	 known	 to	 regulate	
associated	developmental	pathways	or	in	genes	that	cause	a	similar	phenotype	
in	animal	models	or	other	similar	developmental	disorders.	This	 final	strategy	
was	 used	 with	 success	 in	 the	 large	 Deciphering	 Developmental	 Disorders	
study[136,	137].	
	
Once	 a	 putative	 causal	 variant	 has	 been	 identified	 on	WES	 and	 confirmed	 on	
Sanger	sequencing,	corroborating	evidence	is	required	to	confirm	its	pathogenic	
status.	 Recent	 guidance	 has	 been	 published	 on	 strategies	 to	 confirm	
causality[138].	 It	 recommends	 a	 two-step	 process	 to	 first	 assess	 evidence	 of	
involvement	of	the	gene	and	subsequently	to	assess	evidence	of	involvement	of	
the	specific	variant.	Confirmation	often	necessitates	identifying	similar	variants	
in	 individuals	with	 a	 shared	 phenotype.	 Functional	work	 is	 also	 important	 to	
investigate	 the	 consequence	 of	 the	 mutation	 and	may	 include	 replicating	 the	
variant	in	animal	models.		
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Figure 3.4 The Genome Analysis Toolkit (GATK) Best Practice Protocol[132]. 
 
3.1.7 WES and Clinical Applications 
WES	and	WGS	are	powerful,	unbiased	approaches	to	detecting	genetic	variation	
within	an	 individual[130].	The	application	of	WES	 to	 causal	 gene	discovery	 in	
rare	 monogenic	 disorders	 has	 accelerated	 identification	 disease-associated	
genes.	
	
The	 first	 WES	 proof	 of	 concept	 study	 reported	 the	 identification	 of	 variants	
within	MYH3	 in	a	cohort	of	 individuals	with	Freeman	Sheldon	Syndrome[139].	
Although	 causal	 mutations	 of	 MYH3	 had	 previously	 been	 described	 in	 this	
disorder,	this	demonstrated	that	the	technique	and	subsequent	variant	filtering	
strategies	 could	 identify	 pathogenic	mutations	 in	 rare	Mendelian	disease[139,	
140].	This	was	followed	by	the	first	novel	causal	gene	discovery	 in	a	cohort	of	
individuals	 with	 Miller	 syndrome,	 with	 the	 identification	 of	 compound	
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heterozygous	 DHODH	 mutations[1].	 The	 genetic	 aetiology	 of	 numerous	 rare	
diseases	 has	 now	 been	 elucidated,	 including	 Schinzel–Giedion	 syndrome,	
Diamond–Blackfan	 anaemia	 and	 Weaver	 syndrome[141-143].	 Cohort	 studies	
are	 ongoing	 to	 determine	 causal	 variants	 in	 numerous	 other	 Mendelian	
disorders.	One	of	the	largest	and	most	ambitious	projects	is	the	UK	nationwide	
Deciphering	Developmental	Disease	 study[136,	137].	This	aims	 to	 identify	 the	
causal	variants	in	a	wide	range	of	developmental	disorder	by	coordinating	with	
NHS	clinical	genetic	services.	This	has	recently	reported	the	results	of	the	first	
1133	 individuals	 sequenced,	with	aetiology	elucidated	 in	over	25%[136,	137].	
The	 cohort	 comprises	over	8000	 individuals	but	with	plans	 to	expand	 further	
[136,	137].The	DDD	project	demonstrates	the	integration	of	WES	protocols	into	
clinical	 practice.	 While	 the	 DDD	 project	 aims	 primarily	 to	 provide	 cases	 and	
their	 families	with	genetic	diagnosis,	certain	disorders	such	as	 inborn	error	 in	
metabolism	 may	 be	 amenable	 to	 treatment.	 Five	 individuals	 within	 the	 DDD	
cohort	were	identified	with	one	of	these	conditions	and	may	derive	therapeutic	
benefit[136,	 137].	 	 Other	 similar	 cases	 reports	 exist	 of	 WES	 identifying	
previously	unrecognised	treatable	conditions.	 In	one	report,	 identification	of	a	
novel	homozygous	missense	mutation	in	the	Solute	Carrier	26	family	(SL26A3)	
led	 to	 the	diagnosis	 of	 chloride-losing	diarrhoea	 in	 a	 child	misdiagnosed	with	








Although	WES	has	 been	 utilised	 to	 great	 success	 in	Mendelian	 disorders,	 it	 is	
also	now	being	applied	 to	 interrogate	 complex	phenotypes	 including	 common	
disease	 and	 multigenic	 traits.	 Genome	 wide	 association	 studies	 have	
traditionally	used	SNP	microarrays	to	 investigate	association	of	common	SNPs	
and	 common	 diseases	 risk.	 It	 is	 apparent	 that	 common	 SNPs	 explain	 only	 a	
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3.1.8 Ethical issues regarding WES 
It	 is	 necessary	 to	 also	 consider	 ethical	 issues	 related	 to	WES/WGS.	 The	main	
areas	of	concern	involve	informed	consent	and	return	of	results.	This	is	due	to	
the	 incidental	 findings	 that	 may	 be	 identified	 and	 could	 have	 significant	
implications;	 these	 may	 not	 only	 impact	 the	 participant	 but	 also	 family	
members	and	could	influence	the	ability	to	obtain	medical	insurance.	As	the	use	
of	WES	 in	diagnosis	 increases,	 clear	guidance	on	 these	 issues	 is	 required.	The	
American	 College	 of	 Medical	 Genetics	 and	 Genomics	 published	
recommendations	regarding	the	return	of	incidental	findings[146].	This	advised	
the	 return	 of	 results	 related	 to	 the	 primary	 aim	 of	 WES	 and	 the	 return	 of	
incidental	findings	that	require	the	individual	to	be	warned	and	action	taken.	It	
recommended	 that	 laboratories	 undertaking	 WES	 should	 routinely	 seek	 and	
report	specific	variants	in	a	minimum	set	of	56	genes	representing	24	disorders	
that	are	highly	medically	actionable[146].	These	recommendations	are	debated	
and	 the	 DDD	 study	 investigators	 chose	 to	 return	 results	 only	 considered	
relevant	 to	 the	 development	 disorder[136].	 On	 account	 of	 this,	 the	 study	was	
designed	 only	 to	 identify	 putative	 causal	 variants.	 This	 demonstrates	 the	





3.2.1 Library preparation and exome capture  
Library	preparation	for	exome	capture	of	four	individuals	with	Miller	Syndrome	
was	 performed	 using	 the	 SureSelect	 Human	 All	 Exons	 38	 Mb	 kit	 (Agilent	
Technologies)	for	Illumina	paired-end	sequencing.	3	µg	of	high	quality	genomic	
DNA	 was	 sheared	 with	 Bioruptor®	 (Diagenode),	 purified	 using	 Agencourt®	
AMPure®	XP	beads,	end-repaired	and	‘A’	bases	added	to	the	3’	end	of	the	DNA	
fragments.	 	Libraries	were	purified	and	paired-end	adaptors	 ligated.	 	Adaptor-
ligated	 libraries	 were	 amplified	 with	 6	 cycles	 of	 PCR,	 using	 Illumina	 PCR	










3.2.2 Variant calling and exome analysis 
Sequence	 reads	 were	 quality	 checked	 with	 FASTQC	 0.9.1	 and	 aligned	 to	 the	
hg19	human	genome	reference	assembly	with	BWA	0.5.9	 [147]	with	a	quality	
score	cut-off	of	30.	 	Duplicate	reads	were	marked	with	Picard	MarkDuplicates	
1.43.	 	 Reads	were	 re-aligned	 around	 indels	 and	 scores	 re-calibrated	with	 the	
Genome	 Analysis	 ToolKit	 (GATK)	 1.0.5506	 	 [148,	 149].	 	 BAM	 file	 sorting,	
merging,	 and	 indexing	 was	 performed	 by	 SAMtools	 0.1.12a[150].	 	 Single	
nucleotide	 variants	 (SNVs)	 and	 small	 indels	 were	 called	 with	 GATK	 2.5-2-




Non-synonymous	 coding	 variants	 were	 further	 annotated	 with	 dbNSFP	
2.0[154].	
3.2.3 Filtering Strategy  
Variants	were	annotated	with	1000	Genomes	Phase	1	and	ESP6500	minor	allele	
frequencies[152,	 153].	 	 Non-synonymous	 coding	 variants	 were	 further	
annotated	 with	 dbNSFP	 2.0[154].	 Variants	 were	 further	 curated	 by	 genotype	
and	mapping	quality	 score.	Missense	variants	with	GERP	score	greater	 than	2	
were	 included[155].	 Variants	 were	 analysed	 by	 SIFT,	 Polyphen-2	 hdiv,	 LRT,	
Mutation	 taster	predictor	 and	Mutation	assessor	predictor	 and	 required	 to	be	
predicted	 damaging	 in	 at	 least	 three	 of	 these	 algorhythms	 to	 considered	
further[156-158].	Variants	were	checked	using	the	Integrative	Genome	Viewer	
(IGV)[159].	 Finally	 a	 knowledge	 filter	 was	 used	 to	 curate	 the	 candidate	
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Figure 3.5 Filtering Pipeline. The flowchart is an overview of the filtering workflow 
used in this project. This strategy was adapted from the Genome Analysis Tool Kit 






3.2.4 Validation of Variants 
Sanger	 sequencing	 was	 used	 to	 screen	 patients	 for	mutations	 in	DHODH	 and	
confirm	variants	 identified	on	WES.	GenomiPhi	V2	DNA	Amplification	Kit	was	




volume	 12ul)	 comprising;	 20	 ng	 whole-genome	 amplified	 DNA,	 1X	 ReddyMix	
Custom	PCR	Master	Mix,	0.4	mM	forward	oligonucleotide	and	0.4	mM	reverse	
oligonucleotide	 with	 the	 addition	 of	 1X	 GC-rich	 Solution	 when	 required.	 A	
uniform	PCR	cycling	protocol	was	performed:	95	°C	for	5	min;	32	cycles	of	94	°C	
for	1	min,	58	°C	for	1	min,	72	°C	for	1	min;	72	°C	for	10	min.	PCR	products	were	
visualised	 using	 agarose	 gel	 electrophoresis	 to	 ensure	 adequate	 quantity	 and	
expected	 sizing	 of	 each	 exon	 fragment.	 Bidirectional	 direct	 sequencing,	 using	
the	 universal	 primers,	 was	 performed	 using	 BigDye	 Terminator	 v3.1	 Cycle	
Sequencing	Kit	and	resolved	on	an	ABI	3730	DNA	Analyzer	by	 the	 Institute	of	
Genetics	 and	 Molecular	 Medicine	 (IGMM)	 sequencing	 service.	 Sequence	 files	








3.3.1 Patient Selection and Exome Capture  
Exome	 capture	 and	 sequencing	 was	 performed	 in	 four	 unrelated	 individuals	
diagnosed	with	 non-classical	Miller	 Syndrome.	 The	 patients	 were	 included	 in	
exome	 analyses	 if	 there	 was	 no	 detectable	 mutation	 in	 DHODH,	 the	 gene	
responsible	 for	 Miller	 Syndrome[1].	 The	 possibility	 of	 genomic	 deletions	 or	
duplications	 was	 also	 excluded	 on	 array	 comparative	 genomic	 hybridisation	
(array	 CGH)	 prior	 to	 whole	 exome	 sequencing	 (WES).	 The	 patients	 all	





uncommon	 diagnosis[115].	 The	 rarity	 and	 phenotype	 heterogeneity	 of	 the	






Case Reports  
Demographic Details: Individual R24H4 (FAM 3428)[3]  
Individual	 R24H4	 is	 a	 male	 born	 at	 39	 weeks	 gestation,	 weighing	 3628g.	
Maternal	 age	 was	 33	 years	 and	 paternal	 age	 was	 31	 years.	 There	 was	 no	
parental	consanguinity.		Postnatal	growth	was	on	the	75th	centile.		
Medical History, Symptoms and Signs 
The	individual	was	initially	diagnosed	with	Non	Classical	Miller	Syndrome.	The	
proband	presented	with	cleft	lip,	cleft	palate	and	severe	malar	hypoplasia	with	
maxillary	 retrusion.	 There	 was	 no	 micrognathia.	 Eyes	 and	 ears	 were	 normal	
morphology,	with	 no	 impairment	 in	 vision	 or	 hearing.	 The	 upper	 limbs	were	




responsible	 for	Miller	 syndrome.	Whole	exome	 sequencing	 (WES)	 identified	 a	
single	novel	variant	in	the	FGFR1	gene.		
Differential Diagnosis  
Disruptions	 such	 as	 an	 in	 utero	 vascular	 event	 or	 amniotic	 constriction	 band	




the	most	 appropriate	 diagnosis.	 At	 the	 time	 of	 initial	 assessment	 and	 genetic	
analysis	it	was	not	obvious	that	the	individual	had	anosmia	or	delayed	puberty.	
Therefore	 based	 on	 clinical	 findings	 this	 individual	 would	 not	 have	 been	
diagnosed	with	Kallman	syndrome.	No	similar	limb	disorder	had	been	reported	
in	 this	 syndrome	 previously.	 FGFR1	 mutations	 in	 association	 with	 limb	
reduction	 deformities	 have	 been	 reported	 in	 Hartsfield	 syndrome.	 Hartsfield	
syndrome	 is	 a	 rare	 unique	 association	 of	 holoprosencephaly	 and	 ectrodactyly	
with	or	without	features	if	cleft	lip	or	palate[166].	Hartsfield	syndrome	was	not	
considered	 a	 plausible	 differential	 diagnosis	 as	 the	 individual	 did	 not	 suffer	
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Medical History, Symptoms and Signs 




forearm.	The	posterior	 rays	of	 the	hand	were	also	 involved	bilaterally.	On	 the	







were	 considered	unlikely	due	 to	 the	bilateral	 involvement	of	 the	upper	 limbs.	
Therefore	a	genetic	cause	was	investigated.	The	individual	was	reviewed	by	an	
experienced	 Consultant	 in	 Mediacal	 Genetics	 and	 although	 other	 syndromes	
with	 PALLRD	were	 considered	 it	 was	 their	 expert	 opinion	 that,	 although	 not	











Demographic Details: Individual	R24C6	(FAM	3378)[3] 
Individual	 R24C6	 is	 a	male	 born	 at	 37	weeks	 gestation,	weighing	 2500g.	 The	
birth	 length	and	birth	occipital	 frontal	circumference	were	unknown.	At	birth,	
maternal	 age	 was	 43	 years	 and	 paternal	 age	 was	 41	 years.	 There	 was	 no	
parental	 consanguinity.	The	 individual’s	postnatal	 growth	was	below	 the	0.4th	
centile.		
Medical History, Symptoms and Signs 
The	 individual	 was	 initially	 diagnosed	 with	 atypical	 Miller	 Syndrome.	 The	
individual	 presented	 with	 craniofacial	 malformations	 including;	 cleft	 lip,	 cleft	
palate,	 malar	 hypoplasia,	 micrognathia,	 and	 absent	 lower	 eyelashes.	 	 Mild	
hearing	loss	was	diagnosed.	There	was	fusion	of	the	4th	and	5th	metacarpals	and	
syndactyly	in	both	of	the	upper	limbs.		Short	femurs	and	talipes	(club	foot)	was	




were	 considered	 unlikely	 due	 to	 the	 bilateral	 involvement	 of	 the	 upper	 limbs	
and	lower	limbs.	The	individual	was	reviewed	by	an	experienced	Consultant	in	
Medical	 Genetics	 and	 although	 other	 PALLRD	 syndromes	 were	 considered	 it	
was	their	expert	opinion	that,	the	individual’s	presentation	was	most	in	keeping	













Demographic Details: Individual	R24C12	(FAM	3391)[3] 
Individual	R24C12	is	a	female	born	at	40weeks	gestation,	weighing	3370g.	The	
birth	 length	was	47cm	and	birth	occipital	 frontal	 circumference	was	34cm.	At	
birth,	maternal	age	was	26	years	and	paternal	age	was	29	years.	There	was	no	
parental	 consanguinity.	 The	 individual’s	 postnatal	 growth	 was	 below	 the	 9th	
centile.		
Medical History, Symptoms and Signs 
The	 individual	 was	 initially	 diagnosed	 with	 atypical	 Miller	 Syndrome.	 	 The	
individual	presented	with	craniofacial	malformations	including;	cleft	palate	and	
mild	malar	hypoplasia.	Ear	development	and	hearing	were	normal.	The	upper	
limbs	were	affected	bilaterally.	 	The	 left	upper	 limb	had	3	digits	and	 the	right	
had	2	digits.	The	 thumbs	were	absent	bilaterally.	There	was	a	mild	soft	 tissue	




were	 considered	 unlikely	 due	 to	 the	 bilateral	 involvement	 of	 the	 upper	 limbs	
and	lower	limbs.	The	individual	was	reviewed	by	an	experienced	Consultant	in	
Mediacal	 Genetics	 and	 although	 other	 PALLRD	 syndromes	were	 considered	 it	
was	their	expert	opinion	that,	the	individual’s	presentation	was	most	in	keeping	




responsible	 for	 Miller	 syndrome[1].	 Six	 potentially	 pathogenic	 sequence	
variants	 were	 discovered	 on	 WES	 (Table	 3.5).	 	 A	 sequence	 variant	 was	
discovered	 in	HOXD11	however	 this	was	not	confirmed	on	Sanger	sequencing.		
Interestingly	 there	 was	 a	 candidate	 variant	 in	MAP3K3	 gene.	 	MAP3K3	 gene	
directly	 regulates	 the	 extracellular	 signal-regulated	 protein	 kinase	 (ERK)	
pathways	 by	 activating	 SEK	 and	 MEK1/2	 respectively.	 The	 MAPK/ERK	
signalling	cascade	is	a	major	downstream	pathway	of	FGF	signalling[13].	There	
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is	 evidence	 that	 the	 MAPK/ERK	 pathway	 is	 the	 main	 downstream	 signalling	
pathway	for	FGFR1[167,	168].	
	
























Gestation 40 39 37 40
Birth Length 52 UK UK 47
Birth OFC 34.8 UK UK 34
Maternal Age 39 33 43 26
Paternal Age 40 31 41 29
Consanguineous No No No No
Age at last Assessment 3 yrs 17 mo 2.5 yrs 2 yrs 
Post Natal Growth 75th centile <0.4th centile 9th centile
Craniofacial Cleft Lip No Yes Yes No
Cleft Palate No Yes Yes Yes
Malar No Severe Yes Mild
Hypoplasia Maxillary 
Retusion
Micrognathia No No Yes No
Lower Eyelid Coloboma No No No No
Absent Lower Eyelashes No NR Yes No
Ears/Hearing Ear Shape Abnormal Normal Normal Normal Normal
Hearing Loss No No No No
Upper Limbs Short Ulnar Bilateral L > R No No Bilateral
Short Radius Bilateral L > R No No Bilateral
Missing 
Posterior Ray
Left: 3 Digits with 
thumb-like digit on 
radial side; Right: 
fusion of digits 4-5
No Bilateral fusion 
of 4th and 5th 
Metacarpals
Left: only 3 
Phalangeal 
digits and 2 
Metacarpals/
right: 2 digits 
only
Thumbs Abnormal Position 
on Left
Normal Normal Absent 
Bilaterally
Camptodactyly No No No No
Syndactyly Left: 2-3/right: 4-5 Unilateral 
Lower Limb




Lower Limbs Missing 5th Ray of Foot No Bilateral No No
Other Missing Rays No No Talipes No
Cryptorchidism N/A Yes No N/A
Hypospadias N/A No No N/A
Inguinal 
Herniae
No No No No
Polythelia No NR No No





















DHODH Mutations Wt Wt Wt Wt
N/A: not available. UK: unknown.  NR: no result: Wt: wild type. OFC: occipitofrontal circumference. LD: learning difficulty. mo: months. yrs: years




I	 hypothesised	 that	 we	 could	 utilise	 WES	 of	 four	 unrelated	 individuals	 to	
generate	 a	 concise	 list	 of	 candidate	variants	 for	 further	 investigation	and	 that	
these	putative	pathogenic	variants	would	occur	 in	genes	 involved	 in	 limb	bud	
growth	 and	 patterning.	 	 We	 chose	 a	 WES	 strategy,	 as	 it	 was	 cost	 and	 time	
efficient.	 WES	 focuses	 on	 the	 analyses	 of	 the	 protein	 coding	 region	 of	 the	
genome	(approximately	1%	of	the	whole	genome)[124].		Parental	DNA	was	not	
available	for	all	of	the	patients	at	the	time	of	the	initial	WES.	However	there	was	





CCDS)	 (Agilent	 Technologies)	 for	 Illumina	 paired-end	 sequencing	 to	 capture	
exonic	 sequence	 (93.76%	 of	 CCDS).	 The	 quality	 control	 and	 library	
quantification	 was	 carried	 out	 using	 the	 Bioanalyzer	 High	 Sensitivity	 assay	
(Agilent	Technologies)	followed	by	cluster	generation.	Paired-end	sequencing	of	
the	 captured	 exomes	 was	 performed	 on	 an	 Illumina	 HiSeq	 2000	 sequencing	
system	(Illumina)	at	The	GenePool	(University	of	Edinburgh).							
3.3.2 Data Analysis 
Base	 calling,	 sequence	 alignment	 and	variant	 calling	were	 conducted	with	 the	
assistance	of	the	IGMM	Bioinformatics	Service.	The	mean	on	target	read	depth	
was	 between	 229-308X	 (Table	 3.2).	 In	 order	 to	 filter	 the	 large	 number	 of	
variants	I	focused	further	filtering	analysis	on	non-synonymous	variants,	coding	















R24C12 17149567934 442.83 358 97.8 96.0 94.3
R24C6 17904833319 462.33 368 98.8 97.3 95.7
R24H10 16022504974 413.72 336 98.7 97.3 95.8
R24H4 13406558382 346.18 286 98.4 96.8 95.2
	
Table 3.2 This table shows the depth for each individual exome sequenced. 
N.B High depth as each exome was run three times at genepool as they were 
some of the very first exomes that gene pool sequenced. Automated quality 
trimming in the alignment (minimum quality score 30) was used to exclude the poor 
quality sequence from the first two runs.  
	
	





filtering	 out	 non-pathogenic	 Single	 Nucleotide	 Polymorphisms	 (SNPs)	 and	
sequencing	 errors.	 It	 is	 predicted	 that	 95%	of	 variants	 identified	by	WES	will	
have	been	previously	 identified	in	the	general	population[125].	Two	analytical	
models	were	utilised	based	on	the	mode	of	 inheritance	of	causative	variants.	 I	
analysed	 the	 data	 with	 a	 dominant	 model;	 as	 the	 parents	 of	 each	 individual	
were	phenotypically	normal,	I	predicted	that	the	causal	variant	would	occur	de	
novo	in	a	dominant	model.		I	also	studied	the	data	using	a	recessive	model;	the	
unaffected	 parents	 would	 be	 carriers	 of	 one	 or	 two	 rare	 recessive	 alleles.	
Compound	 heterozygous	 mutations	 in	DHODH	 were	 identified	 on	WES	 to	 be	




R24C12 R24C6 R24H10 R24H4
HET HOM HET HOM HET HOM HET HOM
CODON_CHANGE_PLUS_CODON_
DELETION
108 11 105 10 94 13 107 9
CODON_CHANGE_PLUS_CODON_
INSERTION
11 5 10 6 10 7 9 3
CODON_DELETION 92 21 104 28 100 20 100 19
CODON_INSERTION 25 29 36 25 34 28 36 28
FRAME_SHIFT 493 32 490 40 474 33 486 38
NON_SYNONYMOUS_CODING 7761 3220 7615 3229 7658 3124 7819 3114
NON_SYNONYMOUS_START 1 2 5 1 3 2 5 0
SPLICE_SITE_ACCEPTOR 56 17 63 17 50 17 60 15
SPLICE_SITE_DONOR 119 16 145 14 129 10 118 21
START_GAINED 249 150 237 140 256 152 237 147
START_LOST 16 4 12 6 14 6 11 4
STOP_GAINED 170 13 164 19 164 12 163 14
STOP_LOST 16 5 19 4 19 7 17 6
SYNONYMOUS_CODING 6787 3645 6679 3648 6873 3649 6870 3478
SYNONYMOUS_STOP 6 5 13 2 9 2 7 0
TOTAL UNIQUE 15564 7012 15366 7031 15557 6917 15738 6734
	
Table 3.3 Total variants on exome analysis 
The above table shows the number of each type of sequence variation found in 
exome analysis 
	
3.3.3 Dominant Model Analysis 
As	 mentioned	 above	 the	 total	 number	 of	 heterozygous	 variants	 was	
approximately	15000	(Table	2.4).	Following	sequence	alignment,	variants	were	
annotated	 using	 SnpEff	 software[151].	 I	 predicted	 that	 non-synonymous	
variants	 (NS),	 splice	 acceptor	 and	 donor	 site	 variants	 (SS)	 and	 coding	 indels	
were	more	 likely	 to	be	damaging	and	 included	them	for	 further	analyses.	This	
decreased	the	potential	variants	to	approximately	9000	in	the	dominant	model	
(Table	 3.4).	 In	 order	 to	 further	 filter	 the	 data	 and	 exclude	 described	 non-
pathogenic	variants,	I	assessed	variants	in	my	data	set	against	public	databases:	
1000	genomes,	EVS	and	dbSNP137[134,	153,	170].	These	databases	provide	a	
reference	 of	 single	 nucleotide	 polymorphisms	 (SNPs)	 or	 single	 nucleotide	





variants	 responsible	 for	 developmental	 disorders	 should	 be	 included	 in	 these	
databases.	 This	 approach	 enabled	 curating	 of	 the	 data	 to	 approximately	 240	
variants	 per	 individual.	 The	 variants	 were	 next	 compared	 to	 our	 internally	
analysed	 exome	 sequences	 which	 filtered	 out	 approximately	 a	 further	 60	
candidate	variants	(table	3.4).		The	quality	of	the	sequencing	and	the	accuracy	of	
the	 variants	 being	 called	 correctly	 were	 assessed	 using	 genotype	 and	 map	
quality	 scores.	 	 Variants	with	 a	 genotype	 quality	 score	 of	 equal	 to	 or	 greater	
than	60	(an	arbitrary	threshold)	were	included.	The	genotype	quality	score	is	a	
Phred	scaled	value	representing	the	confidence	that	the	base	is	called	correctly,	
the	 higher	 the	 value	 the	 greater	 the	 confidence	 that	 the	 genotype	 is	
correct[171].	A	genotype	score	of	greater	than	60	indicates	that	there	is	a	 less	
than	1	 in	1,000,000	chance	of	the	base	being	called	incorrectly	or	a	99.9999%	
probability	 that	 the	 base	 is	 correctly	 assigned.	 Mapping	 quality	 score	 of	 0	
indicates	that	at	that	site	the	sequence	aligner	had	no	confidence	in	mapping	the	
read	 to	 the	 reference	 genome.	 	 The	 proportion	 of	 the	 reads	 with	 mapping	
quality	0	at	a	site	was	divided	by	the	depth	and	only	if	this	ratio	was	less	than	
10%	(i.e.	90%	of	the	reads	could	be	confidently	aligned)	were	they	included.	It	
is	 vital	 that	 the	 variants	 are	 accurately	 called	 to	 reduce	 the	 rates	 of	 false	













DOMINANT MODEL R24C12 R24C6 R24H10 R24H4
Total Heterozygous Variants 15564 15366 15557 15738
Total Monoallelic Missense/Nonsense/Splice/Indel 9007 8894 8905 9067
Not present in 1000 Genomes or EVS or dbSNP137 or 
other samples
248 278 197 241
Not present in local database 182 226 149 174
*HQRW\SHTXDOLW\$1'0DSTXDOLW\'HSWK 157 194 127 148
Gerp RS score >2 (missense only) 140 168 109 134
'DPDJLQJLQSUHGLFWLRQWRROV6,)73RO\SKHQKGLY/57 
0XWDWLRQWDVWHUSUHGLFWRU0XWDWLRQDVVHVRUSUHGLFWRU
116 140 81 106
9HUL¿HGRQ,*9VRIWZDUH 23 25 15 15
.QRZOHGJH)LOWHULQYROYHGLQNQRZQOLPEGHYHORSPHQW
SDWKZD\VRUSUHVHQWLQ0*,ROLJRGDFW\O\GDWDVHW




Table 3.4 Exome Variants in a Dominant Model  
The total number of heterozygous variants remaining after various filters is shown. 
Variants were filtered by presence in 1000 Genomes, EVS, dbSNP and other 
exomes in the institute (local databases)[134, 153, 170] Quality filters were 
employed to filter further. Missense mutations with a GERP conservation score of 
<2 were excluded. Variants predicted damaging in 3 or more computational 
damaging prediction tools were included for further analysis. Variants verified on 
Integrative Genomics Viewer (IGV) were included. Knowledge filter involved manual 
curation of UCSC, Gene Cards, OMIM, HGNC, Gene Atlas, Decipher and MGI 
Jackson Lab[75, 160-165]. Variants were included if they were involved in limb 
development pathways, parallel pathways or there was a published human or 
animal model phenotype.   
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Variants	 that	 cause	 Mendelian	 disease	 usually	 occur	 within	 highly	 conserved	
regions	 of	 the	 genome	 and	 can	 often	 be	 predicted	 to	 be	 deleterious.	
Computational	 conservation	 tools	 (missense	 mutation	 only)	 and	 damaging	
prediction	 algorithms	 were	 applied	 to	 the	 generated	 sequences	 to	 further	
curate	 the	 data.	 The	 prediction	 tools	 utilise	 information	 such	 as	 evolutionary	
conservation	 and	 protein	 structure	 to	 predict	 the	 affect	 of	 an	 amino	 acid	
substitution,	at	a	particular	position,	on	the	protein	function.		
	
We	utilised	The	Genomic	Evolutionary	Rate	Profiling	 (GERP)	 score	 to	 identify	
conserved	 regions	 where	 variation	 is	 expected	 to	 be	 pathogenic[172].	




been	widely	used	 and	has	been	 shown	 to	 be	 statistically	 rigorous[172].	GERP	
initiates	 with	 a	 multiple	 sequence	 alignment	 from	 multiple	 species	 and	
compares	each	column	of	the	alignment	individually.	It	identifies	the	number	of	
substitutions	and	compares	this	with	the	predicted	rate	of	substitutions	during	
neutral	evolution.	GERP	can	be	utilised	 further	 to	 identify	regions	of	sequence	
with	 putative	 functional	 importance	 with	 unexpected	 constraint,	 known	 as	
constrained	elements.	We	used	this	approach	as	it	confers	scores	on	individual	
nucleotides	 and	 allowed	 SNVs	 to	 be	 ranked	 for	 further	 analyses.	 	 The	 GERP	
score	ranges	from	-12.3	to	6.17,	with	6.17	being	the	most	conserved.	I	included	
SNVs	 with	 a	 GERP	 score	 of	 greater	 than	 2	 for	 further	 investigation.	 This	
threshold	 is	 accepted	 as	 evolutionary	 conserved	 and	 likely	 functional	




variants	were	 only	 retained	 if	 predicted	 damaging	 by	 three	 or	more	 of	 these	
scoring	systems.	The	data	was	annotated	with	SIFT,	a	sequence	similarity	based	
tool	 that	 sorts	 intolerant	 from	 tolerant	 amino	 acid	 substitutions	 and	 predicts	
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the	 consequence	 of	 an	 amino	 acid	 substitution[156].	 SIFT	 utilises	 the	
evolutionary	 theory	 that	 amino	 acids	 important	 for	 protein	 function	 will	 be	
conserved.	 SIFT	 can	 anticipate	 whether	 an	 amino	 acid	 substitution	 in	 the	
protein	 of	 interest	 will	 have	 a	 phenotypic	 affect	 prior	 to	 functional	
interrogation.	 SIFT	 generates	 multiple	 sequence	 alignments	 (MSA)	 from	
databases	such	as	UNIPROT	and	BLAST.	SIFT	then	creates	a	matrix	calculating	
the	probability	of	all	possible	amino	acid	substitutions	in	the	protein	of	interest	




Another	 automatic	 integrative	 software	 tool,	 Polyphen-2	 Human	 Div	 model	
(Polymorphism,	phenotype	version	2)	was	employed	 to	predict	 if	 the	variants	
were	deleterious.	Polyphen	 focuses	on	non-synonymous	SNPs[157].	Like	SIFT,	
Polyphen	 examines	 the	 level	 of	 constraint	 on	 multiple	 sequence	 alignments	
(known	as	Position	Specific	 Independent	Counts,	PSIC)	however	 in	 addition	 it	
examines	 the	 affect	 of	 the	 position	 of	 the	 amino	 acid	 substitution	 on	 the	
proteins	three	dimensional	structure	and	function[157].	Variants	were	classed	
as	benign,	possibly	damaging,	or	probably	damaging.	Mutation	Taster	predictor	
uses	 a	 similar	 algorithm	 to	 Polyphen-2	 however	 it	 can	 be	 used	 to	 examine	
different	types	of	variation	including	splice	sites[158].	It	uses	a	Bayes	classifier	






Post	 filtering	 with	 conservation	 and	 predicting	 damaging	 tools	 (variants	
retained	 if	 predicted	 damaging	 in	 3	 or	 more	 algorithms)	 116	 variants	 in	





Genome	 Viewer	 (IGV)[159].	 This	 allows	 visualisation	 of	 the	 dataset	 and	 used	
colour	to	denote	variation	and	transparency	to	indicate	the	quality	of	the	reads.	
A	 large	 number	 of	 indels	 were	 manually	 identified	 as	 false	 positives	 and	
excluded	 out	 at	 this	 stage.	 	 This	 decreased	 the	 number	 of	 variants	 to	 23	 in	




165].	 Variants	 were	 included	 if	 they	 were	 involved	 in	 limb	 development	
pathways,	parallel	pathways	or	there	was	a	published	human	or	animal	model	
phenotype.	 	This	 resulted	 in	6	candidate	variants	remaining	 for	R24C12,	3	 for	
R24C6,	 0	 for	 R24H10	 and	 2	 for	 R24H4.	 	 Table	 3.5	 shows	 the	 top	 candidate	
variants	 generated	 by	 the	 dominant	 model	 analysis.	 Finally	 targeted	 Sanger	
sequencing	was	commenced	to	confirm	these	variants.		
	
The	 mutation	 c.1987G>A	 (p.Pro663Ser)	 in	 patient	 R24H4	 was	 confirmed	 by	
Sanger	 sequencing	 and	 further	 functional	work	 exploring	 the	 consequence	 of	
this	amino	acid	substitution	on	protein	function	is	presented	in	Chapter	4.		
	
There	 were	 six	 potential	 candidate	 variants	 in	 the	 individual	 R24C12,	 which	
required	targeted	Sanger	sequencing	(Table	3.5).	HOXD11	was	prioritised	as	 it	
known	 to	 be	 involved	 in	 limb	development[176].	 The	 knockout	mouse	model	
shows	 abnormal	 distal	 limb	 patterning.	 However	 HOXD11	 could	 not	 be	
confirmed	 on	 Sanger	 sequencing	 as	 this	 variant	 proved	 to	 be	 a	 false	 positive	
result.	MAP3K3	 is	 another	 potential	 candidate	 variant.	MAP3K3	regulates	 ERK	
and	 is	a	parallel	pathway	 to	 the	developmental	FGFR1	 signalling	pathway[75].		









Table 3.5 Top candidate causative variants for each individual after filtering 
exome sequencing data. This table demonstrates the candidate variants for each 
individual after the knowledge filter was applied. Variants were included if they 
caused a human or animal model limb reduction deformity phenotype or if they were 
in genes involved in limb development pathways or parallel pathways. ∗ ExAC has 
become available since the original analysis and has additionally been used to 






The	 filtering	 pipeline	 was	 replicated	 for	 recessive	models	 with	 one	 caveat.	 A	
limitation	 of	 filtering	 against	 public	 datasets	 is	 that	 dbSNP	now	 contains	 rare	
pathogenic	 alleles[125].	 The	 fact	 that	 dbSNP	 contains	 some	 rare	 pathogenic	
alleles	 is	even	more	relevant	 for	recessive	disorders	because	carriers	who	are	
phenotypically	indistinguishable	from	the	general	population	control	group	will	
be	 included	 in	 these	 databases.	 To	 avoid	 eliminating	 possible	 pathogenic	
variants	in	the	recessive	model	analysis	we	did	not	filter	this	data	against	dbSNP	
and	only	included	variants	with	a	minor	allele	frequency	of	under	0.005	in	1000	
Genomes	 or	 EVS.	 Limb	 reduction	 deformities	 occur	 in	 0.04%[19]	 of	 the	
population	and	therefore	this	was	a	plausible	strategy.	There	were	no	candidate	
variants	 under	 the	 compound	 heterozygous	 (Table	 3.6)	 or	 homozygous	
recessive	models	(Table	3.7).		
RECESSIVE MODEL (COMPOUND HETEROZYGOUS) R24C12 R24C6 R24H10 R24H4
Total Autosomal Heterozygous Variants 15157 15171 15169 15524
Total Missense/Nonsense/Splice/Indel 8768 8750 8663 8906
1RWSUHVHQWRU0$)LQRQHRIJHQRPH
EVS; not present in other case samples
596 579 503 625
1RWSUHVHQWRU0$)LQORFDOGDWDEDVH 460 467 391 504
*HQRW\SHTXDOLW\$1'0DSTXDOLW\'HSWK 407 420 342 457
2+ mutations per gene 17 20 22 26
Gerp RS score > 2 (missense only) & 2+ mutations/gene 12 14 10 13
'DPDJLQJSUHGLFWLRQWRROV6,)73RO\SKHQKGLY/57 
0XWDWLRQWDVWHUSUHGLFWRU0XWDWLRQDVVHVRUSUHGLFWRU
2 4 8 7
9HUL¿HGRQ,*9VRIWZDUH	PXWDWLRQVJHQH
(Excluding indels & 2+ mutations/gene)
0 0 1 1
.QRZOHGJH)LOWHULQYROYHGLQNQRZQOLPEGHYHORSPHQW
SDWKZD\VRUSUHVHQWLQWKH0*,ROLJRGDFW\O\GDWDVHW
0 0 0 0
RECESSIVE MODEL (HOMOZYGOUS) R24C12 R24C6 R24H10 R24H4
Total Autosomal Homozygous Variants 6854 6771 6740 6482
Total Missense/Nonsense/Stop lost/Splice/Indel 3393 3376 3292 3234
1RWSUHVHQWRU0$)LQRQHRIJHQRPH
EVS; not present in other case samples
16 12 14 11
1RWSUHVHQWRU0$)LQORFDOGDWDEDVH 6 2 2 1
*HQRW\SHTXDOLW\$1'0DSTXDOLW\'HSWK 1 0 2 0
Gerp RS score > 2 (missense only) 0 0 2 0
'DPDJLQJSUHGLFWLRQWRROV6,)73RO\SKHQKGLY/57 
0XWDWLRQWDVWHUSUHGLFWRU0XWDWLRQDVVHVRUSUHGLFWRU
0 0 2 0
9HUL¿HGRQ,*9VRIWZDUH 0 0 1 0
.QRZOHGJH)LOWHULQYROYHGLQNQRZQOLPEGHYHORSPHQW
SDWKZD\VRUSUHVHQWLQWKH0*,ROLJRGDFW\O\GDWDVHW
0 0 0 0
 
Table 3.6 Exome Variants in a Recessive Model  (Compound Heterozygous) The total 
number of compound heterozygous variants remaining after various filters are shown. 
Variants were filtered by presence in 1000 Genomes, EVS and other exomes in the institute 
(local databases). Quality filters were employed to filter further. Missense mutations with a 
GERP conservation scor of <2 were excluded.. Variants predicted damaging in 3 or more 
computational damaging prediction tools were included for further analysis. Variants verified 
on Integrativ  Genomics Viewer (IGV) were included. Knowledge filter involved manual 
curation of UCSC, Gene Cards, OMIM, HGNC, Gene Atlas, Decipher and MGI Jackson 
Lab[75, 160-165]. Variants were included if they were involved in limb development 





RECESSIVE MODEL (COMPOUND HETEROZYGOUS) R24C12 R24C6 R24H10 R24H4
Total Autosomal Heterozygous Variants 15157 15171 15169 15524
Total Missense/Nonsense/Splice/Indel 8768 8750 8663 8906
1RWSUHVHQWRU0$)LQRQHRIJHQRPH
EVS; not present in other case samples
596 579 503 625
1RWSUHVHQWRU0$)LQORFDOGDWDEDVH 460 467 391 504
*HQRW\SHTXDOLW\$1'0DSTXDOLW\'HSWK 407 420 342 457
2+ mutations per gene 17 20 22 26
Gerp RS score > 2 (missense only) & 2+ mutations/gene 12 14 10 13
'DPDJLQJSUHGLFWLRQWRROV6,)73RO\SKHQKGLY/57 
0XWDWLRQWDVWHUSUHGLFWRU0XWDWLRQDVVHVRUSUHGLFWRU
2 4 8 7
9HUL¿HGRQ,*9VRIWZDUH	PXWDWLRQVJHQH
(Excluding indels & 2+ mutations/gene)
0 0 1 1
.QRZOHGJH)LOWHULQYROYHGLQNQRZQOLPEGHYHORSPHQW
SDWKZD\VRUSUHVHQWLQWKH0*,ROLJRGDFW\O\GDWDVHW
0 0 0 0
RECESSIVE MODEL (HOMOZYGOUS) R24C12 R24C6 R24H10 R24H4
Total Autosomal Homozygous Variants 6854 6771 6740 6482
Total Missense/Nonsense/Stop lost/Splice/Indel 3393 3376 3292 3234
1RWSUHVHQWRU0$)LQRQHRIJHQRPH
EVS; not present in other case samples
16 12 14 11
1RWSUHVHQWRU0$)LQORFDOGDWDEDVH 6 2 2 1
*HQRW\SHTXDOLW\$1'0DSTXDOLW\'HSWK 1 0 2 0
Gerp RS score > 2 (missense only) 0 0 2 0
'DPDJLQJSUHGLFWLRQWRROV6,)73RO\SKHQKGLY/57 
0XWDWLRQWDVWHUSUHGLFWRU0XWDWLRQDVVHVRUSUHGLFWRU
0 0 2 0
9HUL¿HGRQ,*9VRIWZDUH 0 0 1 0
.QRZOHGJH)LOWHULQYROYHGLQNQRZQOLPEGHYHORSPHQW
SDWKZD\VRUSUHVHQWLQWKH0*,ROLJRGDFW\O\GDWDVHW
0 0 0 0
	
Table 3.7 Exome Variants in a Recessive Model  (Homozygous)	
The total number of homozygous variants remaining after various filters are shown. 
Variants were filtered by presence in 1000 Genomes, EVS and other exomes in the 
institute (local databases). Quality filters were employed to filter further. Missense 
mutations with a GERP conservation score of <2 were excluded. Variants verified 
on Integrative Genomics Viewer (IGV) were included. 
are shown. Variants were filtered by presence in 1000 Genomes, EVS and other 
exomes in the institute (local databases). Quality filters were employed to filter 
further. Missense mutations with a GERP conservation score of <2 were excluded. 
Variants predicted damaging in 3 or more computational damaging prediction tools 
were included for further analysis. Variants verified on Integrative Genomics Viewer 
(IGV) were included. Knowledge filter involved manual curation of UCSC, Gene 
Cards, OMIM, HGNC, Gene Atlas, Decipher and MGI Jackson Lab[75, 160-165]. 
Variants were included if they were involved in limb development pathways, parallel 






patients	 diagnosed	with	 non-classical	Miller	 syndrome	 of	 uncertain	 aetiology.	
The	aim	was	 to	 identify	 the	 causative	 genetic	mutations	 to	 improve	diagnosis	
and	 prognostication,	 to	 elucidate	 mechanisms	 underlying	 the	 disorder	 and	
therefore	provide	insight	into	normal	limb	development.		
3.4.1 Assembly of WES Cohorts 
This	 cohort	was	 assembled	as	part	 of	 a	 larger	 cohort	 of	 cases	diagnosed	with	
postaxial	 acrofacial	 dysostosis	 (POADS)	 /	 Miller	 syndrome.	 Mutations	 were	
identified	within	DHODH,	the	published	disease-associated	gene,	in	five	patients	
from	this	cohort;	no	mutations	within	DHODH	were	identified	in	the	four	cases	
described	 in	 this	 chapter.	 Prior	 to	 WES,	 CAD	 and	 UMPS	 genes	 were	 also	
sequenced	 to	 exclude	 mutations	 in	 either	 gene;	 these	 genes	 encode	 the	 two	
additional	enzymes	required	for	catalyzing	the	reactions	in	de	novo	pyrimidine	




This	 cohort	 therefore	 underwent	 both	 targeted	 and	 genome-wide	 genotype	
interrogation	 prior	 to	WES.	 This	 is	 not	 uncommon	 and	 similar	 findings	were	
described	 in	 the	 large	 Deciphering	 Developmental	 Disorders	 study[136].	
Although	costs	are	decreasing,	WES	remains	an	expensive	undertaking	and	it	is	
conventional	practice	to	exclude	mutations	 in	known	disease-associated	genes	
with	 Sanger	 sequencing	 prior	 to	 WES[177].	 Exome	 coverage	 on	 WES	 is	 not	
complete	and	read	depth	variable[178].	In	addition,	false	negatives	are	reported	
particularly	 in	 areas	 of	 sequence	 repetition	 or	 sequencing	 difficulty,	 such	 as	





will	 become	 the	 first	 line	 investigation	 for	 such	 patients.	 There	 is	 already	
discussion	regarding	the	use	of	WES	rather	than	gene	panels	to	delineate	cancer	
susceptibility	 in	 high-risk	 individuals[180,	 181].	 	 Array	 CGH	was	 used	 in	 this	
cohort	 to	 interrogate	 copy	 number	 variation;	 array	 CGH	 remains	 the	
investigations	of	choice	to	study	genomic	imbalance.	Several	studies	have	used	
array	CGH	to	 investigate	 for	pathogenic	genomic	 imbalances	 in	developmental	
disorders;	 these	 imbalances	 are	 reported	 in	 over	 10%	of	 patient	with	mental	
retardation	 and	 dysmorphic	 features[182,	 183].	 However,	 mild	 learning	
disability	 was	 noted	 in	 only	 one	 of	 these	 four	 cases,	 with	 the	 others	
demonstrating	 normal	 intellectual	 development.	 Given	 this	 phenotype,	 it	 was	
less	 likely	 that	 a	 large	 genomic	 imbalance	 was	 responsible	 but	 array	 CGH	
remains	 useful	 to	 exclude	 small	 imbalances	 affecting	 isolated	 regions	 or	
individual	genes[182].	Protocols	now	exist	for	interrogating	WES	data	for	copy	
number	 variation	 but	 these	 are	 disadvantaged	 by	 the	 uneven	 spread	 of	 exon	
reads;	this	leads	to	a	high	rate	of	false	positive	calls	for	CNV[184].		
3.4.1.1 Phenotype heterogeneity 
Developmental	 disorders	 may	 arise	 due	 to	 varied	 genetic	 or	 environmental	
insults.	 To	 obtain	 the	 greatest	 diagnostic	 benefit	 from	WES,	 it	 is	 important	 to	
select	disorders	likely	to	be	monogenic[177].	Selecting	patients	with	congenital	
or	early	onset	severe	phenotypes	is	expected	to	enhance	the	odds	of	identifying	












cases	 the	 phenotype	 was	 isolated	 to	 the	 upper	 limb	 while	 in	 the	 fourth	 it	








In	 ideal	 circumstances,	 the	 selected	 cohort	 possesses	 a	 consistent	 phenotype.	
This	enables	direct	comparison	of	variants	identified	between	cohort	members	
to	 investigate	 for	 novel	 variants	 within	 the	 same	 gene.	 The	 identification	 of	
mutations	 within	 a	 common	 gene	 assists	 in	 determining	 the	 causality	 of	 any	
variant.	Without	corroborating	evidence	of	gene	involvement,	it	is	more	difficult	
to	 differentiate	 a	 benign	 novel	 variant	 from	 a	 pathogenic	 mutation;	 this	 is	
particularly	 true	 if	 there	 is	 no	 previous	 report	 of	 developmental	 disorders	
associated	with	the	gene[138].		
3.4.1.2 Trio Based WES Strategies 
Each	patient	within	our	cohort	was	sequenced	in	isolation,	in	contrast	to	a	trio-








The	 concurrent	WES	 and	 analysis	 of	 parental	 exomes	 enables	 comparison	 of	
parental	 and	 case	 variants.	 Provided	parents	 possess	normal	 phenotypes,	 any	
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putative	causal	variant,	or	combination	of	variants	in	a	recessive	model,	must	be	
absent	 in	 both	 parents.	 This	 enables	 a	 significant	 reduction	 in	 the	 putative	
causal	 variants	 and	 therefore	 substantially	 reduces	 the	 workload	 and	
complexity	of	subsequent	analysis.	The	DDD	study	reported	a	10-fold	reduction	
in	candidate	variants	if	parental	phenotype	was	normal[136].	It	is	now	common	
to	 undertake	 trio-based	WES,	 particularly	with	normal	 parental	 phenotype	 or	
phenotypic	heterogeneity	within	the	cohort.		
	
The	 first	 WES	 study	 to	 report	 a	 novel	 causal	 gene	 in	 a	 Mendelian	 disorder	
identified	DHODH	mutations	 in	 a	 similar	Miller	 syndrome	 cohort[169].	A	 trio-
based	 strategy	 was	 not	 performed;	 however	 the	 phenotype	 was	 consistent	




Despite	 this,	 parental	 exomes	 and	 cohort	 homogeneity	 are	 not	 essential	 for	
valid	 WES	 analysis.	 The	 first	 WES	 study	 to	 demonstrate	 substantive	 clinical	
benefit,	 identified	a	XIAP	mutation	 though	exome	sequencing	of	 the	patient	 in	
isolation[145].		
3.4.2 Exome capture and sequencing 
Exome	capture	was	undertaken	using	the	solution-based	Agilent	SureSelect	All	
Exome	 38Mb	 system;	 exomes	 were	 sequenced	 on	 the	 Ilumina	 Hiseq	 2000	
platform.	 Three	 different	methods	 of	 exome	 preparation	 are	 described;	 these	
are	PCR	amplification,	selective	circularisation	and	hybrid	capture[185].	Hybrid	
capture	 is	 almost	 exclusively	 used	 in	 WES	 due	 to	 its	 ease	 of	 use	 and	
rapidity[185].	 The	 solution-based	 hybrid	 capture	 has	 surpassed	 solid	 array-




demonstrated	 that	 Agilent	 SureSelect	 had	 the	 greatest	 exome	 coverage	 and	
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similar	variant	identification[187].	Capture	systems	are	continually	undergoing	
development	 and	 current	 comparisons	 have	 been	 published	 between	 Agilent,	
Illumina	and	Nimblegen	systems[188,	189].	Overall	there	is	high	concordance	in	
the	SNVs	identified,	with	the	current	Agilent	technology	identifying	the	highest	
number	 of	 SNVs	 in	 common	 regions	 between	 the	 systems	 but	 overall	 had	 a	
smaller	 capture	 region[188].	 There	 remains	 poor	 correlation	 in	 the	 Indels	
identified	by	each	system[190].		
I	 followed	 the	 best	 practice	 protocols	 as	 recommended	 by	 Broad	 Institute	
(GATK)	in	the	analysis	of	the	WES[11].	This	categorizes	steps	as	pre-processing,	
variant	discovery	and	call-set	refinement[11].		
3.4.3 Variant Modelling 
To	undertake	further	filtering	of	the	data,	it	was	important	to	consider	the	mode	
of	 action	 of	 any	 variant.	 A	 pathogenic	 mutation	 may	 act	 in	 an	 autosomal	
dominant	or	recessive	manner.	If	autosomal	dominant	then	a	single	copy	of	the	









variable	 penetrance	 but	 this	 is	 rare	 and	 causality	 is	 more	 difficult	 to	 assert,	
therefore	dominant	 filtering	 strategies	 exclude	any	 shared	variants.	Obviously	
this	could	not	be	performed	 in	 this	cohort,	 in	which	each	case	was	sequenced	
individually.	Also	if	pathogenic,	a	dominant	variant	will	not	appear	in	dbSNP	or	




Homozygous	 variants	 in	 rare	 recessive	 disorders	 frequently	 occur	 due	 to	
parental	 consanguinity.	 This	 was	 not	 the	 case	 in	 our	 cohort	 therefore	 a	
recessive	 compound	 heterozygous	model	 was	more	 probable;	 classical	 Miller	
syndrome	 is	 caused	by	compound	heterozygosity	of	DHODH	mutations.	Again,	
two	 variants	 must	 be	 present	 in	 a	 single	 gene	 for	 this	 to	 occur.	 Therefore	
heterozygous	and	homozygous	variants	can	be	excluded	that	do	not	fulfil	these	




approximately	 1	 in	 100,000	 live	 births,	 it	 is	 highly	 improbable	 that	 a	 variant	
occurring	more	frequently	than	this	would	contribute	to	the	disorder.		
It	is	also	reported	that	average	read	depth	plays	a	significant	role	in	maximising	
the	 detection	 of	 all	 exomic/genomic	 single	 nucleotide	 variants,	 with	 the	 read	
depth	required	 to	 identify	all	heterozygous	variants	substantially	greater	 than	
for	 homozygous	 variants[178].	 The	 reported	 average	 read	 depth	 to	 detect	
almost	 all	 homozygous	 SNV	 is	 15x,	 whereas	 an	 average	 read	 depth	 of	 33x	 is	
required	to	identify	a	similar	proportion	of	heterozygous	SNV	[191].	
3.4.4 Filtering Strategies 
The	large	quantity	of	data	generated	by	WES	data	requires	appropriate	filtering	
strategies.	Any	variant	identified	may	represent	a	sequencing	error	or	a	genuine	
variant;	 it	 is	 reported	 that	 the	majority	 of	de	novo	 variants	 identified	prior	 to	
filtering	will	represent	sequencing	artefact[192].	A	genuine	variant	(one	present	




to	 maximize	 the	 removal	 of	 erroneous	 sequencing	 variants	 and	 benign	
constitutive	 variants.	 Filtering	 strategies	 must	 balance	 of	 sensitivity	 and	
specificity.		
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3.4.4.1 Quality filters 
Quality	 filters	 provide	 an	 important	 mechanism	 to	 preferentially	 discard	
sequencing	artefact.	The	genotype	quality/Phred	score	was	first	adopted	in	first	
generation	 Sanger	 sequencing[193].	 This	 score	 represents	 the	 likelihood	 that	
the	base	call	 is	 correct.	 It	 is	 calculated	via	an	algorithm	of	 sequencing	metrics	
including	peak	resolution	and	shape;	this	is	then	compared	to	metrics	of	known	
sequence	accuracy	 through	 large	multivariate	 tables[193].	 	The	parameters	 in	
next	 generation	 sequencing	 technologies	 differ	 but	 the	 concept	 is	 equivalent	
with	comparison	to	the	metrics	of	known	sequence	accuracy.		
	
A	 genotype	 quality	 score	 of	 >30	 is	 commonly	 applied	 in	 WES	 as	 a	 filter.	
However,	 it	 is	 reported	 that	 scores	of	higher	values	 continue	 to	preferentially	




The	 second	 filter	 used	was	 a	mapping	 quality	 filter.	 This	 score	 calculates	 the	
alignment	of	the	read	to	the	reference	sequence.	If	the	read	aligns	equally	well	
to	 multiple	 points	 in	 the	 genome,	 its	 position	 is	 assigned	 randomly	 and	 its	




The	 final	 quality	 filter	 comprised	 manual	 curation	 of	 the	 variants	 using	
Integrated	Genome	Viewer	(IGV)	software	[PMC3603213].	This	programme	was	
created	 by	 the	 Broad	 Institute	 to	 enable	 analysis	 of	 large	 data	 sets;	 it	 allows	
genome-wide	 data	 to	 be	 viewed	 at	 base	 pair	 resolution.	 Variants	 and	 their	
associated	 reads	 can	 be	 interrogated	 to	 confirm	 the	 variant	 appears	 genuine.	
This	 comprises	 assessment	 of	 read	 depth,	 alternate	 allele	 frequency,	 the	
location	within	the	read	and	strand	bias	[PMC3603213].	Combined	assessment	
of	base	quality	 score,	 read	depth	and	alternate	allele	 frequency	 is	 reported	 to	
	 129	
provide	 a	 good	 filter	 of	 sequencing	 artefact	 [192].	 Excellent	 concordance	 of	
called	 variants	 was	 reported	 in	 WES	 of	 the	 discrete	 samples	 from	 same	
individual	 obtained	 from	 different	 sources	 (blood,	 saliva	 and	 buccal	 mucosa)	
[192].	Numerous	features	may	indicate	that	a	variant	represent	a	false	positive	
call.	 Alternate	 allele	 frequency	 is	 expected	 to	 be	 1	 if	 homozygous	 and	 0.5	 if	
heterozygous,	however	allele	PCR	bias	may	lead	the	frequency	to	diverge	from	
these	 parameters.	 Significant	 divergence	 however	 is	 more	 likely	 due	 to	
sequence	 artefact.	 Similarly,	 variants	 are	more	 likely	 to	 be	 false	 if	 they	 occur	
only	 on	 forward	 or	 reverse	 reads,	 or	 only	 at	 the	 end	 of	 reads.	 Other	 features	
such	 as	 multiple	 adjacent	 low	 quality	 bases	 may	 indicate	 a	 high	 density	 of	




GATK	 Variant	 Quality	 Score	 Recalibration	 (VQSR)	 [PMC4098776,	 25681258].	
The	 VQSR	 assigns	 a	 well-calibrated	 probability	 to	 each	 variant	 based	 on	 a	
continuous,	covarying	estimate	of	the	relationship	between	variant	parameters	
and	 the	 probability	 that	 the	 variant	 is	 a	 true	 genetic	 variant	 rather	 than	 a	
sequencing	 or	 data	 processing	 artifact	 [GATK].	 It	 uses	 a	 Gaussian	 Mixture	
method	 trained	 on	 determined	 variants.	 It	 requires	 sufficient	 samples	 for	
accurate	 estimation	 and	was	 not	 used	 on	 our	 cohort	 of	 only	 four	 individuals.	
The	parameters	used	in	the	algorithm	are	similar	to	those	inspected	visually	in	
our	cohort	using	IGV,	such	as	strand	bias,	location	within	the	read	and	alternate	
allele	 frequency	 [PMC4098776].	 Finally,	 in	 my	 data	 very	 few	 of	 the	 putative	





3.4.4.2 Variant filters 
We	chose	to	include	only	mutations	that	altered	protein	amino	acid	sequence	as	
previously	reported.	It	is	now	common	to	use	computational	tools	to	predict	the	
effect	 of	mutations	 on	 protein	 function,	with	 numerous	 tools	 available.	 There	
are	three	methods	used	by	different	tools	to	determine	pathogenicity;	these	are	
based	on	evolutionary	sequence	conservation,	protein	structure	and	statistical	
inference.	 The	 British	 Society	 of	 Genetic	 Medicine	 recommends	 the	 use	 of	 at	
least	 three	 prediction	 tools	 in	 their	 guidelines,	 preferably	 using	 tools	 with	
different	 determination	 strategies	 [www.acgs.uk.com].	 We	 therefore	 chose	 to	
use	 five	 scores	 and	 include	 any	 variant	 predicted	 damaging	 on	 three;	 SIFT,	
Mutation	 Assessor	 and	 LRT	 are	 based	 primarily	 on	 conservation,	 PolyPhen-2	
includes	 protein	 structural	 analysis	 and	 MutationTaster	 also	 uses	 Bayesian	
learning	 strategies[156,	 175].[157,	 158]	 Other	 recent	 studies	 have	 also	 used	
three	 scores	 to	 predict	 pathogenicity.	 Despite	 several	 scores	 using	 similar	
mechanisms	 the	 correlation	 between	 scores	 is	 variable.	 It	 is	 reported	 that	
Mutation	Taster	 is	more	 accurate	 than	 other	 prediction	 tool	 in	 differentiating	
known	 pathogenic	 variants	 from	 polymorphisms[158].	 However	 in	 the	 DDD	
study,	Polyphen-2	and	Mutation	Taster	discriminated	variants	equally	well	but	
were	both	unable	to	predict	diagnostic	variants	accurately.			
3.4.4.3 Knowledge filter 
The	 remaining	 variants	 were	 manually	 curated;	 variants	 were	 included	 for	
further	 investigation	 if	 they	 were	 involved	 in	 limb	 development	 pathways,	
parallel	 pathways	 or	 there	 was	 a	 published	 human	 or	 animal	 model	
developmental	 phenotype.	 Pathways	 included	 in	 this	 analysis	 included	 SHH,	
BMP,	FGF	and	WNT,	with	a	variety	of	sources	used	 to	undertake	 this	 filtering.	
This	filter	discriminates	on	putative	involvement	and	criteria	for	filtering	can	be	
altered	depending	 on	 study	 aims.	 The	 knowledge	 filter	 in	 the	DDD	 study	was	




within	 this	 database	 was	 excluded.	 Therefore	 with	 its	 current	 filter	 strategy	
novel	 disease-associated	 genes	 would	 not	 be	 identified,	 although	 novel	
phenotypes	 associated	 with	 a	 DDP2G	 gene	 may	 be.	 Determining	 the	
pathogenicity	 of	 novel	 candidate	 genes	 is	 complex,	 particularly	 as	 the	 variant	




filter	 is	 subjective	 and	 therefore	 open	 to	 debate.	 The	 filter	 relies	 on	 current	
knowledge	and	understanding	of	developmental	processes;	it	is	improbable	that	
SMOC1	 or	 DHODH	 mutations	 would	 have	 been	 identified	 using	 knowledge	
filtering.	 Therefore,	 as	 with	 any	 filtering	 process,	 there	 is	 the	 potential	 to	
exclude	causal	genes.	This	illustrates	the	importance	of	selecting	a	homogenous	
cohort	to	 identify	a	common	disease	associated	gene	and	circumvent	the	need	




3.5 Conclusion and Future Work 
Confirmation	of	variants	was	undertaken	using	Sanger	sequencing.	HOXD11,	an	
interesting	candidate	in	case	R24C12,	proved	to	be	a	false	positive.	In	contrast,	
FGFR1	 in	 case	R24H4	was	 confirmed	 on	 Sanger	 sequencing.	 This	 represented	
the	 single	 candidate	 variant	 returned	 via	 the	 filter	 strategy	 for	 R24H4.	
Therefore,	 I	 decided	 to	 prioritise	 investigation	 of	 this	 mutation;	 Chapter	 4	
describes	the	work	to	evaluate	this	variant.	
	
Given	 the	 exciting	 candidate	 in	 R24H4,	 variants	 in	 other	 individuals	 have	 not	
been	investigated	at	present.	Further	work	will	require	sequencing	of	parental	
DNA	 in	 individuals	R24C12	and	R24C6	 to	allow	 filtering	of	 inherited	variants;	
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these	 variants	 were	 returned	 in	 the	 dominant	 model	 and	 all	 parents	 were	
phenotypically	 normal.	 Despite	WES,	 no	 convincing	 putative	 candidates	 were	
identified	in	R24H10;	this	is	not	unique	and	has	been	reported	in	other	studies	
[24906018].	This	poses	two	questions:	were	candidates	within	the	exome	missed	




exome	 capture	 /	 sequencing	 or	 due	 to	 the	 filtering	 protocols	 applied.	
Considering	WES	analysis,	the	filtering	protocols	adopted	represent	a	balance	of	
sensitivity	and	specificity.	 Increasing	sensitivity	of	 the	analysis	will	 impair	 the	
specificity	 of	 the	 output,	 with	 the	 converse	 also	 true.	 WES	 analysis	 must	 be	
considered	 an	 iterative	 process;	 filters	 can	 be	 modulated	 as	 knowledge	
increases	 and	 bioinformatic	 tools	 evolve.	 Repeat	 filtering	 can	 be	 undertaken;	
therefore	although	elements	of	our	 filtering	may	have	been	stringent,	 the	data	
can	be	reanalysed	to	reassess	variants.	One	example	is	the	recent	application	of	
the	ExAc	 to	 filter	our	data;	 although	not	 available	when	 initially	 analysed,	 the	





its	 more	 even	 exome	 coverage	 despite	 lower	 average	 read	 depth.	 There	 is	
evidence	 that	 WGS	 provides	 comparable	 variant	 calling	 in	 targeted	 coding	
regions[25038816].	However,	 it	 also	enables	better	 interpretation	of	CNV	and	






the	 validation	 of	 this	 mutation.	 This	 therefore	 demonstrates	 the	 successful	
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Investigation of the functional consequence of the 
novel FGFR1 variant identified in case R24H4  
	
4.1. Introduction  
This	 chapter	 aims	 to	 investigate	 the	 novel	FGFR1	 variant	 identified	 on	whole	
exome	 sequencing	 of	 case	 R24H4,	 diagnosed	 with	 non-classical	 Miller	
syndrome.	 This	 patient	 exhibits	 a	 post-axial	 transverse	 limb	 reduction	
deformity	 (PATLRD).	 The	 hypothesis	was	 that	 the	 variant	 in	 FGFR1	 acts	 as	 a	
dominant	negative.		
4.1.1 The structure of Fibroblast Growth Factor Receptor 1 (FGFR1) 
FGFR1	 is	 a	 transmembrane	 tyrosine	kinase	 receptor	protein	 (Figure	4.1).	 The	
longest	 isoform	 comprises	 822	 amino	 acids	 and	 has	 a	 molecular	 mass	 of	
approximately	92	kilodaltons	(kDa)[75].	It	is	a	member	of	the	FGFR	family	that	
has	 four	 principal	 members[194].	 The	 basic	 structure	 of	 these	 four	 FGFRs	 is	











Figure 4.1 The Structure of FGFR1. Adapted from Turner and Grose Nature 
Reviews Cancer[118]. This diagram of the basic structure of FGFR1 demonstrates 
the receptor/ligand complex stabilised by Heparin Sulphate Glycosaminoglycan 
(HSGAG) chains. FGFR1 consists of three extracellular immunoglobulin domains 
(Ig). IgII and IgIII domains bind the ligand and HSGAGs. Splice variant isoforms of 
IgIII exist with different ligand affinity. FGFR1 has an intracellular tyrosine kinase 
domain which transphosphorylates on dimerization initiating a cascade of 
phosphorylation and activation of intracellular substrates.  
 
4.1.2  The interaction between FGFRs and their ligands, Fibroblast 
Growth Factors (FGF) 
There	 are	22	known	human	FGF	glycoproteins,	 18	of	which	 act	 as	 ligands	 for	
FGFRs;	FGF	11,	12,	13	and	14	do	not	bind	with	FGFRs[118].	No	human	FGF15	
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gene	 exists[118].	 The	 FGFs	 are	 divided	 into	 subfamilies	 based	 on	 sequence	
homology	and	mode	of	action[196].	There	are	five	paracrine	acting	subfamilies	
and	 one	 endocrine	 acting	 group	 (FGF19,	 21	 and	 23).	 	 Paracrine	 FGFRs	 are	
involved	 in	 patterning	 and	 morphogenesis	 during	 development.	 In	 contrast,	
endocrine	FGFs	are	considered	to	primarily	regulate	metabolic	processes[197].		
Different	members	of	the	FGF	family	preferentially	bind	to	particular	members	
of	 the	 FGFR	 family[198]	 (Figure	 4.2).	 Tissue	 specific	 expression	 of	 discrete	
FGFRs	 directs	 FGF	 signalling.	 Important	 co-receptors	 Heparin	 Sulphate	
Glycoaminoglycans	 (HSGAG)	 and	 Klotho	 receptors	 facilitate	 and	 stabilise	 the	
paracrine	 and	 endocrine	 ligand	 receptor	 complexes	 respectively[199].	
Alternative	splicing	of	the	third	immunoglobulin	like	domain	of	FGFR1-3	results	
in	two	splice	variants,	termed	FGFRb	and	FGFRc	[200];	this	alters	affinity	to	the	
FGF	 ligand.	 These	 two	 isoforms	 demonstrate	 tissue	 specificity,	 with	 FGFRb	
primarily	 expressed	 in	 epithelial	 cells	 and	 FGFRc	 expressed	 in	 mesenchymal	
cells.	 	 FGFs	 released	 from	 the	 mesenchyme	 and	 epithelium	 demonstrate	
preferential	 affinity	 for	 FGFRb	 and	 FGFRc	 respectively[201].	 This	 generates	
directional	 signalling	 between	 the	 epithelium	 and	 mesenchyme	 that	 is	
important	for	the	biological	functions	coordinated	by	FGFs	during	development	
and	 adult	 homeostasis[2].	 Examples	 of	 these	 signalling	 loops	 can	 be	 found	
during	limb	bud	development.	FGF8	secreted	from	the	ectoderm	preferentially	
interacts	with	 FGFR2c	 located	 in	 the	mesenchyme	 and	 FGF10	 released	 in	 the	
mesenchyme	binds	with	FGFR2b	expressed	in	the	ectoderm[202].	This	chapter	
focuses	on	FGFR1,	which	during	 limb	development	 is	principally	 expressed	 in	






matrix.	 	A	universal	 feature	of	paracrine	FGFs	 is	 their	affinity	 for	HSGAG.	This	
interaction	results	in	a	local	gradient	of	FGFs	and	stabilises	the	ligand-receptor	
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complex[203].	This	 is	 in	contrast	 to	endocrine	FGFs,	which	have	a	 low	affinity	
for	 HSGAG	 allowing	 them	 to	 diffuse	 and	 use	 Klotho	 proteins	 as	 co-
receptors[204].	HSGAG	sequester	the	FGF	ligand	resulting	in	the	ligand	binding	
to	 the	 FGFR	 and	 dimerization[118].	 FGFRs	 can	 form	 homodimers	 and	
heterodimers.	 As	 a	 consequence	 of	 receptor	 dimerization,	 a	 conformational	
change	 in	 the	 receptor,	 brings	 the	 intracellular	 kinases	 into	 closer	 proximity.	
This	 allows	 the	 intracellular	 kinases	 to	 phosphorylate	 each	 other	
(transphosphorylation)	and	activate	the	tyrosine	residues[118].	This	initiates	a	





Figure 4.2 FGF-FGFR affinities  This diagram details the relative affinities of 
Fibroblast growh factor ligands (FGFs) for Fibroblast Growth Factor Receptors 
(FGFR)[198]. 
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4.1.3 FGFR1 signalling  
FGFRs	 share	 common	 downstream	 signalling	 pathways,	 with	 evidence	 of	
redundancy	between	the	receptors	under	certain	conditions[205].	The	principal	
intracellular	 substrates	 activated	 on	 stimulation	 of	 FGFRs	 are	 FGFR	 Substrate	
2α	(FRS2α)	and	Phospholipase	Cγ1	(PLCγ1)[206].	
	
Phosphorylated	 FRS2α	 initiates	 the	 MAPK/ERK	 signalling	 cascade,	 a	 major	
downstream	 pathway	 of	 FGF	 signalling[13].	 FRS2α	 recruits	 Growth	 Factor	
Receptor	 Bound	 2	 (GRB2)	 that	 in	 turn	 activates	 Son	 of	 Sevenless	 (SOS),	 a	
guanine	 nucleotide	 exchange	 factor.	 SOS	 activates	 the	 MAPK/ERK	
pathway[118].	MAPK	translocates	into	the	nucleus,	where	it	activates	numerous	
transcription	 factors.	 The	 main	 reported	 outcome	 is	 cellular	 proliferation,	
although	 other	 cellular	 functions	 such	 as	 differentiation	 and	 migration	 also	




null	 mutant,	 which	 is	 lethal	 at	 the	 embryonic	 implantation	 stage[207].	 This	
demonstrates	the	influence	of	alternate	pathways	on	phenotype.		
Other	 relevant	 downstream	 pathways	 are	 shown	 in	 Figure	 4.3	 and	 include	




factor)[210].	 FGFR1	 also	 phosphorylates	 and	 activates	 PLCγ1[211].	




Figure 4.3 FGF Signalling, downstream pathways.   The ligand, receptor and 
Heparin Sulphate Glycoaminoglycans (HSGAG) form a 2:2:2 complex. The ligand 
binding to FGFR results in dimerisation causing a conformational change that brings 
the intracellular kinases into closer proximity. This results in transphosphorylation 
and activation of the tyrosine kinase domains. This initiates a cascade of 
phosphorylation of intracellular substrates and activation of signaling pathways. The 
main downstream signaling pathway is the MAPK/ERK pathway (B). (B) Activated 
FGFR substrate 2α (FRS2α) recruits Growth Factor Receptor-Bound 2 (GRB2) 
adaptor protein which activates Son of Sevenless (SOS) a guanine nucleotide 
exchange factor. SOS activates RAS that ultimately results in MAPK translocation 
into the nucleus where it activates transcription factors involved in cell proliferation. 
(A) GRB2 can also bind GRB2-associated binding protein 1 (GAB1) activating 
Phosphoinositide 3-kinase (P13K) and AKT kinase. This inhibits mediators of 
apoptosis and promotes cell survival. (C) Phospholipase Cγ1 (PLCγ1) binds FGFR1 
and is activated by phosphorylation. Phosphorylated PLCγ1 hydrolyses 
phospholipid phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)(P2)) into 
diacylglycerol (DAG) and inositol-1,4,5,-trisphosphate (IP3). DAG activates protein 
kinase C (PKC) resulting in activation of myristoylated Ala-rich C kinase substrate 
(MARCKS) which regulates cell motility. IP3 regulates intracellular calcium stores. 
Release of calcium results in activation of calcium dependent proteins, such as 
calcineurin. Calcineurin causes nuclear translocation of nuclear factor of activated T 
cells (NFAT), a transcription factor that has a role in cell motility. 
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FGF	signaling	is	regulated	by	several	inhibitory	proteins,	including	the	Sprouty	
(SPRY)	 family,	 SEF	 and	 DUSP6.	 Animal	 knockout	 models	 of	 Dusp6	 or	 Spry	
demonstrate	 craniosynostosis	 and	 skeletal	 malformations[213].	 In	 addition,	
mutations	 in	 DUSP6	 and	 SPRY4	 have	 been	 discovered	 in	 patients	 with	
Congenital	 Hypogonadotropic	 Hypogonadism	 (CHH)	 [214],	 highlighting	 the	
importance	of	FGF	signaling	and	its	regulation	in	human	development. 
4.1.4 The role of FGF signalling in normal limb development 
FGFR1	 has	 a	 vital	 role	 in	 limb	 development.	 FGF	 signalling	 is	 involved	 in	
mesoderm	patterning	and	skeletal	morphology[205].	Limb	bud	development	is	
dependent	 on	 two	 specialized	 regions	 namely	 the	 Apical	 Ectodermal	 Ridge	
(AER)	and	the	Zone	of	Polarising	Activity	(ZPA)[202],	as	described	in	chapter	2.	
According	to	the	progress	zone	model	there	is	a	third	area	of	importance	known	
as	 the	 progress	 zone	 (PZ)[50].	 These	 three	 areas	 act	 together	 to	 promote	
growth	 in	 both	 the	 proximo-distal	 (PD)	 and	 the	 anterior-posterior	 axis	
(AP)[215,	216].		
The	principle	 function	FGF	and	FGFRs	 in	the	 limb	bud	 is	 to	regulate	signalling	
between	 the	 epithelium	 and	 mesenchyme.	 At	 limb	 bud	 initiation,	 FGF10	
released	from	the	lateral	plate	mesenchymal	cells	interacts	with	FGFR1IIIb	and	
FGFR2IIIb	in	the	overlying	epithelium	resulting	in	an	epithelial	to	mesenchymal	
transition.	 This	 increase	 in	 mesoderm	 initiates	 limb	 bud	 formation.	 FGF10	
signalling	promotes	development	of	 the	AER,	a	specialised	region	of	ectoderm	
around	 the	 distal	 limb	 bud.	 FGF8	 and	 FGF9	 released	 from	 the	 AER	 signal	
through	FGFR1IIIc	and	FGFR2IIIc	in	the	mesenchyme	to	promote	growth	in	the	
PD	axis	and	 to	mediate	patterning[216].	AER	also	expresses	FGF4	and	FGF17.	
Removal	 of	 the	 AER	 results	 in	 limb	 truncation	 that	 can	 be	 rescued	 with	 the	
implantation	in	the	mesenchyme	of	FGF	soaked	beads[41].	Deletion	of	both	Fgf4	




4.1.5 The affect of conditional inactivation of Fgfr1 on limb bud 
development in murine models 
Mouse	models	have	been	generated	to	elucidate	further	the	role	of	Fgfr1	in	limb	
development.	 The	 study	 of	 Fgfr1	 in	 limb	 bud	 initiation	 and	 patterning	 is	
complicated	 by	 gastrulation	 phase	 embryonic	 lethality	 in	 Fgfr1	 null	
mutants[218].	In	order	to	overcome	this,	conditional	inactivation	of	Fgfr1	using	
Cre-recombinase	 models	 has	 been	 performed.	 The	 Tcre:Fgfr1	 line	 uses	
promoter	T(Brachyury)	to	drive	Cre	expression	in	the	primitive	streak-derived	
mesoderm.	 The	 Tcre:Fgfr1	 mutant	 demonstrates	 inactivation	 of	 Fgfr1	
throughout	 the	 limb	 bud	mesenchyme	 (LBM)[2];	 the	mouse	 is	 not	 viable	 and	
dies	at	birth.	However,	study	of	mutant	embryos	reveals	disturbed	growth	and	
patterning	of	the	autopod	(hand/feet)	[2].	There	is	a	 limb	reduction	deformity	
with	 only	 three	 digits	 present	 in	 the	 forelimb.	 Following	 digit	 identification	
using	discrete	Hox	expression	profiles,	this	was	found	to	represent	a	post-axial	
reduction	deformity	with	loss	of	the	posterior	digits.	In	addition,	 in	this	model	
the	hindlimbs	are	more	severely	affected	 than	 the	 forelimb.	This	phenotype	 is	





loss	 is	 initially	 confined	 to	 the	 anterior,	 distal	 limb	 bud.	 Although,	 Fgfr1	 is	
eventually	deleted	throughout	the	entire	developing	limb	mesenchyme,this	may	
occur	 too	 late	 to	 disrupt	 the	 development	 of	 the	 posterior	 digits[202].	 These	
models	demonstrate	the	 importance	of	Fgfr1	 to	normal	 limb	development	and	
show	loss	results	in	a	reduction	deformity.	
4.1.6 The Role of FGFRs in Human Disease 
The	 essential	 roles	 of	 FGFRs	 in	 human	development	 have	 been	demonstrated	
through	the	discovery	of	pathogenic	mutations	within	the	FGFR	genes	in	human	
developmental	 disorders.	 This	 project	 has	 focused	 on	 developmental	 disease,	
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with	 particular	 reference	 to	 the	 limb	 bud,	 but	 there	 is	 considerable	 evidence	




mutation	 in	 achondroplasia	was	 the	 first	 insight	 into	FGF	 signalling	 in	human	
developmental	 disorders[220];	 this	 FGFR3	 mutation	 was	 found	 to	 lead	 to	







in	 FGFR3	 were	 also	 discovered	 in	 other	 skeletal	 dysplasias	 including	
hypochondroplasia,	 a	milder	 form	of	achondroplasia.	Thanatophoric	Dysplasia	
is	 a	 severe	 skeletal	 dysplasia	 leading	 to	 death	 in	 perinatal	 period;	 it	 too	 is	





Craniosynostosis	 is	 the	 premature	 fusion	 of	 skull	 suture	 lines.	 Numerous	
craniosynostosis	 syndromes	 have	 now	 been	 discovered	 to	 result	 from	
mutations	 with	 in	 FGFR	 1,	 2	 and	 3.	 These	 are	 all	 characterized	 by	
craniosynostosis	in	association	with	discrete	facies	and	varied	limb	phenotypes;	
limb	phenotypes	range	from	normal,	through	digit	broadening	or	syndactyly	to	
limb	 shortening.	 However,	 no	 associated	 true	 transverse	 limb	 reduction	
deformity	 is	 described.	 All	 disease-associated	 mutations	 in	 FGFR2	 result	 in	
craniosynostosis	 with	 distinct	 FGFR2	 mutations	 involved	 in	 Pfieffer,	 Crouzon,	
Aperts	 and	 Jackson	 Weiss	 syndromes.	 FGFR3	 mutation	 causes	 Muenke	




De	novo	mutation	of	FGFR2	 or	FGFR3	 is	estimated	 to	occur	 in	1	 in	10000	 live	
births;	FGFR3	pathogenic	mutant	c.(G1138A),	the	causative	mutation	in	97%	of	
cases	 of	 achondroplasia,	 may	 be	 the	 most	 frequently	 occurring	 germline	
nucleotide	 substitution	 in	 the	 entire	 human	 genome[222].	 The	 frequency	 of	
pathogenic	FGFR1	variants	is	less	well	characterized	but	appears	to	occur	much	
less	 commonly	 than	 in	FGFR	2	 or	3;	 pathogenic	mutations	 in	FGFR4	 have	 not	
been	described.		
	
FGFR1	 mutations	 cause	 two	 craniosynostosis	 syndrome,	 Osteoglophonic	
Dysplasia	 and	 Pfeiffers	 syndrome[223,	 224].	 Osteoglophonic	 Dysplasia	 is	 a	
disorder	 characterized	 by	 craniosynostosis	 and	 short	 stature	 but	 normal	
autopod	morphology.	 Pfeiffer	 Syndrome	 is	 an	 autosomal	 dominant	 syndrome	
with	associated	craniofacial	anomalies;	the	limb	phenotype	is	characterized	by	
broad	 first	 digits	 in	 hands	 and	 feet	 and	 variable	 syndactyly.	 Both	 FGFR1	 and	
FGFR2	 mutations	 are	 reported	 in	 this	 disorder,	 although	 only	 one	 specific	
variant	 in	 FGFR1	 cases	 is	 described;	 this	 leads	 to	 amino	 acid	 substitution	
P252R[223].	 The	 limb	 phenotype,	 in	 those	 with	 the	 FGFR1	 mutation,	 is	 less	
severe;	 only	 cutaneous	 syndactyly	 is	 reported.	 As	 with	 the	 other	 FGFR	




Kallmann	 Syndrome.	 Kallmann	 syndrome	 is	 characterised	 by	
hypogonadotrophic	hypogonadism	in	conjunction	with	hyposmia	or	anosmia,	a	
reduction	or	loss	of	the	sense	of	smell[225].	These	FGFR1	mutations	are	loss	of	
function	 mutations,	 with	 the	 phenotype	 presumed	 secondary	 to	
haploinsufficiency.	 Kallmann	 syndrome	 is	 also	 be	 caused	 by	mutations	 in	 the	
KAL1	 gene,	 located	 on	 the	 short	 arm	 of	 the	 X	 chromosome	 at	 position	
22.32[225].	KAL1	encodes	the	protein	anosmin-1,	which	interacts	with	FGF8	to	
promote	 FGF8	 -	 FGFR1	 interactions[226].	 This	 pathway	 is	 requisite	 for	 the	
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correct	 migration	 of	 olfactory	 and	 gonadotrophin	 releasing	 hormone	
neurons[225].	These	findings	generated	the	hypothesis	that	structures,	such	as	




These	 disorders	 demonstrate	 the	 importance	 of	 FGFR	 mediated	 signalling	 in	
skeletal	development	but	despite	this,	at	the	outset	of	this	work,	no	transverse	
limb	 reduction	 deformity	 had	 been	 described	 in	 association	 with	 these	 FGFR	
mutations	and	specifically	none	with	FGFR1	variants.	This	work	therefore	aimed	






4.2.1 Sanger Sequencing 
GenomiPhi	 V2	 DNA	 Amplification	 Kit	 was	 used	 as	 per	 the	 manufacturers	
protocol	 with	 genomic	 DNA	 as	 a	 template	 for	 whole	 genome	 amplification.	
Primer3	 (http://primer3.ut.ee)	was	used	 to	design	primers	 encompassing	 the	
coding	 exons	 and	 the	 intronic	 splice	 sites	 (see	 below	 for	 oligonucleotide	
sequences).	 Target	 sequences	 were	 amplified	 by	 PCR	 (total	 volume	 12ul)	
comprising;	 20	 ng	 whole-genome	 amplified	 DNA,	 1X	 ReddyMix	 Custom	 PCR	
Master	 Mix,	 0.4	 mM	 forward	 oligonucleotide	 and	 0.4	 mM	 reverse	
oligonucleotide	 with	 the	 addition	 of	 1X	 GC-rich	 Solution	 when	 required.	 A	
uniform	PCR	cycling	protocol	was	performed:	95	°C	for	5	min;	32	cycles	of	94	°C	
for	1	min,	58	°C	for	1	min,	72	°C	for	1	min;	72	°C	for	10	min.	PCR	products	were	
visualised	 using	 agarose	 gel	 electrophoresis	 to	 ensure	 adequate	 quantity	 and	
expected	 sizing	 of	 each	 exon	 fragment.	 Bidirectional	 direct	 sequencing,	 using	
the	 universal	 primers,	 was	 performed	 using	 BigDye	 Terminator	 v3.1	 Cycle	
Sequencing	Kit	and	resolved	on	an	ABI	3730	DNA	Analyzer	by	 the	 Institute	of	
Genetics	 and	 Molecular	 Medicine	 (IGMM)	 sequencing	 service.	 Sequence	 files	
were	analysed	with	Mutation	Surveyor	v3.30.		
4.2.2 Stable cell line development using HEK293 FlpIn TREx (Invitrogen) 
& pcDNA5/FRT/TO-FGFR1.tGFP vector constructs 
HEK293	FlpIn	TRex	cell	 lines	 (Invitrogen)	were	removed	 from	 liquid	nitrogen	
storage	and	 cultured	 in	 standard	 culture	media	 (DMEM	+	10%FCS	+	1%	Pen-
Strep)	 for	 24	 hours	 at	 37oC.	 After	 24	 hours	 the	 media	 was	 replaced	 with	















4.2.3 Immunofluorescence microscopy  
Cells	 (1x105)	 were	 plated	 on	 a	 12	 well	 plate	 on	 coverslips	 and	 cultured	 in	
standard	 culture	media	 and	 tetracycline	 (1ug/ml)	 for	 24	 hours	 (37oC).	Media	
was	removed	and	cells	fixed	with	4%	Paraformaldehyde	(PFA)	for	10	minutes	at	
room	temperature	(RT).	Subsequent	steps	were	all	performed	in	the	dark.	Cells	
were	 washed	 three	 times	 with	 PBS	 and	 permeabilised	 with	 TBS/0.1%	
saponin/20	mM	glycine	 for	20	minutes	(RT).	PBS	washes	were	repeated.	Cells	
were	blocked	in	1%	BSA	in	PBS	for	10	minutes.	Coverslips	were	then	removed	
from	 the	 12	 well	 plate,	 blotted	 dry	 and	 placed	 onto	 a	 tray	 in	 a	 humidified	
container	 followed	 by	 incubation	 with	 Phalloidin	 for	 one	 hour	 (RT).	 The	








performed	 with	 5µg	 of	 DNA	 (approximately	 2µl),	 20	 U	 of	 the	 appropriate	
enzyme(s),	5µl	of	compatible	buffer	made	up	to	50µl	with	Nuclease	free	water	
and	 incubated	 for	 1	 hour	 at	 37°C.	 For	 double	 digests	 the	 optimal	 buffer	
	 147	
conditions	were	selected	for	both	enzymes	using	the	manufacturers’	guidelines.	
Where	 blunting	 was	 required	 1µl	 dNTP	 (final	 concentration	 10mM)	 and	 1µl	




electrophoresis.	 The	 DNA	 fragment	 of	 interest	 was	 excised	 with	 a	 size	 10-
scalpel	 blade	 and	 purified	 with	 the	 QiaQuick	 Gel	 Extraction	 kit	 as	 per	
manufacturers	 instructions.	 The	 DNA	 was	 eluted	 in	 30μl	 elution	 buffer	 and	
stored	at	-40	̊C.	
4.2.5 Gateway Cloning Method 
The	 gateway	 entry	 clone	 was	 created	 as	 per	 manufacturer	 protocol	
(Thermofisher	 scientific).	 The	 reaction	 mix	 included:	 3µl	 attB-PCR	 product	
(final	amount	30ng),	2µl	donor	vector	(80ng/µl)	and	3µl	of	TE	buffer	(pH	8.0),	
mixed	 in	 a	1.5ml	 tube.	The	BP	 clonase	 II	 enzyme	mix	was	placed	on	 ice	 for	2	







media	 (prewarmed)	 was	 added	 and	 the	 reaction	 incubated	 at	 37oC	 with	
agitation	for	1	hour.	The	transformation	was	plated	onto	ampicillin	plates.	After	
overnight	 incubation	 at	 37	 oC,	 colonies	 were	 picked	 and	 grown	 up	 in	 liquid	
culture	 at	 37	oC	 	with	 agitation	 overnight.	 Liquid	 cultures	were	purified	using	
the	Qiagen	Miniprep	kit	as	per	manufacturers	instructions.		
	
The	 gene	 of	 interest	 was	 transferred	 from	 the	 entry	 clone	 to	 the	 destination	
vector	by	the	1	hour	LR	reaction	as	per	manufacturers	manual.	The	LR	reaction	
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consisted	 of	 1-7µl	 (50-150ng)	 of	 the	 entry	 clone,	 1µl	 (150ng/µl)	 of	 the	







grown	 up	 in	 liquid	 culture	 and	 Miniprep	 protocol	 carried	 out	 as	 above.	
Destination	 vector	 was	 checked	 with	 restriction	 digestion	 and	 Sanger	
sequencing.		
4.2.6 DNA Transfections  
DNA	was	transfected	into	monolayer	cells	using	Lipofectamine	2000.	Cells	were	
90%	to	95%	confluent	at	time	of	transfection.	For	each	transfection	of	one	well	
of	 a	 6-well	 plate,	 two	 complexes	were	 prepared.	 The	 first	 contained	 1.6μg	 of	
DNA	in	100μl	of	Opti-MEM	Medium	and	the	second	contained	4μl	Lipofectamine	
in	 100μl	 Opti-MEM.	 After	 5	 minutes	 incubation	 at	 room	 temperature,	 the	




4.2.7 Site Directed Mutagenesis 
4.2.7.1 Primers for site directed mutagenesis 
Mutagenic	primers	for	use	in	site	directed	mutagenesis	were	designed	using	the	
Quikchange	 Primer	 Design	 Program	 (available	 online	 at	
www.genomics.agilent.com)	 The	 following	 considerations	 were	 made	 by	 the	
design	algorithm;	The	primers	were	between	25	and	55	bases	in	length,	with	a	
melting	temperature	(Tm)	of	≥78	̊C	(see	below)	and	the	desired	mutation	was	
located	 near	 the	 middle	 of	 the	 primer	 with	 a	 minimum	 of	 ~10–15	 bases	 of	
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4.2.7.2 Site directed mutagenesis (QuikChange Method) 
Point	 mutations	 were	 introduced	 into	 plasmid	 vectors	 using	 the	 PCR	 based	
QuikChange	 method.	 In	 summary,	 two	 complimentary	 oligonucleotides	
containing	the	desired	mutation	were	designed	to	anneal	to	the	same	sequence	
on	 opposite	 strands	 of	 the	 plasmid.	 The	 primers	 are	 extended	 by	 PCR	
generating	a	mutated	plasmid.	The	PCR	product	is	treated	with	DpnI.	The	Dpn	I	
endonuclease	 (target	 sequence:	 5	́-Gm6ATC-3	́)	 is	 specific	 for	 methylated	 and	
hemimethylated	DNA	and	 is	 used	 to	 digest	 the	 parental	DNA	 template	 and	 to	
select	 for	 mutation-containing	 synthesized	 DNA.	 Almost	 all	 E.	 coli	 strains	
contain	 DNA	 that	 is	 dam	 methylated	 and	 therefore	 susceptible	 to	 DpnI	
digestion.	
	
The	 PCR	 was	 composed	 as	 follows:	 50ng	 plasmid,	 0.25mM	 dNTPs,	 0.2μM	
mutagenic	oligonucleotide	primers	(forward	and	reverse),	1X	DNA	polymerase	
buffer	with	MgCl2	and	1.25U	of	PfuUltra	DNA	polymerase.	Cycling	parameters	
for	site	directed	mutagenesis	were	as	 follows:	95oC	 for	30	seconds	 for	1	cycle	
followed	 by	 95	oC	 for	 30	 seconds,	 55	oC	 for	 1	 minute,	 68	oC	 for	 1	 minute/kb	
plasmid	length	for	18	cycles.		
	
The	 PCR	 product	 was	 incubated	 with	 1μl	 of	 DpnI	 restriction	 enzyme	
(10U/ul)(NEB)	 at	 37	̊C	 for	 1	 hour	 to	 digest	 parental	 vector	 DNA.	 Following	
incubation,	1μl	of	the	DpnI	treated	DNA	was	used	for	transformation	into	DH5α	
E.	 coli	 chemically	 compotent	 cells	 as	 described.	 Resultant	 colonies	 were	
screened	by	sequencing.		
	 150	
4.2.8 Transformation of chemically competent cells 
Approximately	 1ng	 of	 vector	 +	 insert	 DNA	 or	 2ul	 of	 a	 ligation	 reaction	 was	
added	to	50ul	of	competent	DH5α	Ecoli	cells.	Cells	and	DNA	were	incubated	on	
ice	 for	 30	 min	 before	 heatshock	 at	 42	̊C	 for	 50	 seconds.	 Following	 2	 min	
recovery	on	ice,	the	cells	were	resuspended	in	450μl	of	SOC	media	(preheated	to	
42oC)	 and	 incubated	 at	 37	̊C	 for	 50	minutes	with	 shaking.	500μl	 of	 cells	were	
spread	 onto	 LB	 agar	 plates	 containing	 the	 appropriate	 antibiotic.	 The	 plates	
were	incubated	overnight	at	37	̊C	to	produce	discrete	colonies.	
4.2.9 Western blotting 
SDS	 PAGE	 protein	 separation	 was	 used	 to	 analyse	 protein	 expression	 and	
quantification.	 Cells	 were	 lysed	with	 radioimmuno-precipitation	 assay	 (RIPA)	
buffer.	 Micro	 Bicinchoninic	 Acid	 (BCA)	 protein	 assay	 kit	 was	 used	 as	 per	
manufacturers	 instructions	 for	 protein	 quantification	 with	 absorbance	
measured	at	562nm	on	a	BP800	spectrophotometer.	20μg	of	protein	from	each	
sample	was	made	up	to	equal	volume	with	RIPA	buffer	prior	to	addition	of	6X	









Membranes	 were	 blocked	 with	 5%	 milk/TBST	 for	 60	 minutes	 with	 gentle	
agitation.	Membranes	were	 then	washed	three	 times	 in	TBST	(10	minutes	per	
wash).	Membranes	were	probed	with	a	primary	antibody	 in	2%	BSA/TBST	at	
appropriate	 concentrations	 (see	 table)	 at	 4°C	 overnight,	with	 gentle	 agitation.	
The	antibody	was	removed	and	the	membranes	washed	again	three	times	with	
TBST	 (5	 minutes	 per	 wash).	 Mouse	 or	 rabbit	 HRP-conjugated	 secondary	
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antibody	 (1:5000)	 in	 2%	 BSA/TBST	 was	 used	 for	 detection.	 Enhanced	
chemiluminescence	(ECL	protocol)	as	per	manufacturers	instructions	was	used	
for	visualisation.	1ml	of	ECL	solution	 (1:1	mixture	solution	A:	 solution	B)	was	
pipetted	 on	 to	 the	 protein	 side	 of	 the	 membrane	 and	 incubated	 at	 room	
temperature	 for	 1	minute.	 The	membrane	was	 blotted	 to	 remove	 excess	 ECL	
solution	and	wrapped	in	saran	film	and	transferred	to	the	radiograph	box.	The	
membrane	 was	 exposed	 to	 blue-light	 sensitive	 autoradiography	 film	 for	 the	
required	duration.	The	 film	was	developed	using	an	AGFA	Curix	60	processor.	
Membranes	were	then	rinsed	with	TBST	four	times	(5	minutes	per	wash).	After	
washing	 membranes	 were	 reprobed	 with	 a	 second	 primary	 antibody,	 alpha-
tubulin	 control	 (1/25000)	 in	 2%	 BSA	 TBST	 as	 described	 above.
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4.3 Results	
4.3.1. Confirmation of de novo FGFR1 variant in R24H4 
The	novel	genetic	variant	within	FGFR1	 identified	on	whole	exome	sequencing	
of	 case	 R24H4,	 a	 patient	 diagnosed	 with	 non-classical	 Miller	 syndrome,	 may	
represent	 the	 causative	 mutation	 or	 alternatively	 an	 unreported	 rare	




of	 inheritance.	This	 required	both	 the	parental	phenotype	and	genotype	 to	be	
determined.	A	mendelian	pathogenic	variant	may	exert	its	effect	in	a	dominant	
or	recessive	manner[227].	A	single	allele	of	a	dominant	mutation	will	cause	the	
condition	 in	 the	 heterozygous	 individual[227].	 In	 the	 presence	 of	 unaffected	
parents,	 dominant	 mutations	 often	 have	 occurred	 de	 novo,	 although	 parental	
mosacism	 or	 variable	 penetrance	 may	 also	 occur[227].	 In	 contrast,	 recessive	
variants	require	both	alleles	of	the	gene	to	be	affected	and	are	most	frequently	
homozygous	 variants[227].	 Rare	 recessive	 conditions	 caused	 by	 such	
homozygous	 genetic	 variants	 are	 frequently	 associated	 with	 parental	
consanguity[227].	 Recessive	 disorders	may	 also	 occur	 as	 a	 result	 of	 different	
rare	 recessive	pathogenic	 variants	within	 each	 allele	 of	 the	 gene[227].	 This	 is	
termed	 compound	 heterozygosity	 and	 has	 been	 previously	 described	 in	 a	
number	 of	 conditions	 including	 cystic	 fibrosis[228],	 Tay	 Sachs[229]	 and	
recently	 through	 exome	 sequencing	 in	 Millers	 syndrome,	 with	 DHODH	
mutations[169].	
	
Whole	 exome	 sequencing	 (WES)	 identified	 this	 variant	 to	 be	 heterozygous	 in	
case	R24H4.	No	other	rare	variant	was	present	on	the	alternate	allele	to	suggest	




if	 causative,	was	 likely	 to	 have	 occurred	de	novo.	 To	determine	 the	 functional	
significance	 of	 the	 novel	 FGFR1	 variant	 identified	 in	 case	 R24H4,	 it	 was	
necessary	to	confirm	that	the	variant	was	genuine	and	that	it	was	de	novo.	
	
Figure 4.4. Clinical images demonstrating lower limb postaxial transverse limb 
reduction deformity and Sanger sequencing confirmation of de novo mutation 
in FGFR1 
(A) Clinical Images of the proband’s right hand and feet. A post axial transverse limb 
reduction deformity isolated to the lower limbs is demonstrated. (B) Sanger 
sequencing chromatogram confirming de novo mutated base in FGFR1. (C) The 
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results of inheritance analysis are shown in the table. Paternity was verified by 
confirming 12 randomly selected SNPs (from exome data) in the proband and 





Primers	 were	 designed	 to	 sequence	 the	 novel	 variant	 within	 FGFR1.	 Both	
parental	 DNA	 and	 that	 of	 case	 R24H4	 were	 then	 sequenced	 using	 Sanger	






within	 the	 patient	 sample	 on	 WES.	 Twenty	 rare	 SNPs	 were	 chosen,	 with	
satisfactory	 priming	 and	 sequence	 obtained	 in	 12	 of	 these	 (Figure	 4.4).	 This	
demonstrated	 the	 presence	 of	 all	 the	 selected	 rare	 SNPs	 in	 either	 parental	
sample.	Although	only	4	of	the	SNPs	were	identified	in	the	paternal	sample,	the	
frequency	of	these	rare	SNPs	was	between	1	in	1000	and	1	in	10,000.	Assuming	
the	 absence	 of	 any	 undetermined	 linkage,	 these	 4	 SNPs	 alone	 provided	
reasonable	 confidence	 in	 paternity.	 Therefore,	 having	 demonstrated	 that	 the	




be	 functionally	 inconsequential,	 it	does	exclude	that	 the	variant	 is	 inherited.	A	
pathogenic	 variant	present	 in	both	a	parent	 and	 the	 case	 could	potentially	 be	
explained	 by	 mosacism	 or	 variable	 expressivity	 but	 it	 would	 harder	 to	
confidently	determine	causation,	without	 further	 cases	or	others	 in	 the	 family	
affected.	It	was	therefore	reasonable	to	investigate	the	variant	further.		
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4.3.2 To investigate the Functional Significance of FGFR1 mutation 






tetracycline	 induction.	 The	 Flp-In™	 T-REx™	 System	 (Invitrogen)	was	 used	 for	
this	work.	This	 system	allowed	 the	 rapid	and	 reliable	 insertion	of	 the	desired	
FGFR1	 cDNA	under	the	control	of	TETR,	with	addition	of	 tetracycline	enabling	
expression	of	 the	protein	 through	binding	of	 tetracycline	 to	 the	Tet	repressor.	
The	HEK293	cell	line	carrying	a	single	Flp	Recombination	Target	(FRT)	site	for	
insertion	 of	 the	 construct	 and	 constitutive	 expression	 of	 TetR	 was	 obtained	
from	 Thermo-Fischer	 Scientific.	 This	 cell	 line	 allows	 consistent	 inducible	
expression	 of	 the	 desired	 protein	 in	 an	 isogenic	 cell	 line,	 with	 insertion	 of	 a	
single	 copy	 of	 the	 construct	 at	 the	 same,	 albeit	 random,	 site	 of	 insertion.	 In	




part	 due	 to	 its	 availability	 and	 the	 attributes	 of	 the	 system	 described	 above.	
There	 are	 also	 significant	 limitations	 to	 the	 use	 of	 available	 limb	 bud	 cell	
lines[88,	230].	There	are	no	cell	lines,	in	common	use,	considered	to	accurately	
represent	limb	bud	mesenchyme[88].		The	immortalized	limb	bud	lines	that	do	
exist	 appear	 to	 represent	 distinct	 types	 of	 mesenchyme	 and	 have	 not	 been	
extensively	characterized[230].	Primary	limb	bud	cells	lines	exist	but	if	cultured	
in	 standard	 conditions	 rapidly	 differentiate,	 limiting	 their	 usefulness.	
Differentiation	 can	be	prevented	by	 the	 addition	of	 factors	 such	as	WNT3a	or	
FGF8	 but	 this	 itself	 may	 influence	 experimental	 results[29,	 231].	 In	 addition	




I	obtained	 the	pCMV6	vector	containing	FGFR1	 tagged	with	 turboGFP	at	 its	C-
terminus	 from	Origene.	 There	 are	 numerous	 isoform	 variants	 of	FGFR1	 and	 I	
chose	 to	 use	 the	 longest	 isoform,	FGFR1	 isoform	1,	which	 also	 represents	 the	
isoform	 FGFR1IIIc[232].	 This	 variant	 contains	 the	 three	 Ig	 domains	 in	 its	
extracellular	portion;	 it	 is	not	only	the	 isoform	commonly	used	in	the	study	of	
FGFR1	 signalling	 but	 is	 also	 found	 to	 be	 the	 isoform	 critical	 to	 normal	 limb	
development[232].	 The	 GFP	 tagged	 protein	 was	 used	 to	 allow	 direct	
visualization	on	immunofluorescence.	The	addition	of	any	tag	may	alter	protein	
function	but	tagging	of	the	protein	was	necessary	to	differentiate	the	exogenous	
protein	 from	 endogenous	 FGFR1.	 Although	 the	 GFP	 tagged	 protein	 of	 this	
specific	 isoform	 has	 not	 been	 used	 previously	 in	 published	 studies,	 the	 C-
Terminal	 GFP	 tagged	 FGFR1	 isoform	 3	 (Origene),	 using	 the	 identical	 linker	
sequence,	has	been	shown	to	be	functional[233].	Isoform	1	and	3	differ	in	their	
extracellular	 domain	 but	 their	 C-termini	 are	 identical.	 	 I	 did	 not	 undertake	
definitive	 rescue	 experiments	 to	 confirm	 protein	 function	 as	 this	would	 have	
required	the	use	of	additional	cell	lines	with	stable	expression	of	FGFR1	as	well	
as	 synonymous	mutagenesis	 of	 DNA	 sequence	 to	 allow	 it	 to	 be	 refractory	 to	
siRNA.	The	localization	experiments	and	the	stimulation	experiments	described	
below	however	demonstrated	that	the	wild	type	protein	fused	to	GFP	localized	
in	 a	 similar	manner	 to	 endogenous	 FGFR1	 and	 the	 fusion	 protein	 stimulated	
pathways,	 normally	 activated	 via	 endogenous	 FGFR1.	 I	 believe	 this	 provided	




using	 site	 directed	 mutagenesis	 to	 recapitulate	 the	 mutation	 found	 in	 the	
patient	 sample.	 PCR	of	 both	wild	 type	 and	mutant	GFP	 tagged	 sequences	was	
undertaken	using	AttB	 tagged	primers;	 the	sequence	was	 then	cloned	 into	 the	
pcDNA5/FRT/TO	expression	vector	using	the	Gateway	cloning	system.	Prior	to	
this,	 a	 Gateway	 cassette	 had	 been	 inserted	 into	 the	 pcDNA5/FRT/TO	 vector,	
using	restriction	enzymes.	The	correct	wild	type	and	mutant	FGFR1	sequences	
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were	 confirmed	 by	 Sanger	 sequencing,	 prior	 to	 transfection	 into	 the	 HEK293	
cells.	 Following	 transfection,	 cells	 were	 selected	 with	 hygromycin	 and	
expression	 of	 the	 wild	 type	 or	 mutant	 fusion	 protein	 confirmed	 under	
immunofluorescent	microscopy	following	addition	of	tetracycline.	




FGFR1-WT.GFP	 or	 FGFR1-P663S.GFP,	 cells	 were	 fixed,	 permeabilised	 and	
counter-stained	with	DAPI	 and	phalloidin,	 a	marker	 of	 the	 actin	 cytoskeleton.	
Immunofluorescence	 demonstrated	 that	 both	 proteins	 localize	 in	 a	 similar	
manner	throughout	the	cell	cycle;	interphase	cells	are	shown	(Figure	4.5).	There	
was	 localization	 of	 the	 FGFR1	 protein	 to	 the	 cell	 membrane	 and	 also	 to	 oval	
cytoplasmic	perinuclear	structures.	This	 is	similar	 to	 the	 localisation	observed	
in	 previous	 published	 studies	 of	 exogenous	 and	 endogenous	 FGFR1	
















Figure 4.5 Immunofluorescence of wild type (FGFR1-WT.GFP) and mutant 
(FGFR1-P663S.GFP) FGFR1 protein expression.  
HEK293 cells transfected with GFP-tagged wild type FGFR1 or GFP-tagged mutant 
FGFR1 p.(P663S) were fixed, permeabilised and immunostained with DAPI (nuclear 
staining) and Phalloidin (F-actin staining). FGFR1 wild type and FGFR1 mutant 
localised to the cell membrane.  Scale bar 10µM. 
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FGFR1	 was	 primarily	 localised	 to	 the	 cell	 membrane	 and	 cytoplasm	 in	 this	
experiment;	 there	 was	 minimal	 signal	 within	 the	 nucleus.	 As	 stated	 this	 is	
similar	to	the	localization	previously	described	and	correlates	with	the	function	
of	 FGFR1	 as	 a	 receptor	 tyrosine	 kinase	 containing	 a	 transmembrane	 domain.	
The	importance	of	FGFR1	localisation	in	limb	development	and	signalling	is	not	
fully	 understood.	 Its	 role	 in	 the	 activation	 of	 cytoplasmic	 signalling	 cascades	
including	 ERK	 has	 been	 found	 to	 be	 essential	 to	 normal	 limb	 development,	
indicating	 its	 membrane	 localization	 is	 vital[13].	 There	 is	 however	 growing	
evidence	that	the	nuclear	translocation	of	FGFR1	also	plays	an	important	role	in	
transcription	activation.	This	has	been	described	in	cancer	cells[234,	235]	but	is	
also	 considered	 true	 from	 developmental	 pathways[236].	 Obviously,	 as	 the	
model	used	in	my	work	does	not	demonstrate	nuclear	signalling,	it	is	impossible	
to	determine	whether	the	mutation	may	alter	nuclear	localization.	
4.3.2.3 Ability of mutant FGFR1 to signal through ERK 
To	investigate	the	function	of	the	mutant	FGFR1	receptor,	I	decided	to	examine	
its	 capacity	 to	 activate	 the	 MAPK	 signalling	 pathway.	 The	 importance	 of	 the	
MAPK/ERK	 signalling	 pathway	 and	 ERK	 activation	 in	 limb	 development	 has	
been	established[13].	The	majority	of	ERK	activation	in	the	limb	bud	is	reported	
to	 occur	 through	 FGFR	members	 and	ERK	 activation	 is	 considered	 one	 of	 the	
most	 important	 signaling	 events	 downstream	 of	 FGFR1[13].	 I	 therefore	










Culture	with	 tetracycline	 demonstrated	 adequate	 induction	 of	 both	wild	 type	
and	mutant	FGFR1.GFP	in	the	two	cell	lines.	There	was	no	observed	difference	
in	the	level	of	wild	type	or	mutant	protein	induced	as	detected	on	western	blot.	





The	 western	 blot	 (Figure	 4.6),	 representative	 of	 3	 separate	 replicate	
experiments,	demonstrated	that	in	the	absence	of	FGFR1.GFP	expression	and	its	
ligand	 FGF2,	 there	 is	 limited	 ERK	 activation.	 On	 stimulation	with	 FGF2,	 there	
was	 significant	 ERK	 activation	 even	 in	 the	 absence	 of	 FGFR1.GFP	 expression.	
This	may	have	occurred	due	to	signalling	through	either	endogenous	FGFR1	or	
alternate	FGFR	members	on	 the	HEK293	 cells;	 FGF2	 is	not	 specific	 for	FGFR1	
and	will	also	signal	 through	other	FGFRs.	 In	our	cell	 lines,	endogenous	FGFR1	
was	 not	 detectable	 by	Western	Blot.	 The	 specificity	 of	 the	 FGFR1	 antibody	 to	
individual	FGFR1	isoforms	has	not	been	determined	but	published	studies	have	
demonstrated	detection	of	different	isoforms.		It	was	possible	that	the	antibody	
used,	 although	 well	 published,	 did	 not	 detect	 an	 alternate	 isoform	 of	 FGFR1	
expressed	 in	 our	 HEK293	 cells.	 However,	 this	 is	 unlikely	 as,	 although	 the	
antibody	is	polyclonal,	it	is	targeted	to	an	epitope	within	the	C	Terminal	domain,	
an	 area	 with	 little	 variability	 between	 isoforms.	 Other	 members	 of	 the	
laboratory	have	examined	RNA	expression	of	FGFR1	in	these	HEK293	cells	and	
this	 has	 failed	 to	 identify	 FGFR1	 expression.	 This	 indicates	 that	 the	 ERK	






Figure 4.6. Western blot analysis of HEK293 cells expressing FGFR1-WT.GFP 
or FGFR1-P663S.GFP (A) Western blot analysis of HEK293 cells expressing 
FGFR1-WT.GFP or FGFR1-P663S.GFP under the control of tetracycline. Cells 
were incubated with or without tetracycline for 24 hours, then stimulated with vehicle 
or ligand (basic human recombinant FGF) for 30 minutes in serum free media. (A) 
FGFR1-WT.GFP (MW 119kDA) or FGFR1-P663S.GFP were detected using anti-
FGFR1 antibody (Santa Cruz). In FGFR1-WT.GFP cells, incubation with tetracycline 
or addition of the ligand resulted in the detection of a pERK 42/44 band. In FGFR1-
P663S.GFP cells, treatment with the ligand resulted in the detection of pERK 42/44 
in the absence of tetracycline. On induction of the mutant FGFR1-P663S with 
tetracycline there was a significant decrease in the pERK 42/44 band suggesting a 
dominant negative effect of the mutant. Alpha tubulin was used as a loading control. 







concentration	 of	 FGF2.	 In	 contrast,	 expression	 of	 FGFR1-P663S.GFP	 inhibited	
ERK	 activation	 induced	 by	 the	 addition	 of	 FGF2	 at	 both	 concentrations.	 This	







FGFRs.	 It	 is	 therefore	difficult	 to	be	certain	over	which	receptor	signalling	 the	




variety	 of	 receptors	 and	 these	 interactions	 can	have	 stimulatory	 or	 inhibitory	
effects	 on	 downstream	 signalling.	 A	 recent	 paper	 demonstrated	 the	
dimerization	 of	 PGDR	 and	 FGFR1	 in	 the	 presence	 of	 FGF2	 had	 an	 inhibitory	
action	 of	 ERK	 activation[237].	 It	 is	 proposed	 that	 the	 mutant	 FGFR1	 may	
negatively	 influence	 a	 dimer	 that	 activates	 ERK	 or	 alternately	 interact	 more	
avidly	 to	 form	 an	 inhibitory	 dimer.	 This	 experiment,	 although	 useful	 in	
indicating	 potential	 causation,	 has	 limitations.	 The	 mutant	 FGFR1	 expression	




all	 FGFR1	 signalling	 as	 the	 FGFR1	 is	 essential	 at	 various	 stages	 of	




Further	work	 is	 required	 to	 elucidate	 the	precise	mechanisms	of	 inhibition	of	
the	mutant	FGFR1.	To	do	this,	it	would	be	useful	to	determine	the	effect	of	the	
mutant	 protein	 in	 the	 presence	 of	 wild	 type	 FGFR1.	 This	 would	 be	 more	




This	 work	 aimed	 to	 identify	 novel	 disease	 causing	 gene	 mutations	 within	 a	
cohort	 of	 patients	 classified	 as	 non-classical	 Miller	 syndrome.	 This	 cohort	 all	
had	limb	reduction	deformities.	The	discovery	of	novel	disease	associated	genes	




The	 recent	 application	 of	 next	 generation	 sequencing	 (NGS)	 strategies	 to	
identify	 novel	 disease	 associated	 variants	 in	Mendelian	 disorders	 has	 proved	
productive[124].	However	the	ability	to	study	the	whole	genome	or	exome	for	
causative	 variants	 generates	 new	 challenges.	 Strategies	 must	 be	 adopted	 to	
screen	and	curate	the	huge	number	of	variants	that	may	be	identified	in	a	single	
individual[137].	 Chapter	 3	 describes	 a	 pipeline	 for	 filtering	 the	 variants	 to	 a	
small	number	of	candidate	genes	 that	warranted	 further	 investigation.	 I	chose	
to	investigate	further	the	variant	in	FGFR1,	as	it	was	a	strong	candidate	to	be	the	
causative	 genetic	mutation.	Fgfr1	 is	 essential	 for	 normal	 limb	development	 in	
murine	 models[2,	 202]	 and	 pathogenic	 mutations	 in	 FGFR1	 are	 described	 in	
human	developmental	disorders[223,	225].		
4.4.1 Putative dominant negative mutation FGFR1 
The	 FGFR1	 mutation,	 in	 case	 R24H4,	 is	 a	 non-synonymous	 missense	 single	




consequences	 for	 protein	 function[227].	 It	 may	 have	 no	 significant	 effect;	
alternately	it	may	result	in	gain	of	function	or	loss	of	function.	A	gain	of	function	
mutation	 confers	 new	 or	 enhanced	 activity	 on	 the	 protein.	Whereas	 a	 loss	 of	
function	mutation	 results	 in	 reduced	 or	 abolished	 protein	 function.	 The	 limb	
reduction	 deformity	 observed	 in	 the	 patient	 parallels	 the	 phenotype	 seen	 in	
mouse	models,	with	 loss	of	Fgfr1	 in	 the	 limb	bud[2].	 If	 the	mutation	 found	on	
WES	in	FGFR1	was	causative,	I	postulated	that	the	mechanism	was	likely	to	be	
due	to	loss	of	function.	In	the	heterozygote,	such	as	case	R24H4,	loss	of	function	
may	 occur	 due	 to	 haploinsufficiency	 or	 a	 dominant	 negative	 effect[227].		
Haploinsufficiency	occurs	due	to	impaired	function	of	the	mutant	protein,	with	a	
single	 unaffected	 copy	 of	 the	 gene	 incapable	 of	 providing	 sufficient	wild	 type	
protein	 to	 ensure	 normal	 function.	 In	 contrast	 a	 dominant	 negative	 mutant	
protein	 adversely	 affects	 wild	 type	 protein	 function.	 The	 heterozygous	 Fgfr1	









mice	 heterozygous	 for	 the	 Fgfr3	 null	 allele	 show	 normal	 development[240].	
Patients	 with	 Wolf	 Hirschhorn	 Syndrome	 caused	 by	 a	 chromosome	 4p16	
deletion	frequently	have	heterozygous	 loss	of	FGFR3;	 they	do	not	manifest	the	
skeletal	 defects	 observed	 in	 CATSHL	 syndrome[239,	 241].	 Therefore	 it	 is	
implausible	 that	CATSHL	syndrome	 is	due	 to	haploinsufficiency	of	FGFR3.	The	
site	 of	 the	 FGFR3	 mutation	 (p.R621H)	 is	 within	 the	 catalytic	 /	 activation	
loop[239].	 The	 activation	 loop	 undergoes	 conformational	 change	 on	
autophosphorylation	of	 the	protein	 to	allow	substrate	access	 to	 the	active	site	
(proton	acceptor)	at	Aspartic	Acid	623[242].	The	mutation	within	the	activation	
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loop	 is	 considered	 to	 hinder	 access	 to	 the	 active	 site	 and	 therefore	 limit	 the	
kinase	activity	of	FGFR3[239].	 	Other	pathogenic	dominant	negative	mutations	
that	 affect	 the	 tyrosine	 kinase	 activation	 loop	 have	 been	 described;	 these	
include	 inactivation	 of	 the	 insulin	 receptor	 resulting	 in	 inherited	 insulin	
resistance[243].	The	p.P663S	substitution	in	case	R24H4	lies	at	the	distal	end	of	
the	 activation	 loop;	 it	 is	 therefore	 plausible	 that	 this	 mutation	 could	 also	
influence	protein	function	in	a	similar	manner.		








is	 not	 merely	 inactive	 but	 has	 a	 dominant	 negative	 effect	 in	 our	 cell	 culture	
model.	Therefore,	the	mutant	protein	is	likely	forming	heterodimers	with	FGFRs	
other	 than	 FGFR1.	 FGFRs	 are	 known	 to	 dimerise	 and	 it	 has	 been	 suggested	 a	





pathways	 act;	 these	 are	 a	 pathway	 modularity	 model	 or	 pathway	 additive	
model[207].	 In	 the	 former	 the	 distinct	 pathways	 are	 used	 independently	 for	
different	 functions,	 whereas	 in	 the	 additive	 model	 multiple	 pathways	 are	
required	 simultaneously	 for	 each	 function[207].	 It	 has	 been	 suggested	 that	




FGFR1	 remain	 active	 although	 it	 is	 unclear	 to	 what	 extent	 these	 could	
compensate	 for	 the	 loss	 of	 ERK	 activation.	 	 However,	my	work	 demonstrates	
that	 the	 mutant	 protein	 does	 have	 aberrant	 effects	 on	 FGFR	 signalling	 and	
provides	 a	 potential	 mechanism	 for	 the	 developmental	 disorder	 observed	 in	
this	patient.		
4.4.3 Determining pathogenicity of FGFR1 variant 




above,	would	be	 to	 co-transfect	 the	wild	 type	and	mutant	protein	 to	 replicate	
the	 heterozygous	 state.	 In	 addition	 to	 the	 study	 of	 cellular	 function,	 other	
approaches	have	been	used	to	provide	evidence	of	causality.	Published	studies	
demonstrate	 the	 benefit	 of	 animal	 models	 to	 investigate	 putative	 pathogenic	
mutations	 and	 determine	 whether	 variants	 recapitulate	 the	 human	 disease	
phenotype	 using	 in	 vivo	 models[243,	 244].	 However,	 this	 is	 potentially	 time	
consuming	 and	 costly,	 particularly	 given	 existing	 knowledge	 of	 murine	
phenotypes	on	loss	of	FGFR1	signalling	in	limb	bud	development.		
	
To	 determine	 causation,	 any	 novel	 variant	 (or	 combination	 of	 variants	 in	 a	
recessive	model)	 should	 be	 unique	 to	 the	 case	 over	 both	 unaffected	 parents.	
However	 the	 identification	 of	 a	 novel	 variant	 in	 a	 single	 individual	 requires	
corroboration	 and	 additional	 cases	 of	 the	 disorder	 with	 similar	 mutations	
should	be	sought.	This	reduces	the	possibility	of	identifying	novel	SNPs,	with	no	
functional	consequence,	as	causative	mutations.	Although	FGFR1	mutations	had	
been	 identified	 in	 Kallmann	 syndrome[225],	 Pfeiffer	 syndrome[223]	 and	
Osteoglophonic	dysplasia[224]	no	similar	transverse	limb	reduction	phenotype	
had	been	observed	in	these	disorders	previously.	However	since	this	work	was	
undertaken	 two	 studies	 have	 been	 published	 describing	 FGFR1	 mutations	 in	
association	with	limb	reduction	deformities	in	patients	with	Kallmann[245]	and	
Hartsfield	 Syndromes[166].	 Harstfield	 syndrome	 is	 a	 rare	 and	 unique	
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association	of	holoprosencephaly	and	ectrodactyly,	with	or	without	features	of	
cleft	 lip	and	palate;	 there	are	also	other	variable	 features[166].	This	 therefore	
demonstrates	 that	 human	 mutations	 in	 FGFR1	 can	 lead	 to	 transverse	 limb	
reduction	 deformity.	 This	 finding,	 in	 combination	 with	 the	 genetics	 of	 the	
variant	 in	 R24H4	 (de	 novo),	 the	 knowledge	 of	 FGFR1	 function	 in	 limb	 bud	
development	and	the	functional	work	undertaken	in	this	chapter,	indicates	that	
the	variant	identified	in	R24H4	is	the	causative	mutation.	
4.4.4 Comparison of disease associated FGFR1 mutations 
FGFR1	 is	 associated	 with	 a	 number	 of	 development	 disorders	 with	 distinct	
phenotypes;	this	section	aims	to	discuss	the	genotype	/	phenotype	relationship	
in	 these	 disorders.	 Causative	 mutations	 within	 FGFR1	 in	 Osteoglophonic	
Dysplasia	 (OD)	and	Pfeiffer	Syndrome	are	believed	 to	be	gain	of	 function[224,	
246].	In	OD,	mutations	occur	within	the	extracellular	IgIII	and	transmembrane	
domains	of	FGFR1.	Functional	analysis	of	one	of	these	transmembrane	missense	




FGFR2	 (p.P253S)	 that	 results	 in	 Apert	 Syndrome	 [248].	 Both	 Osteoglophonic	
Dysplasia	 and	 Pfieffer	 syndrome	 are	 therefore	 caused	 by	 different	 activating	
mutations	 of	 FGFR1;	 neither	 manifests	 a	 longitudinal	 limb	 reduction	
deformities.	











Kallmann	and	Hartsfield	 syndromes	are	 shown	 in	Figure	3.7.	The	mutation	at	
position	 167	 represents	 a	 patient	 with	 Kallmann	 syndrome,	 the	 mutation	 at	
position	 663	 is	 case	 R24H4	 and	 the	 other	 mutations	 represent	 cases	 of	
Hartsfield	 syndrome[166,	 245].	 This	 demonstrates	mutations	 associated	 with	
limb	 deformity	 are	 not	 localised	 to	 a	 single	 region	 of	 the	 protein.	 Three	
mutations	 are	 reported	 in	 the	 extracellular	 domain;	 these	 occur	 around	 the	
heparin-binding	 domain.	 It	 is	 plausible	 that	 altered	 heparin	 binding	 may	 de-




limb	 deformity	 associated	 with	 FGFR1[245].	 It	 was	 published	 while	 I	 was	
undertaking	this	work	and	I	decided	to	examine	the	effect	of	 this	mutation	on	
FGFR1	localization	and	FGFR1	function	in	ERK	signalling.	I	generated	a	HEK293	
FGFR1-A167S.GFP	 cell	 line	 using	 the	 HEK293	 FlpIn	 cells	 as	 described	
previously.	 Again,	 localisation	 of	 the	mutant	 protein	was	 similar	 to	wild-type	
FGFR1.	 On	 investigation	 of	 ERK	 signalling,	 FGFR1-A167S.GFP	 appeared	 to	












3.7. Western blot 
analysis of HEK293 cells expressing FGFR1-WT.GFP or FGFR1-A167S.GFP (A) 
Western blot analysis of HEK293 cells expressing FGFR1-WT.GFP or FGFR1-
A167S.GFP under the control of tetracycline. Cells were incubated with or without 
tetracycline for 24 hours, then stimulated with vehicle or ligand (basic human 
recombinant FGF) for 30 minutes in serum free media. (A) FGFR1-WT.GFP (MW 
119kDA) or FGFR1-A167S.GFP were detected using anti-FGFR1 antibody (Santa 
Cruz). In FGFR1-WT.GFP cells, incubation with tetracycline or addition of the ligand 
resulted in the detection of a pERK 42/44 band. In FGFR1-A167S.GFP cells acted 
as the wild type . Alpha tubulin was used as a loading control. (B) Graph 










Figure 4.8 Structure of FGFR1.  FGFR1 protein with amino acid positions 
and major protein domains/elements illustrated. FGFR1 comprises an 
extracellular domain containing three Ig Domains, a Signal Peptide, an Acid 
Box and the CAM (Cell Adhesion Molecule) Homology Domain (CHD). The 
heparin-binding domain lies within the 2nd Ig domain. There is a 
Transmembrane domain and an Intracellular domain. The Intracellular domain 
comprises two Tyrosine Kinase subdomains. The ATP binding domain lies 
within the first subdomain and the active site (Proton acceptor) at Aspartic 
Acid 623 lies within the second subdomain. Below the protein structure is an 
illustration showing the sites of FGFR1 variants associated with transverse 
limb reduction deformity; the mutations marked with asterix are homozygous.  
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observed	 with	 FGFR1-P663S.GFP	 and	 it	 is	 unclear	 how	 mutation	 p.(A167S)	
effects	downstream	pathways	to	cause	the	observed	phenotype.	It	may	be	that	
the	 mutation	 effects	 protein	 stability,	 as	 has	 been	 described	 with	 MAB21L2	
variants	 causing	 human	 developmental	 anomalies[250].	 Alternately,	 the	
mutation	may	impair	interaction	with	HSGAG.	Transient	activation	of	FGFR	with	







site	 aspartic	 acid	 is	 mutated	 in	 one	 of	 these,	 resulting	 in	 inactivation	 of	 the	
tyrosine	kinase.	The	mutation	at	position	490	lies	within	the	ATP	binding	site,	
also	 necessary	 for	 kinase	 activity.	 The	 locations	 of	 these	 FGFR1	 mutations	
therefore	 provide	 potential	 mechanisms	 for	 their	 influence	 on	 downstream	
signalling.		
	
Numerous	 pathogenic	mutations	 have	 been	 identified	 through	 out	 the	 FGFR1	
gene	but	there	is	significant	phenotypic	heterogeneity[225,	249,	252].	Although	
the	 location	of	 the	mutations	provides	some	 insight	 into	how	these	may	affect	
protein	function,	it	 is	unclear	why	certain	mutations	result	in	limb	phenotypes	
while	other	adjacent	mutations	do	not.	For	example,	mutation	at	position	666	
(p.W666R)	 or	 618	 (p.K618N)	 results	 in	 Kallmann	 syndrome	 without	 limb	
anomalies,	 compared	 to	 the	 limb	deformity	observed	with	mutations	p.H621R	
and	 p.P663S[166].	 It	 remains	 unclear	 whether	 these	 mutations	 with	 similar	
localization	 in	 the	 protein	 result	 in	 different	 phenotypes	 because	 of	 different	
effects	 on	 the	 protein	 or	 because	 of	 alternate	 influences,	 ie	 genetic	 or	
environmental.	 It	 has	 been	 postulated	 that	 the	 precise	 phenotype	 may	 be	






reduction	 deformity	 have	 been	 reported	 more	 than	 once.	 It	 is	 therefore	
uncertain	 whether	 each	 variant	 will	 consistently	 lead	 to	 the	 limb	 phenotype	
observed.		
4.4.5 Diagnosing Kallmann Syndrome in R24H4 
Finally,	in	case	R24H4,	the	identification	of	a	loss	of	function	mutation	in	FGFR1,	
commonly	associated	with	Kallmann	syndrome,	led	us	to	establish	whether	the	
patient	 had	 any	 features	 of	 Kallmann	 syndrome.	 Patient	 R24H4	 was	 pre-
pubertal	 at	 the	 time	 of	 study	 and	 therefore	 hypogonadism	 had	 not	 been	
identified,	 however	 the	 patient	 was	 found	 to	 be	 hyposmic.	 This	 led	 us	 to	
diagnose	 R24H4	 with	 Kallmann	 syndrome.	 The	 patient	 had	 been	 previously	
classified	 as	 atypical	 Millers	 syndrome.	 The	majority	 of	 these	 syndromes	 are	
based	 on	 phenotypic	 classifications	 and	 predate	 molecular	 characterisation.	





accurate	 clinical	 phenotyping	 also	 has	 limitations;	 as	 demonstrated	 the	
phenotype	 can	 vary	 markedly	 depending	 on	 the	 precise	 of	 the	 mutation,	 its	
expressivity	and	other	undetermined	influences.		
4.5 Conclusion 
I	have	demonstrated	that	 the	FGFR1	variant	 identified	 in	 this	case	R24H4	was	
genuine	and	de	novo.	I	have	provided	evidence	that	indicates	the	mutation	may	
have	dominant	negative	effect	on	FGFR	signalling	and	thereby	a	mechanism	by	


















of	 gene	 expression	 (SAGE)	 was	 performed.	 The	 work	 in	 this	 chapter	 was	
undertaken	 with	 Dr	 Pedro	 Coutinho	 and	 Professor	 Richard	 Baldock.	 Dr	
Coutinho	 and	 I	 undertook	 limb	 dissection	 and	 RNA	 extraction.	 Sample	
preparation	 and	 sequencing	 was	 undertaken	 at	 GenePool.	 Dr	 Coutinho	




5.1.1 Limb Development at E14.5 
Analysis	 of	 limb	 development	 has	 delivered	 profound	 insights	 into	 the	
mechanisms	 that	 control	 growth	 and	 patterning,	 with	 wider	 implications	 for	
morphogenesis.	 The	 murine	 limb	 initiates	 at	 E9.5	 from	 the	 lateral	 plate	
mesoderm	 and	 within	 five	 days	 the	 structure	 has	 developed	 such	 that	 both	
skeletal	and	soft	tissue	structures	are	fully	patterned.	At	this	stage	(E14.5),	the	
limb	elements	are	essentially	 equivalent	 to	 their	 adult	 form[254].	From	E14.5	
onwards,	 the	major	process	 that	occurs	within	 the	developing	 limb	 is	growth.	
However,	 the	 genetic	 pathways	 that	 control	 this	 growth,	 at	 later	 stages	 of	
development	(E14.5+),	remain	poorly	characterized.		
	
In	 the	 murine	 embryo,	 the	 forelimb	 and	 hindlimb	 develop	 heterochronically	
under	 the	 precise	 regulation	 of	 similar	 molecular	 pathways.	 The	 majority	 of	
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genes	known	to	play	a	role	in	limb	development	are	expressed	in	near	identical	
patterns	 in	 both	 the	 forelimb	 and	 hindlimb[255].	 	 However,	 despite	 the	
common	 core	 genetic	 programmes,	 forelimbs	 and	 hindlimbs	 are	
morphologically	different.		Several	identity	modulators	have	been	discovered	to	
mediate	 the	 distinct	 morphogenesis	 of	 the	 two	 appendages.	 Tbx5	 is	
predominantly	expressed	in	the	forelimb,	whereas	Pitx1	and	Tbx4	are	expressed	
in	 the	 hindlimb.	 These	 genes	 are	 reported	 to	 be	 major	 determinants	 of	 limb	
identity.	Several	studies	have	demonstrated	that	forced	mis-expression	of	Tbx5	
in	 the	 hindlimb	 or	Pitx1	 in	 the	 forelimb	 leads	 to	 aberrant	morphogenesis[16,	
256].	Limb	ontogeny	alters	so	that	the	limb	resembles	the	opposite	appendage,	
ie	the	forelimb	develops	hindlimb	characteristics	and	hindlimb	shows	forelimb	
features.	 However,	 detailed	 understanding	 of	 the	 mechanisms	 that	 regulate	
forelimb	and	hindlimb	identity	requires	elucidation.		
	
The	 analysis	 of	 differentially	 expressed	 genes	 is	 a	 powerful	 approach	 to	











are	 distinct.	 It	 also	 aimed	 to	 determine	 whether	 markers	 that	 influence	
appendage	patterning	remain	upregulated	after	specification	 is	complete.	This	
is	 important	 not	 only	 to	 inform	 models	 of	 limb	 development	 but	 also	 to	
understand	 human	 developmental	 disorders.	 It	 is	 particularly	 relevant	 to	




All	 mouse	 procedures	 were	 performed	 in	 accordance	 with	 UK	 Home	 office	
regulation	and	approved	by	the	University	of	Edinburgh	Ethical	committee.	
5.2.2 DGE-SAGE Processing 
The	 limbs	 from	 E14.5	 CD1	 mice	 embryos	 were	 dissected	 and	 preserved	 in	
RNAlater	 (Qiagen),	 at	 -20oc.	 	 Two	 biological	 replicas	were	 generated	 for	 each	




Edinburgh	 GenePool	 service	 (http://genepool.bio.ed.ac.uk/)	 in	 order	 to	
generate	and	sequence	the	respective	DGE-SAGE	libraries.	This	was	performed	
according	to	standard	protocols	using	tag	profiling	with	NlaIII	from	Illumina.	
5.2.3 DGE-SAGE Differential Analysis 
Fastaq	 data	 was	 parsed	 to	 select	 sequences	 with	 a	 probability	 of	 nucleotide	
error	 at	 any	 given	 position	 of	 less	 than	 0.001.	 	 These	 were	 then	 trimmed	 to	
remove	 adapters	 and	 the	 remaining	 tags	 mapped	 against	 the	 NCBI	 SAGE	
repository	 file	Mm_long.best_gene	 (ftp://ftp1.nci.nih.gov/pub/SAGE/MOUSE/).	
Tags	that	did	not	match	were	processed	using	Bowtie	[260]with	parameters	-S	-
a	 -v	1	 -m	1	 --best	 –strata,	 against	M.musculus	NCBI37	assembly.	 	The	mapped	
tags	were	associated	to	genes	using	the	GTF	transcript	annotation	files	 for	the	
Ensembl	 NCBIM37	 (http://cufflinks.cbcb.umd.edu/igenomes.html).	 This	
information	 was	 used	 to	 generate	 the	 tag	 count	 per	 gene	 data	 for	 all	 the	
samples.	 	 All	 these	 tasks	 were	 performed	 using	 PERL	 scripts	 developed	 in	
house.	Tag	count	data	files	were	then	analyzed	using	the	R	package	DESeq	[261]	
in	 order	 to	 determine	 genes	 that	 are	 differentially	 expressed	 between	 the	
forelimb	and	the	hindlimb	(fold	difference	>	2;	padj	<	0.05).	
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5.2.4 Quantitative Real Time PCR (qRT-PCR) 
Genes	 up-regulated	 in	 forelimb	 or	 hindlimb	 were	 ranked	 according	 to	 fold	
difference	of	expression	and	expression	value.	 	From	the	 top	25	of	each	set,	6	
were	 selected	at	 random	and	 investigated	by	qRT-PCR,	using	mouse	Actb	 and	
Gapdh	 as	 control	 housekeeping	 genes.	 Quantification	 was	 performed	 in	
triplicate	 on	 the	 individual	 cDNA	 samples	 and	 normalized	 to	 Actb	 RNA	
measurements	using	CT	values	exported	from	RT-PCR	instrument.	
5.2.5 Whole Mount in situ hybridization  
Wholemount	in-situ	hybridization	(WISH)	was	performed	on	14.5dpc	wild-type	
mouse	embryos	using	methods	as	described	in	Chapter	2.	




the	appendages;	genes	 that	were	uniquely	expressed	 in	either	 the	 forelimb	or	
the	hindlimb	were	also	annotated.	
The	molecular	function	of	the	differentially	expressed	genes	was	studied	using	
the	 DAVID	 [262]	 and	 the	 GOTERM_MF_FAT	 analysis.	 Putative	 molecular	
processes	 that	 are	 modulated	 by	 the	 differentially	 expressed	 genes	 were	
analyzed	 using	 the	mammalian	 phenotype	 ontology	 data.	 [263]The	 statistical	
significance	 of	 the	 results	 was	 determined	 using	 a	 bootstrap	 method	 by	
sampling	 from	a	 set	of	Ensembl	 genes	5000	 times.	 	All	 the	parsing	of	 the	data	
was	performed	using	PERL	scripts.	
5.2.7 Data availability 
The	 raw	 and	 processed	DGE-SAGE	data	 is	 deposited	 at	 GEO	 (GSE41222).	 The	






The	 forelimbs	and	 the	hindlimbs	were	dissected	 from	E14.5	murine	 embryos,	
using	 2	 biological	 replicates	 for	 each	 structure.	 Total	 RNA	was	 extracted	 and	
used	 to	 generate	 DGE-SAGE	 libraries	 at	 GenePool	 (University	 of	 Edinburgh).		
These	libraries	were	sequenced	at	a	depth	ranging	from	1.8	to	5.3	millions	tags	
per	 sample	 (Table	 5.1).	 Sequence	 tags	 were	 trimmed	 to	 remove	 adapters,	
parsed	 according	 to	 fastq	 quality	 scores	 and	 mapped	 to	 the	 NCBI	 SAGE	
repository	 (ftp://ftp1.nci.nih.gov/pub/SAGE/MOUSE/Mm_long.best_gene).	
Bowtie	was	 used	 to	map	 unaligned	 tags	 to	 the	M.musculus	 NCBI37	 assembly.	
81.3%	of	 forelimb	tags	and	85.2%	of	hindlimb	tags	were	mapped	successfully.	
Tags	were	 then	 assigned	 to	 genes	 according	 to	 the	 Ensembl	 gene	 annotation.	
19820	and	21213	genes	were	identified	in	forelimb	and	hindlimb	respectively;	
of	these,	1949	and	3342	were	unique	to	either	forelimb	or	hindlimb	(Table	4.2).		






Table 1  - The forelimb and hindlimb DGE-SAGE libraries and mapping 
 
FL1 FL2 HL1 HL2 






















Table 1. The DGE-SAGE libraries for forelimb (FL) and hindlimb (HL) had between 
1.8 million and 5.3 million tags.  Between 78.7% and 82.9% of these tags were 
successfully mapped to the NCBI SAGE repository and these numbers increased to 
from 81.3% to 85.9%, when Bowtie was used to analyse the unmapped sets of tags.  
 








Unique genes 1949 3342 
Table 2. The compiled DGE-SAGE gene count datasets have matches to 19820 genes 
in the forelimb dataset and 21213 genes in the hindlimb dataset.  Within these sets, 
there are 954 genes that are expressed in the forelimb and not in the hindlimb and 





Table 5.1 The forelimb and hindlimb DGE-SAGE libraries and mapping. 
FL, forelimb. HL, hindlimb. Experiment carried out in duplicate  
	






Table 1  - The forelimb and hindlimb DGE-SAGE libraries and mapping 
 
FL1 FL2 HL1 HL2 






















Table 1. Th  DGE-SAGE libraries for forelimb (FL) and hindlimb (HL) had between 
1.8 million and 5.3 million tags.  Between 78.7% and 82.9% of these tags were 
successfully mapped to the NCBI SAGE repository and these numbers increased to 
fro  81.3% to 85.9%, when Bowtie was used to analyse the unmapped sets of tags.  
 








Unique genes 1949 3342 
Table 2. The compiled DGE-SAGE gene count datasets have matches to 19820 genes 
in the forelimb dataset and 21213 genes in the hindlimb dataset.  Within these sets, 
there are 954 genes that are expressed in the forelimb and not in the hindlimb and 





Table 5.2 The forelimb and hindlimb genes with DGE-SAGE tags 
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5.3.1 Differential expression profiles of forelimb and hindlimb 
We	 analyzed	 the	 expression	 profile	 of	 both	 forelimb	 and	 hindlimb	 to	 identify	
genes	 that	 are	 differentially	 expressed	 between	 the	 structures	 at	 E14.5.	 This	
was	 performed	 using	 DESeq,	 an	 R	 package	 to	 analyse	 count	 data	 from	 high-
throughput	assays;	it	uses	a	model	based	on	the	negative	binomial	distribution.	
The	 statistical	 significance	 of	 differential	 gene	 expression	 was	 calculated	
following	 correction	 for	multiple	 testing.	We	 identified	 1065	 and	 1047	 genes	
enriched	 in	 the	 forelimb	 compared	 to	 hindlimb	 and	 hindlimb	 compared	 to	





Of	 the	 200	 genes	 analyzed,	 19	 were	 differentially	 expressed	 between	 the	
forelimb	and	hindlimb	(enrichment	fold	>	2;	padj	<	0.05)(Table	4.3).	There	was	
conservation	 of	 the	 differential	 expression	 of	 certain	 genes;	 at	 E14.5,	Pitx1	 is	
still	 highly	 expressed	 in	 the	 hindlimb	 but	 minimally	 expressed	 the	 forelimb.	
Also,	 Tbx4	 and	 Tbx5	 remain	 up-regulated	 in	 the	 hindlimb	 and	 forelimb,	
respectively.	Other	genes	such	as	Hoxc5	 that	had	previously	been	identified	as	
up-regulated	 in	 the	 forelimb	 from	E9.5	 to	E13.5	are	no	 longer	up-regulated	at	
E14.5[258].	 Conversely,	 Hoxa11as	 is	 not	 differentially	 expressed	 prior	 to	
E14.5[264]	but	it	is	up-regulated	in	the	hindlimbs	at	this	stage.		
5.3.2 Functional characterisation of differentially expressed limb genes 
DAVID,	 an	 online	 tool	 for	 functional	 annotation	 of	 genes,	 was	 used	 to	
characterise	differentially	expressed	genes.	Genes	up-regulated	in	the	forelimb,	
relative	to	the	hindlimb,	were	enriched	in	metal	ion	binding	genes	(in	particular	




Genes	 were	 also	 annotated	 using	 the	mammalian	 phenotype	 ontology.	 Genes	
up-regulated	 in	 the	 forelimb	 comprised	 186	 genes	 that	 mediate	 growth,	 234	
genes	essential	to	life,	87	genes	that	regulate	skeletal	development	and	55	genes	
involved	in	limb/digit/tail	morphology	(p	<	0.0008).	Genes	up-regulated	in	the	
hindlimb	 were	 enriched	 for	 genes	 essential	 to	 life	 (226),	 gene	 involved	 in	
embryogenesis	(110)	and	gene	that	regulate	growth	(174)	(p<0.0018).		
5.3.3 Validation of Results with qRT-PCR and WISH 
Validation	 of	 the	 findings	was	 attempted	 using	 qRT-PCR	 and	whole	mount	 in	
situ	hybridisation	(WISH).	Twelve	genes	were	chosen	randomly	 for	validation,	
six	up-regulated	in	the	forelimb	and	six	up-regulated	in	the	hindlimb.	We	found	
that	 both	 qRT-PCR	 and	 WISH	 confirm	 the	 DESeq	 results	 in	 8	 and	 6	 genes	
respectively		(Figure	5.1	and	5.2).	With	four	genes	(Hoxb5,	Hoxa11,	Mypn,	Tifa),	
qRT	 PCR	 was	 not	 consistent	 with	 the	 DESeq	 result,	 showing	 no	 differential	
expression.	WISH	was	 not	 performed	with	 three	 of	 the	 selected	 genes	 due	 to	
failure	to	synthesise	adequate	riboprobe.	In	a	fourth,	no	signal	was	obtained	on	
























Figure 5.1 Results of qRT PCR validationExpression profiling of limb genes in 
fore and hindlimbs of 14.5dpc limb buds. Expression was determined using 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Values 
were normalized to housekeeping gene and are presented relative to forelimb 
expression. Data shown is the mean of 3 biological independent experiments. Each 













Figure 5.2 Whole mount in situ hybridization (WISH) of limb bud differentially 






Limb Bud Genes Upregulated in Forelimb or Hindlimb 













Table 5.3 Limb Bud Genes Upregulated in Forelimb or Hindlimb. Differentially 






of	 limb	 development,	 to	 identify	 putative	 regulators	 of	 limb	 growth	 in	 later	
embryogenesis	 and	 to	 determine	 differential	 fore-	 and	 hind-	 limb	 gene	
expression,	 after	 completion	 of	 limb	 specification.	 Although	 my	 interest	 in	
forelimb/hindlimb	 identity	was	 prompted	 by	 our	 POADS	 cohort	with	 isolated	
upper	 or	 lower	 limb	 phenotypes,	 this	 study	 did	 not	 aim	 to	 identify	 novel	
regulators	 of	 patterning.	 Earlier	 stages	 of	 limb	 morphogenesis	 have	 been	
assessed	by	similar	studies	previously.		
5.4.2 Novel regulators of limb growth 
The	 study	 aimed	 to	 utilise	 the	 heterochronic	 development	 of	 forelimb	 and	
hindlimb	to	identify	putative	regulators	of	growth.	It	was	postulated	that	as	the	
forelimb	 is	 more	 developmentally	 advanced,	 it	 may	 differentially	 up-regulate	




in	 limb	 growth.	 This	 work	 found	 that	 genes	 involved	 in	 purine	 biosynthesis	
were	preferentially	expressed	in	the	forelimb.	Purine	biosynthesis	is	reported	to	
modulate	 growth	 through	 its	 regulation	 of	 cell	 proliferation[265,	 266].	 Again,	
this	highlights	 the	 importance	of	nucleotide	biosynthesis	 in	 limb	development	
and	 correlates	 with	 the	 DHODH	 mutations	 found	 in	 Miller	 syndrome.	 In	
addition,	 metal-ion	 binding	 genes	 were	 significantly	 up-regulated	 in	 the	
forelimb,	 particularly	 zinc-ion	 binding	 genes.	 Zinc	 is	 a	 well-established	
modulator	of	growth;	zinc	deficiency	causes	growth	retardation,	amongst	other	
phenotypes	 including	 thyroid	 dysfunction	 and	 delayed	 sexual	
development[267,	268].		
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5.4.3 Limb Identity Modulators	
Although	 the	 majority	 of	 genes	 identified	 demonstrate	 similar	 expression	 in	
both	 forelimb	 and	 hindlimb,	 we	 show	 that	 forelimb	 and	 hindlimb	 each	
differentially	 regulate	over	1000	genes.	To	 identify	 the	most	 relevant	of	 these	
genes,	we	compiled	a	 list	of	over	200	genes	associated	with	 limb	ontogenesis.	
This	 list	 included	all	major	morphogen	 families	 (SHH,	BMP,	FGF	and	WNT),	 in	





forelimb)	 remain	 differentially	 expressed.	 However,	 other	 forelimb	 identity	












specification.	 It	 is	 reassuring	 to	 observe	up-regulation	of	 known	 limb	 identity	
modulators	 in	 the	 appropriate	 appendage;	 this	 is	 useful	 in	 confirming	 the	
validity	of	the	data.		





method,	 which	 were	 only	 able	 to	 identify	 around	 44%	 of	 known	 genes[257,	
269].	In	addition,	our	study	identified	significantly	more	transcribed	genes	than	
previous	 limb	 expression	 profile	 studies[257-259].	 The	 sensitivity	 of	 the	




RT	 PCR	 is	 considered	 the	 gold	 standard	 investigation	 for	 quantification	 of	
mRNA	levels.	 In	contrast,	WISH	allows	the	sites	of	expression	to	be	visualised;	
this	will	show	altered	distribution	or	localized	up-regulation	that	may	be	missed	
on	 PCR	 of	 the	 heterogenous	 limb	 bud.	Unfortunately	 I	was	 unable	 to	 validate	
these	 findings	with	WISH	 for	 four	of	 the	genes,	due	either	 to	 failure	 to	obtain	
adequate	riboprobe	synthesis	or	failure	to	achieve	satisfactory	signal.		However,	
qRT	 PCR	 also	 failed	 to	 validate	 up-regulation	 of	 four	 genes.	 The	 inability	 to	
confirm	 one	 third	 of	 the	 differentially	 regulated	 genes	 chosen	 for	 validation	
does	 raise	 concerns	as	 to	 the	validity	of	 the	data.	However,	 this	 finding	 is	not	
unprecedented	 [270]	 and	 a	 proportion	 of	 false	 positives	 are	 to	 be	 expected,	
particularly	 when	 using	 the	 Benjamini	 correction	 for	 multiple	 testing.	 This	
correction	 controls	 for	 false	 discovery	 rate,	 unlike	 the	 Bonferroni	 correction	





on	 gene	 ontology	 or	 functional	 annotation	 tools,	 rather	 than	 published	
involvement	 in	 limb	 growth	 or	 empirical	 data.	 Future	 work	 will	 require	





5.4.5 Heterochrony of mouse limb 
Heterochrony	describes	the	altered	timing	of	equivalent	developmental	events.	
Heterochrony	 of	 forelimb	 and	 hindlimb	 development	 defines	 the	 different	







murine	species	 is	at	best	mild;	one	study,	examining	heterochrony,	 found	 that	
the	 mouse	 forelimb	 and	 hindlimb	 develop	 synchronously[272].	 In	 addition,	
even	 if	 forelimb/hindlimb	 heterochrony	 exists,	 it	 is	 not	 certain	 that	 growth	
genes	 will	 be	 up-regulated	 at	 more	 advanced	 stages	 in	 development.	
Heterochrony	may	also	confound	comparison	of	expression	profiles;	genes	may	
be	 upregulated	 in	 one	 appendage	 over	 the	 other	 due	 to	 differences	 in	 the	
developmental	 stage	 rather	 than	 functional	 differences	 related	 to	 the	
appendage[15].		
5.4.6 Forelimb and hindlimb homology 





selective	 pressure	 on	 the	 pelvic	 and	 pectoral	 appendage	 in	 humans,	 due	 to	
bipedalism[273].	
	
The	 forelimb	 and	 hindlimb	 do	 not	 demonstrate	 serial	 homology	
phylogenetically[273].	 This	 is	 due	 to	 the	 absence	 of	 any	 tetrapod	 progenitor	
with	 identical	 fore-	 and	 hind-limbs.	 Many	 of	 the	 bones	 and	 virtually	 all	 soft	
	 187	
tissue	elements	found	in	the	vertebrate	forelimb	and	hindlimb	have	developed	
subsequent	 to	 the	 appearance	 of	 distinct	 pectoral	 and	pelvic	 fins,	 from	which	
each	 appendage	 is	 derived[273].	 Therefore,	 there	 is	 no	 structure	with	 similar	
soft	 tissue	 morphology	 from	 which	 both	 appendages	 have	 evolved.	 The	
similarity	of	 the	forelimb	and	hindlimb	of	tetrapods	 is	 therefore	considered	to	





determinants	 of	 forelimb	 and	 hindlimb	 identity	 remain	 up-regulated	 in	 their	
respective	 appendage,	 despite	 the	 completion	 of	 limb	 patterning.	 This	 data	
constitutes	a	useful	resource	for	the	further	characterisation	of	the	dynamics	of	
limb	 development	 networks	 and	 will	 therefore	 inform	 limb	 development	
pathways.	 Due	 to	 time	 constraints,	 only	 a	 limited	 number	 of	 genes	 were	
validated	using	both	whole-mount	in	situ	hybridization	and	qRT-PCR.	Ideally	a	
greater	 number	 of	 genes	 would	 be	 validated	 to	 confirm	 the	 veracity	 of	 the	
results;	these	would	include	the	limb-associated	genes	identified.		
	
This	 work	 looked	 primarily	 at	 later	 stages	 of	 limb	 development,	 when	
patterning	 is	 complete.	 The	 analysis	 was	 undertaken	 at	 this	 later	 stage	 on	
account	of	previous	studies	that	have	examined	differential	expression	at	early	
stages	of	development.	However,	this	protocol	may	provide	a	useful	strategy	to	




of	 transcriptional	 elongation	 of	 genes	 required	 for	 neural	 crest	
development[106].	 It	 would	 be	 of	 interest	 to	 determine	 whether	 a	 similar	
pattern	 of	 gene	 inhibition	 is	 observed	 in	 murine	 limbs.
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deficit	 is	 frequently	 observed	 in	 both	 classical	 and	 non-classical	 Miller	





Mutations	 within	 DHODH	 have	 recently	 been	 identified	 as	 causative	 genetic	
variants	in	classical	Miller	Syndrome.	In	Chapter	2,	I	 investigated	the	influence	
of	DHODH	 in	 limb	development.	 I	 found	 that	DHODH	 is	expressed	 in	 the	 limb	
and	 brachial	 arches	 during	 early	 murine	 development:	 a	 specific	 expression	
pattern	was	 observed	 consistent	with	 regions	 affected	 in	 the	 individuals	with	
Miller	 syndrome.	 Specifically,	 I	 have	 shown	 that	 DHODH	 is	 expressed	 in	 the	
distal	 limb	 bud	 mesenchyme	 underlying	 the	 Apical	 Ectodermal	 Ridge.	
Furthermore,	 I	have	provided	evidence	that	the	expression	of	Dhodh	occurs	 in	
areas	 of	 cell	 proliferation.	 I	 undertook	 comparative	 expression	 analysis	 of	






To	 study	 the	 effect	 of	 DHODH	 inhibition	 on	 proliferation,	 I	 generated	 and	
validated	 an	 immorto-mouse	 limb	 bud	 cell	 line	 from	 10.5dpc	murine	 embryo	




demonstrated	 that	 this	 was	 not	 due	 to	 increased	 cell	 death	 and	 therefore	
inhibition	of	DHODH	impaired	proliferation	in	my	limb	bud	cells.		
	
The	 hypothesis	 for	 this	work	was	 that	 the	 limb	 reduction	 defect	 observed	 in	
Miller	Syndrome	was	secondary	to	 impaired	proliferation	due	to	a	decrease	in	
the	 available	 pyrimidine	 pool.	 Evidence	 to	 support	 this	 include	 a	 phenotype	




human	 phenotype.	 Published	 studies	 of	 the	 treatment	 of	 murine	 dams	 with	
Leflunomide,	 a	 chemical	 inhibitor	 of	 DHODH	 also	 results	 in	 an	 analogous	






established	 causative	 mutations,	 including	 in	DHODH.	 Genomic	 deletions	 and	
duplications	were	excluded	on	array	comparative	genomic	hybidisation	prior	to	
whole	 exome	 sequencing	 (WES).	 Approximately	 15000	 unique	 heterozygous	
variants	 and	 approximately	 7000	 unique	 homozygous	 variants	 per	 individual	
were	identified	on	whole	exome	sequencing.	I	developed	a	filtering	strategy	to	
identify	causative	variants	based	on	the	genome	analysis	tool	kit	best	practice.	
Using	 this	 strategy,	 a	 single	 variant	 was	 identified	 on	 the	 dominant	 model	
analysis	in	individual	R24H4	within	the	FGFR1	gene.	This	was	confirmed	to	be	a	







altered	 amino	 acid	 sequence	 of	 the	 protein	 (p.P663S).	 The	 variant	 is	
heterozygous	with	one	wild	type	FGFR1	allele	present.	 I	postulated	that	 if	 this	
variant	were	pathogenic	it	would	act	through	a	dominant	negative	mechanism,	
with	 the	 mutant	 protein	 adversely	 affecting	 the	 wild	 type	 protein.	 This	 was	
based	on	 the	 fact	 that	 the	human	reduction	deformity	parallels	 the	phenotype	
seen	in	mouse	models	with	complete	loss	of	FGFR1	in	the	limb	bud.		
	
To	 investigate	 the	 functional	 significance	 of	 the	 novel	 variant	 in	 FGFR1	 I	





proteins	 co-localized	 to	 the	 cell	 membrane	 in	 a	 similar	 manner	 to	 the	
localisation	observed	in	published	studies	of	endogenous	FGFR1.	
	
To	 investigate	 the	 function	 of	 the	 mutant	 FGFR1	 receptor	 I	 examined	 its	
capacity	to	activate	the	MAPK/ERK	signaling	pathway,	an	important	pathway	in	
limb	 development.	 HEK	 293	 cells	 containing	 inducible	 FGFR1	WT	 protein	 or	
inducible	FGFR1	(p.P663S)	protein	were	cultured	in	the	presence	or	absence	of	
the	FGF2	ligand,	with	or	without	induction	of	the	protein.	I	found	that	induction	
of	 the	 wild	 type	 protein	 resulted	 marked	 ERK	 phosphorylation.	 In	 contrast,	
induction	of	FGFR1	(p.P663S)	protein	impaired	ERK	phosphorylation	compared	
to	wild	type	controls.	This	indicates	that	the	FGFR1	(p.P663S)	protein	impaired	
FGFR	 activation	 in	 my	 model	 and	 provides	 a	 mechanism	 through	 which	 the	
variant	protein	may	influence	limb	development.		
	
In	 chapter	 5,	 I	 describe	 work	 that	 Dr	 Pedro	 Countinho	 and	 I	 undertook	 to	





grow.	 The	 genetic	 pathways	 that	 regulate	 growth	 at	 this	 later	 stage	 of	
development	remain	poorly	characterized.	This	project	aimed	to	investigate	the	
genes	 expressed	 differentially	 at	 this	 later	 stage	 of	 development	 and	 to	
determine	if	pathways	involved	in	growth	are	distinct	between	the	forelimb	and	
hindlimb.	 In	 addition	 we	 examined	 the	 expression	 of	 genes	 known	 to	 be	
involved	in	fore	and	hindlimb	patterning	at	earlier	stages	of	development	to	see	
if	they	remain	up	regulated	after	specification	is	complete.		
The	 forelimb	 and	 hindlimb	 were	 found	 to	 differentially	 regulate	 1000	 genes.	
When	 filtered	 against	 over	 200	 known	 limb	 development	 genes,	 10	 limb-
associated	genes	were	up	regulated	in	hindlimb	and	9	were	up	regulated	in	the	
forelimb.	Furthermore,	patterning	associated	genes	such	as	Tbx5	in	the	forelimb	







cell	 proliferation.	 In	 addition,	 I	 have	 identified	 a	 novel	 causative	 variant	 of	
PALLRD	 using	 whole	 exome	 sequencing;	 this	 work	 led	 to	 the	 diagnosis	 of	
Kallman’s	 syndrome	 in	 the	 proband.	 Furthermore,	 I	 have	 demonstrated	 a	





Chapter 7 Materials 
Reagents 
Experiment Material  Supplier 
Cell culture plastic 
ware 
Falcon tissue culture dishes  
(60 mm, 100 mm) 
Cell strainers (40 and 70µm) 
BD Biosciences, 
Oxford, UK 
Cell culture flasks (T25, T75,) 
96-well, 24-well, 12-well plates ,  














Cell culture reagents Sterile PBS IGMM Central Services 
DMEM 
Fetal calf serum 
L-Glutamine 200mM 
Trypsin solution 2.5% 
Invitrogen Life Sciences 




Library efficiency chemically 
compotent cells, DH5α 
Flp-In™ T-REx™ 293 Cell Line 
Invitrogen Life Sciences 
Ltd, Paisley, UK 
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Dimethyl sulphoxide (DMSO) 
 










Invitrogen Life Sciences 
Ltd, Paisley, UK 
Gel Extraction Kit 
RNA Extraction Kit 
Miniprep Kit 
PCR Purification Kit 
Qiagen, Crawley, UK 
Dimethyl sulphoxide (DMSO) 
Paraformaldehyde 
Sigma Chemical Co, 
Poole, UK 
 T4 Ligase enzyme 
Ligation Buffer 




Propidium iodide (PI) 












Anti-Rat alexa 488 Lfe technologies, UK 
Anti-BrdU antibody Santa Cruz, UK. 
FACSScalibur BD Biosciences Life, Sciences, UK. 
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Immunofluorescence Superfrost Plus Slides 
Coverslips 









Invitrogen, Paisley, UK 
Formaldehyde 
Sigma Chemical Co, 
Poole, UK 





Immunohistochemistry PAP pen 
Gelatine 
Glycerol 
Bovine Serum Albumin 
(BSA) 







(DAPI, blue) and coverslips 
Vectastain Universal Elite ABC 
Kit 















In Situ Hybridisation  BM Purple 
(11442074001) 
Roche, West Sussex, 
UK 
Ultrapure H20 
Invitrogen Life Sciences 










 Triton X-100 
Tween 20 








Sigma Chemical Co, 
Poole, UK 












Microscopy and Image 
Analysis 
ImageJ software 
National Institute of 
Health, Bethseda, USA 
Olympus FV1000 Confocal 
microscope 
Olympus UK Ltd, 
Hertfordshire, UK 
Axioplan II fluorescence 
microscope 
Carl Zeiss, Welwyn 






2100 Bioanalyzer Agilent, Berkshire, UK 
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Agarose gel 
Bioline Reagents ltd., 
London, UK 
Complete ULTRA Tablets 
















Nuclease free water 
Life technologies, 
Paisley UK. 
1Kb DNA ladder Invitrogen, Paisle. 
100bp DNA ladder Promeg, UK. 
 UV Transiluminator Bio Doc-IT 
system 
UVP, UK. 




Quik Change Site Directed 
Mutagenesis Kit 










Biohit, Ellsmere Port, 
Cheshire, UK 
ECL reagent 
Semi-Dry and Rapid Blotting 
Systems 
Life Science, Biorad 
Laboratories,  
Hertfordshire, UK. 


















New England Biolabs, 
Hertfordshire, UK 













Schleicher and Schuell, 
London, UK 
	 199	










GenomiPhi V2 Amplification 
kit 
GE Health, Life 
Sciences, 
Buckinghamshire, UK. 






GC Mix Reagent 
Roche Diagnositics, 
West Sussex, UK. 
BigDye® Terminator v3.1 and 
v1.1 
Cycle Sequencing Kits 
 




Mutation surveyor v3.30 
Soft genetics, 
Pennsylvania, USA. 
Bioanalyser Agilent, stockport, UK. 
Agencourt AMPure XP Kit 
Beckman Coulter, High 
Wycomb, UK. 
DynaMag-2 Magnetic Rack 
Life technologies, 
Paisley UK 




100% Ethanol IGMM Central Services 
 





6.1 Stock Solutions and Buffers 
All commomly used stock solutions were autoclaved or passed through a 
0.22µm filter.  
 
Buffer for DNA PCR product electrophoresis 
TBE – 5X: 
54g Tris Base 
27.5g Boric acid 
20ml 0.5M EDTA 
to 1000ml water 
 
6xDNA Loading Buffer  
30% (v/v) glycerol 
0.4% (w/v) Orange 
 
Protein extraction and western blotting 
Blocking buffer 
0.2% Tween 20 in Tris Base Solution 
5% bovine serum albumin 
PBS–Tween 20 (PBST) 
1X PBS 
0.1% (v/v) Tween 20 
 
Radioimmuno-precipitation assay (RIPA) buffer 
50mM Tris/HCl, pH 7.4 (25ml of 1M) 
150mM NaCl (15ml 5M) 
1% sodium deoxycholate (5g) 
1% NP40 (5ml) 
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0.1% sodium dodecyl sulphate (SDS) (0.5g) 
to 500ml water 
Filter with 0.22µm filter prior to addition of Complete ULTRA Tablets 
Phosphatase inhibitor cocktail immediately before use.  
 
NP40 Buffer 
5M NaCl 30mls 
10% NP40 50mls 
1M Tris pH8 50mls 
Filter with 0.22µm filter prior to addition of Complete ULTRA Tablets 
Phosphatase inhibitor cocktail immediately before use.  
 
Running gel -10% 
4.43ml 30% acrylamide 
5ml Tris pH 8.8 
3.9ml H2O 
130ul 10% SDS 




Sample buffer – 2x 
800ìl 2-mercaptoethanol 
1.3ml Tris pH 6.8 
2ml glycerol 
5ml 10% SDS 
1.3ml H2O 
Bromophenol to colour 
 
Stacker gel 
1.07ml 30% acrylamide 
0.83ml Tris pH 6.8 
4.67ml H2O 
99 
70ul 10% SDS 
70ul 10% APS 
20ul TEMED 
 
Tank Buffer – 10x 
50mM Tris Base (60.4g) 
50mM glycine (288g) 
0.1% SDS (20g) 
to 2000ml water 
 
Transfer Buffer 
50mM Tris Base (60.4g) 
40mM glycine (230g) 
0.04% SDS (4g) 
20% methanol (400ml) 
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to 2000ml water 
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6.2 Whole Mount In Situ Hybridisation Solutions 
 
PBT 
Use tablets to make a 10x stock and store at RT. Add 0.1% Tween 20 to 1x 
dilution when making PBT (2ml of 50% Tween 20 in 1L). 
 
0.1M Triethanolamine (pH 7.8) (500ml) 
Triethanolamine (neat = 7.5M)    6.7ml 
Make to 450ml, pH to 7.8 and then top-up to 500ml  
Filter and store at 4ºC 
 
Hybridisation buffer (50ml) 
50% Formamide     25ml 
5x SSC       12.5ml of 20x 
1mg/ml yeast RNA     1ml of 50mg/ml 
Heparin (100µg/ml)    100µl of 50mg/ml 
Blocking reagent (BMB)     5ml of 10% 
0.1 % Tween 20     100µl of 50% 
0.1% Chaps      500µl of 10% 
10mM EDTA      1ml of 0.5M 
Top up with ultrapure H2O 
 
SSC solutions (2x and 0.2x) (50ml each) 
2x = 5ml of 20x, 0.1% Tween 20 (100µl of 50%), top up with dH2O 
0.2x = 500µl of 20x, 0.1% Tween 20 (100µl of 50%), top up with dH2O 
 
Maleic acid buffer (2x stock,1L) (pH7.8) 
0.1M maleic acid     23.2g 
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0.15M NaCl      7g 
pH to 7.8 (beginning by using 15g NaOH pellets) 
Store 2x solution at RT 
Add 0.1% Tween 20 to 1L of 1x solution  2ml of 50% 
 
Antibody solution (10ml) 
2% BMB      2ml of 10%  
20% Heat-treated lamb serum    2ml 
Top up to 10ml with MAB.  
 
50mg/ml Yeast RNA – make 25ml and then dispense in 1ml aliquots  
(incubated ON at -800C to get into solution)   
50mg/ml Heparin – make 2ml and then dispense in 100µl aliquots. 
10% Chaps – make 10ml and dispense in 500µl aliquots.  
10 % BMB – make 100ml in 1x MAB and dispense into 5ml aliquots.  
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